
Title: A Phase 1 Study to Evaluate the Effects of Rifampin on Pharmacokinetics of Pevonedistat in 
Patients with Advanced Solid Tumors
Study ID: [REMOVED]
Protocol Approve Date: 04 September 2018
Certain information  within this protocol has been  redacted (ie,  specific content is masked irreversibly from 
view with a black/blue bar) to protect either personally identifiable information (PPD) or company 
confidential information (CCI). 
This may include, but is not limited to, redaction of the following: 
Named persons or organizations associated with the study.
Proprietary information, such as scales or coding systems, which are considered confidential  
information under prior agreements with license holder.
Other information as needed to protect confidentiality of Takeda or partners, personal  information, or 
to otherwise protect the integrity of the clinical study.
PRE -TEAM.0 TITLE PAGE
PROTOCOL
A Phase 1 Study to Evaluate the Effects of Rifampin on Pharmacokinetics of Pevonedistat in 
Patients With Advanced Solid Tumors
TAK -924/MLN4924: Effect of Rifampin (Strong Metabolic Enzyme Inducer)
on 50 mg/m2Dosing of Pevonedistat
Sponsor: Millennium Pharmaceut icals, Inc, a who lly owned subsidiary o f Takeda 
Pharmaceut ical Co mpany Limited
40 Lansdowne Street
Cambridge, MA 02139
USA
Telephone: +1 (617) 679 -7000
Please note : Millennium Pharmaceut icals, Inc, a who lly owned 
subsidiary  of Takeda Pharmaceut ical Company Limi ted, m ay be 
referred to in this protocol as “Millennium,” “Sponsor,” or “Takeda”.
Study Number: Pevonedistat -1015
IND Number: 78,427 EudraCT Number: Not Applicable
Compound: Pevonedistat (TAK -924/MLN4924)
Date: 04 September 2018 Version/Amendment 
Number: 02
Date Amendment No. Amendment Type Region
29 November 2017 Initial Protocol Not applicable United States
28 February 2018 01 Substantial United States
04 September 2018 02 Nonsubstantial United States
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 2of 102
Protocol Incorporating Amendment 02 04 September 2018
1.0 ADMINISTRATIVE 
1.1 Contacts 
A separate contact informat ion list will be provided to each site.
Serious adverse event a nd pregnancy reporting information is presented in Section 10.0, as is 
inform ation on reporting product complaints.
Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceut ical 
Com pany Limi ted-sponsored investigators per individual country  requi rements will  be provi ded 
with emergency  medical contact informat ion cards to be carried by  each subject.
General advice on protocol procedures should be obtained through the monitor assigned to the 
study  site. Inf ormation on service providers is given in Sect ion 3.1and relevan t guidelines 
provi ded to the si te.
Contact Type/RoleUnited States of America (USA)
Contact
Serious adverse event and pregnancy reporting See Section 10.0
Medical Monitor
(medical advice on protocol and compound)Refer to Study Manual
Responsible Medical Officer 
(carries overall responsibility for the conduct of the study)Refer to Study Manual
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK-924/MLN4924)
Study No. Pevonedistat-1015 Page 3 of 102Protocol Incorporating Amendment 02 04 September 2018
1.2 Approval 
REPRESENTATIVES OF TAKEDA This study will be conducted with the highest respect for the individual participants in accordance 
with the requirements of this clinical study protocol and also in accordance with the following:
!The ethical principles that have their origin in the Declaration of Helsinki.
!International Council for Harmonisation (ICH) E6 Good Clinical Practice (GCP): 
Consolidated Guideline.
!All applicable laws and regulations, including, without limitation, data privacy laws, clinical 
trial disclosure laws, and regulations.
SIGNATURES
The signature of the responsible Takeda medical officer (and other signatories, as applicable) can 
be found on the signature page.
Electronic Signatures may be found on the last page of this document.
PPD
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedance ance
wing:wing:
GCP): GCP): 
a privacpriva
other sigther si
thihis docs do
keda: For Non-Commercial Use Only an
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 4of 102
Protocol Incorporating Amendment 02 04 September 2018
INVESTIGATOR AGREEMENT 
I confirm that I have read and that I understand this protocol, the Invest igator’s Brochure, and any 
other product information provided by the sponsor. I agree to conduct this study  in accordance 
with the requirements of this protocol and also to protect the rights, safet y, privacy, and well -being 
of study  subjects in accordance with the following:
The ethical principles that have their origin in the Declaration of Helsinki.
ICH, E6 GCP: Consolidated Guideline.
All applicable laws and regulat ions, includin g, wi thout limi tation, data privacy laws and 
regul ations.
Regulatory  requi rements for reporting serious adverse events defined in Sect ion10.2 of this 
protocol .
Terms outlined in the Clinical Study  Site Agreement.
Responsibilit ies o f the Invest igator (Appendix B).
I further authorize that my  personal informat ion may be processed and transferred in accordance 
with the uses contem plated in Appendix Cof this protocol .
Signature of Investigator Date
Invest igator Name (print or ty pe)
Invest igator’s Tit le
Locati on of  Facilit y (Ci ty, State/ Provi nce)
Locati on of  Facilit y (Country )
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 5of 102
Protocol Incorporating Amendment 02 04 September 2018
1.3 Protocol Amendment 02 Summary of Changes
Rationale for Amendment 02
This document describes the changes in reference to the protocol incorporating Amendment 02. 
The primary reason for this amendment is to clarify the timing of the assessment of left ventricular 
ejection fraction (LVEF) as it relates to study  eligibilit y.
Minor grammat ical, editorial, formatting, and administrative changes not affect ing the conduct of 
the study  are included for clarificat ion and administrative purposes only.
For specif ic descriptions of text changes, the rationale for each change, and where the changes are 
located, see Appendix L.
Changes in Amendment 02
1.Clarify  the exclusio n criterion regarding the assessment of LVEF.
2.Delete the requi rement that, for inclusio n in the study, patients must have a tumor that is 
radiographically  or clinically evaluable and/or measurable.
3.Change serious adverse event reporting from a paper -based system to electronic data capture.
4.Clarify  the timing of chemistry  and hematol ogy laboratory  assessments before administration 
of the Day  1 dose of pevonedistat in Part A (drug -drug interaction) of the study .
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 6of 102
Protocol Incorporating Amendment 02 04 September 2018
TABLE OF CONTENTS
1.0 ADMINISTRATIVE ....................................................................................................... 2
1.1 Contacts ..................................................................................................................... 2
1.2 Approval .................................................................................................................... 3
1.3 Protocol  Amendment 02 Summary  of Changes .......................................................... 5
2.0 STUDY SUMMARY .................................................................................................... 12
3.0 STUDY REFERENCE INFORMATION ...................................................................... 17
3.1 Study -Related Responsibilit ies................................................................................. 17
3.2 Principal Invest igator ............................................................................................... 17
3.3 List of Abbreviat ions............................................................................................... 18
3.4 Corporate Identificat ion........................................................................................... 19
4.0 INTRODUCTION ......................................................................................................... 20
4.1 Background ............................................................................................................. 20
4.1.1 Study  Drug......................................................................................................... 20
4.1.2 Nonclinical Background Information ................................
.................................20
4.1.3 Clinical Background Information ....................................................................... 21
4.1.4 Potenti al Risks and Benefits ............................................................................... 22
4.2 Rationale for the Proposed Study ............................................................................. 27
4.2.1 Rationale for Dose and Duration of PK Assessments in Part A ........................... 27
4.2.2 Rationale for Continued Treatment Wit h Pevonedistat in Co mbination Wit h 
Chem otherapy  in Opt ional Part B ....................................................................... 28
5.0 STUDY OBJECTIVES AND ENDPOINTS .................................................................. 30
5.1 Object ives................................................................................................................ 30
5.1.1 Primary Object ives............................................................................................. 30
5.1.2Secondary  Object ives......................................................................................... 30
5.1.3 Safety Objectives ............................................................................................... 30
5.1.4 Exploratory /Additional Object ives..................................................................... 30
5.2 Endpoints ................................................................................................................. 30
5.2.1 Primary Endpo int............................................................................................... 30
5.2.2 Secondary  Endpo ints.......................................................................................... 31
5.2.3 Safety Endpo ints................................................................................................ 31
5.2.4 Exploratory /Additional Endpoints ...................................................................... 31
6.0 STUDY DESIGN .......................................................................................................... 32
6.1 Overview of Study  Design ....................................................................................... 32
6.2 Number of Patients .................................................................................................. 34
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 7of 102
Protocol Incorporating Amendment 02 04 September 2018
6.3 Durati on of  Study .................................................................................................... 34
6.3.1 Durati on of  an Individual Pat ient’s Study  Parti cipati on...................................... 34
6.3.2 EOS/Study  Com pletion Definit ion and Planned Reporting .................................35
6.3.3 Timeframes for Primary and Secondary  Endpo ints to Support Disclosures ......... 35
6.3.4 Total  Study  Durati on.......................................................................................... 35
6.3.5 Post Trial Access ............................................................................................... 36
6.3.6Durati on of  PTA ................................................................................................ 36
7.0 STUDY POPULATION ................................................................................................ 37
7.1 Inclusio n Cri teria..................................................................................................... 37
7.2 Exclusion Criteria.................................................................................................... 38
7.3 Criteria for Continuat ion into Opti onal Part B .......................................................... 40
8.0 STUDY DRUG ............................................................................................................. 42
8.1 Study  Drug Administration ...................................................................................... 42
8.1.1 Part A: Pevonedistat and Rifampin Administration ............................................. 42
8.1.2 Part B (Opti onal): Pevonedistat in Combinat ion With SOC Chem otherapy  
Agents ............................................................................................................... 43
8.2 Reference/Control Therapy ...................................................................................... 44
8.3 Dose Modificat ion Guidelines (Part B) .................................................................... 45
8.3.1 Criteria for Beginning or Delaying a Subsequent Treatment Cy cle..................... 45
8.3.2 Criteria for Dose Interruption During a Cycle ..................................................... 45
8.3.3 Criteria for Dose Reduction ................................................................................ 45
8.3.4 Criteria for Di scontinuati on of  Study  Drug ......................................................... 46
8.4 Excluded Conco mitant M edications and Procedures ................................................ 47
8.4.1 Part A ................................................................................................................ 47
8.4.2 Part B ................................................................................................................. 47
8.5 Permi tted Co ncomitant Medications and Procedures ................................................ 48
8.5.1 Part A ................................................................................................................ 48
8.5.2 Part B ................................................................................................................. 48
8.6 Precauti ons and Restri ctions.................................................................................... 49
8.6.1 Pevonedistat ....................................................................................................... 49
8.6.2 Rifampin ............................................................................................................ 50
8.6.3 Docetaxel ........................................................................................................... 50
8.6.4 Carbopl atin........................................................................................................ 51
8.6.5 Paclitaxel........................................................................................................... 51
8.7 Management of Clinical Events ............................................................................... 51
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 8of 102
Protocol Incorporating Amendment 02 04 September 2018
8.7.1 Guidance for Clinical Assessment and Management of Hemodynamic 
Com promise (Part A and Part B) ........................................................................ 52
8.7.2 Guidance for Use of Granulocy te-Colony Stimulating Factor ............................. 52
8.7.3 Guidance for Clinical Assessment and Management of Anemia ......................... 52
8.7.4 Guidance for Managem ent of Extravasation ....................................................... 53
8.8 Blinding and Unblinding .......................................................................................... 53
8.9 Descript ion of Invest igational Agents ...................................................................... 53
8.9.1 Pevonedistat ....................................................................................................... 53
8.9.2 Rifampin ............................................................................................................ 53
8.9.3 Docetaxel ........................................................................................................... 53
8.9.4 Carbopl atin........................................................................................................ 53
8.9.5 Paclitaxel ........................................................................................................... 54
8.10 Prepara tion, Reconstitution, and Dispensat ion.......................................................... 54
8.10.1 Pevonedistat ................................
....................................................................... 54
8.10.2 Docetaxel, Carboplat in, Paclitaxel and Rifampin ................................................ 54
8.11 Packaging and Labeling ........................................................................................... 54
8.11.1 Pevonedistat ....................................................................................................... 54
8.11.2 Docetaxel, Carboplatin, and Paclitaxel ............................................................... 54
8.11.3 Rifampin ............................................................................................................ 55
8.12 Storage , Handling, and Accountabilit y..................................................................... 55
8.12.1 Pevonedistat ....................................................................................................... 55
8.12.2 Docetaxel, Carboplat in, Paclitaxel and Rifampin ................................................ 55
8.13 Other Protocol -Specified Materials .......................................................................... 55
9.0 STUDY CONDUCT ...................................................................................................... 56
9.1 Study  Personnel and Organizations .......................................................................... 56
9.2 Arrangements for Recruit ment of Patients ................................................................ 56
9.3 Treatment Group Assignments ................................................................................. 56
9.4 Study  Procedures ..................................................................................................... 56
9.4.1 Inform ed Consent ............................................................................................... 56
9.4.2 Patient Dem ographi cs........................................................................................ 56
9.4.3 Medical History .................................................................................................56
9.4.4 Physical Examinat ion......................................................................................... 57
9.4.5 Patient Hei ght.................................................................................................... 57
9.4.6 Vital Signs ......................................................................................................... 57
9.4.7 Pregnancy Test ................................................................................................... 57
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 9of 102
Protocol Incorporating Amendment 02 04 September 2018
9.4.8 Concomitant Medications and Procedures .......................................................... 57
9.4.9 AEs.................................................................................................................... 58
9.4.10 Enrollment ......................................................................................................... 58
9.4.11 Electrocardiogram .............................................................................................. 58
9.4.12Echocardi ogram .................................................................................................58
9.4.13 Clinical Laboratory  Evaluat ions......................................................................... 58
9.4.14 Disease Assessment ........................................................................................... 59
9.4.15 Biomarker, Pharm acodynamic, and PK Samples ................................................ 60
9.4.16 PK Measurements .............................................................................................. 60
9.4.17 Pharmacodynamic Measurements ...................................................................... 61
9.4.18 DNA Measurements ........................................................................................... 61
9.4.19Banked Tum or Specimen Measurements ............................................................ 61
9.4.20 Immunogenicit y Sample Collect ion................................................................... 61
9.5 Com pletion of Study  Treatm ent (f or Individual Patients) ......................................... 61
9.5.1 Part A ................................................................................................................ 61
9.5.2 Part B ................................................................................................................. 61
9.6 Discontinuati on of  Treatment Wi th Study  Drug and Pati ent Repl acement ................ 62
9.7 Withdrawal o f Patients From  Study ......................................................................... 62
9.8 Study  Com pliance .................................................................................................... 63
10.0 ADVERSE EVENTS .................................................................................................... 64
10.1 Definit ions............................................................................................................... 64
10.1.1 PTE Definit ion................................................................................................... 64
10.1.2 AE Definit ion.................................................................................................... 64
10.1.3 SAE Definit ion.................................................................................................. 64
10.2 Procedures for Recording and Reporting AEs and SAEs .......................................... 65
10.3 Moni toring of AEs and Period of Observat ion......................................................... 66
10.4 Procedures for Reporting Drug Exposure During Pregnancy and Birth Events ......... 66
10.5 Procedures for Reporting Product Complaints or Medicat ion Errors (Including 
Overdose) ................................................................................................................ 67
10.6 Safety Reporting to Invest igators, IRBs or IECs, and Regulatory  Authori ties........... 67
11.0 STUDY -SPECIFIC COMMITTEES ............................................................................. 68
12.0 DAT A HANDLING AND RE CORDKEEPING ............................................................ 69
12.1 eCRFs ...................................................................................................................... 69
12.2 Record Retention ..................................................................................................... 69
13.0 STATISTICAL METHODS .......................................................................................... 71
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 10of 102
Protocol Incorporating Amendment 02 04 September 2018
13.1 Statistical and Analyt ical Plans ................................................................................ 71
13.1.1 Analysis Sets ...................................................................................................... 71
13.1.2 Analysis of Demographics and Other Baseline Characterist ics........................... 71
13.1.3 Efficacy Analysis ............................................................................................... 71
13.1.4 PK Analysis ....................................................................................................... 71
13.1.5 Safety Analysis .................................................................................................. 72
13.2 Interim Analysis and Criteria for Early Terminat ion................................................ 73
13.3 Determinat ion of Sample Size .................................................................................. 73
14.0 QUALITY CONTROL AND QUALITY ASSURANCE ............................................... 74
14.1 Study -Site Moni toring Visit s................................................................................... 74
14.2 Protocol  Deviat ions.................................................................................................. 74
14.3 Qualit y Assurance Audits and Regulatory  Agency  Inspect ions................................ 74
15.0 ETHICAL ASPECTS OF T HE STUDY ........................................................................ 75
15.1 IRB and/or IEC Approval ........................................................................................ 75
15.2 Subject Informat ion, Inform ed Consent, and Subject Authorizat ion......................... 76
15.3 Subject Confidentialit y............................................................................................ 77
15.4 Publicat ion, Di sclosure, and Clinical Trial Registr ation Policy .................................77
15.4.1 Publicat ion......................................................................................................... 77
15.4.2 Clinical Trial Registration .................................................................................. 78
15.4.3 Clinical Trial Result s Disclosure ........................................................................ 78
15.5 Insurance and Co mpensation for Injury .................................................................... 78
16.0 REFERENCES .............................................................................................................. 79
LIST OF IN -TEXT TABLES
Table 6.a Primary and Secondary  Endpo ints for Di sclosures: Part A .................................35
Table 6.b Primary and Secondary  Endpo ints for Di sclosures: Part B .................................. 35
Table 8.a Dose Modificat ion Guidelines for Specific Toxicit ies........................................ 46
Table 8.b Excluded Conco mitant Medi cations and Procedures During Part A .................... 47
Table 8.c Excluded C onco mitant Medi cations and Procedures During Part B .................... 47
Table 8.d Permi tted Concomitant Medications and Procedures During Part A ................... 48
Table 8.e Permi tted Concomitant Medications and Procedures During Part B .................... 49
Table 9.a Clinical Chemistry  and Hematol ogy Tests .......................................................... 59
Table 9.b Clinical Urinalysis Tests .................................................................................... 59
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 11of 102
Protocol Incorporating Amendment 02 04 September 2018
LIST OF IN -TEXT FIGURES
Figure 6.a Study  Overview .................................................................................................33
LIST OF APPENDICES
Appendix A Schedules of Events ........................................................................................... 80
Appendix B Responsibilit ies o f the Invest igator ..................................................................... 85
Appendix C Invest igator Consent to Use of Personal Informat ion.......................................... 87
Appendix D ECOG Scal e for Perf ormance Status .................................................................. 88
Appendix E Drugs Associated Wit h Nephrotoxicit y.............................................................. 89
Appendix F Definit ion of Postmenopausal ............................................................................ 90
Appendix G Acceptable Methods of Contraception Considered Highly Effective ................... 91
Appendix H Response Criteria ............................................................................................... 93
Appendix I Hem atologic Toxi city of Carbopl atin Alo neand in Combinat ion Wit h 
Paclitaxel ........................................................................................................... 94
Appendix J New York Heart Associat ion Classificat ion of Cardi ac Disease .......................... 96
Appendix K Excluded Strong CYP3A Inducers ..................................................................... 97
Appendix L Detailed Descript ion of Amendments to Text ..................................................... 98
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 12of 102
Protocol Incorporating Amendment 02 04 September 2018
2.0 STUDY SUMMARY
Name of Sponsor(s):
Millennium Pharmaceuticals, Inc, a wholly owned 
subsidiary of Takeda Pharmaceutical Company LimitedCompound:
Pevonedistat (TAK -924; MLN4924)
Title of Protocol: A Phase 1 Study to Evaluate the Effects 
of Rifampin on Pharmacokinetics of Pevonedistat in 
Patients with Advanced Solid TumorsIND No.: 78,427 EudraCT No.:
Not applicable
Study Number: Pevonedistat -1015 Phase: 1
Study Design:
Part A: Assessment of the effect of rifampin on pevonedistat pharmacokinetics (PK)
Eligible patients will receive a single dose of 50 mg/m2pevonedistat via a 1 -hour intravenous (IV) infusion on Day 1. 
Plasma PK samples will be collected at a series of predetermined time points up to 48 hours (Day 3) following the 
single dose of pevonedistat. Patients will then receive an oral dose of 6 00 mg rifampin once daily (QD) starting from 
Day 3 (after collecting the 48 -hour PK sample) through Day 11. There will be no pevonedistat doses from Day 2 
through Day 9. On Day 10, a single dose of 50 mg/m2pevonedistat will be administered, and plasma sam ples will be 
collected at predetermined time points up to 48 hours (Day 12) following the second single dose of pevonedistat. 
Study drug will be discontinued early if a patient experiences study drug ‒related toxicities.
Both doses of pevonedistat (Days 1 a nd 10) will be administered in the clinic, followed by the required PK sampling. 
Serial blood plasma samples for determination of the plasma concentration of pevonedistat will be obtained during 
Part A at prespecified time points. The first dose of rifampi n will be given orally in the clinic on the morning of Day 3 
after collection of the 48 -hour PK sample. Patients will self -administer rifampin (oral capsules) QD on Days 4, 5, 6, 7, 
8, and 9 at home. Patients are encouraged to take rifampin at approximatel y the same time each day (±2hours from the 
time of first rifampin dose). On Days 10 and 11, patients will report to the clinic to continue to receive oral 600 mg 
rifampin co -administered with pevonedistat on Day 10, and at the time of the 24 -hour pevonedi stat PK sampling on 
Day 11. The last PK sampling is on Day 12 (48 -hour post pevonedistat infusion on Day 10). There will be no 
pevonedistat dosing on Days 11 and 12. There will be no rifampin dosing on Day 12.
All doses of rifampin will be administered on an empty stomach with patients taking nothing by mouth (NPO) except 
for water and prescribed medications for 2 hours before and at least 1 hour after each rifampin dose. Patients who miss 
any rifampin doses on Days 3 to 9 will not be considered evaluable a nd pevonedistat dosing and PK sampling on 
Day 10 will not be required for these patients. Patients will have a washout period from the last dose of rifampin for at 
least 1 week to allow reversal of metabolic enzyme induction before the start of Part B of t he study.
Part B (OPTIONAL): Continued Treatment with Pevonedistat in Combination with Standard of Care (SOC)
After completion of Part A of this study, patients will have the option of participating in Part B. Any patient who 
decides to participate in Part B will need to meet the continuation criteria of the study before treatment in Part B can 
begin. Patients will receive pevonedistat in combination with either docetaxel or carboplatin+paclitaxel, as 
recommended by the investigator. As in Part A, safety assessments will also be conducted in Part B of the study. In 
addition, Part B will conduct disease assessments using radiological evaluations (computed tomography scan or 
magnetic resonance imaging).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 13of 102
Protocol Incorporating Amendment 02 04 September 2018
Primary Objective:
To assess the effect of multiple -dose administration of rifampin on the single -dose PK of pevonedistat in adult patients 
with advanced solid tumors (Part A).
Secondary Objectives:
Part A: The secondary objective of Part A is to further characterize pevonedistat PK following a si ngle dose at 
50mg/m2in the absence or presence of rifampin.
Part B: The secondary objective of Part B is to evaluate disease response that may be observed following treatment 
with pevonedistat in combination with either docetaxel or carboplatin+paclitaxe l in patients with advanced solid 
tumors.
Safety Objectives:
Part A: The safety objective for Part A is to evaluate the safety and tolerability of pevonedistat in patients with 
advanced solid tumors following a single IV dose at 50 mg/m2in the absence or presence of rifampin.
Part B: The safety objective for Part B is to evaluate the safety and tolerability of pevonedistat in combination with 
either docetaxel or carboplatin+paclitaxel in patients with advanced solid tumors.
Subject Popu lation: Adult patients, aged ≥18 years, who have a histologically or cytologically confirmed metastatic 
or locally  advanced solid tumor that is appropriate for treatment with pevonedistat in combination with either 
docetaxel or carboplatin+paclitaxel in Pa rt B of this study, or have progressed, despite standard therapy, or for whom 
conventional therapy is not considered effective.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 14of 102
Protocol Incorporating Amendment 02 04 September 2018
Number of Subjects:
Approximately 20 patients (for approximately 
12PK-evaluable patients).Number of Sites:
Estimated total: approximately 4 to 6 sites in the 
United States of America (USA).
Dose Level(s):
Part A:
Pevonedistat is given IV at 50 mg/m2on Day 1 and Day 10.
Rifampin is given orally at 600 mg on Days 3 through 11; it 
is co-administered with pevonedistat on Day 10.
Part B:
Pevonedistat is given IV at 25 mg/m2in combination with 
docetaxel 75 mg/m2or at 20 mg/m2in combination with 
carboplatin AUC5+paclitaxel 175 mg/m2; pevonedistat is 
given in combination on Day 1 and as a single agent on 
Days 3 and 5 of each 21 -day cycle.Route of Administration:
Part A:
Pevonedistat: IV infusion
Rifampin: oral dose
Part B (Optional):
Pevonedistat: IV infusion
Docetaxel, carboplatin, and paclitaxel: IV infusion
Duration of Treatment:
Part A: Single IV dose of pevonedistat at 50 mg/m2on 
Day 1 and Day  10, followed by a period of at least 1 week 
for washout and safety observation.
Part B (Optional): Eligible patients may continue to 
receive treatment in Part B of this study until they 
experienc e symptomatic deterioration or disease 
progression, treatment is discontinued for another reaso n, or 
until the study is stopped.
Follow -up:Patients will attend an End of Study (EOS) visit 
30days (+10 days) after the last dose of study drug or 
before the start of subsequent therapy in Part B, if that 
occurs sooner.Period of Evaluation:
Screening: Within 28 days before the first dose of 
study drug in Part A.
Part A: 12 days with an EOS visit at 30 (+10) days 
(safety follow -up) after the last dose of study drug for 
patients who do not continue on to optional Part B.
Part B (Optional): The duration of treatment for 
Part B is 12 cycles. If the sponsor and investigator 
determine that a patient would derive clinical benefit 
from continued treatment, the patient may remain on 
the current combination therapy or receive 
pevonedistat as a single agent beyond 12 cycles.
Patients who have achieved clinical benefit from 
combinatio n therapy  (chemotherapy+pevonedistat) 
and w ho have developed intolerance that is reasonably
attributable to the chemotherapy after 2 or more cycles 
may continue on single -agent pevonedistat at the same 
dose and schedule, upon request by the investigator 
and agreement by the sponsor.
All patients in optional Part B will attend an EOS visit 
at 30 (+10) days (safety follow -up) after the last dose 
of study drug or before the start of subsequent therapy 
for their disease, if that occurs sooner.
Main Criteria for Inclusion:
Adult patients who have a histologically or cytologically confirmed metastatic or locally advanced solid tumor 
that is appropriate for treatment with 1 of the 2 combination therapies in Part B of this study, or have progressed 
despite standard therapy, or for whom conventional therapy is not considered effective.
Adequate renal, hepatic, and cardiac functions, and other safety parameters to reflect the risk mitigation strategy 
in place in all ongoing pevonedistat studies, and with special consideration to the safety profile of the SOC agents 
(Part B of the study).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 15of 102
Protocol Incorporating Amendment 02 04 September 2018
Main Criteria for Exclusion:
Systemic treatment with strong metabolic enzyme inducers must be discontinued at least 14 days before the first 
dose of pevonedistat.
Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of 
rifampin, including difficulty swallowing capsules.
Main Criteria for Evaluation and Analyses:
Primary
Ratios of geometric mean pevonedistat maximum observed plasma concentration (C max), area under the plasma 
concentration versus time curve from time 0 to the time of the last quantifiable concentration (AUC last), and area 
under the plasma concentration versus time curve from time 0 to infinity (AUC ∞) in the presence of rifampin in 
reference to C max, AUC last, and AUC ∞in the absence of rifampin and associated 90% CIs.
Secondary
Part A:
PK parameters: total clearance after intravenous administration (CL), volume of distribution at steady state 
after intravenous administration (V ss), and terminal disposition phase half -life (t 1/2z) of pevonedistat 
following a single dose administration of 50 mg/m2on Day 1 (in the absence of rifampin) and Day 10 (in the 
presence of rifampin) .
Part B:
Measures of disease response based on the investigator’s assessment using the Response Evaluatio n Criteria in 
Solid Tumors (RECIST, Version 1.1) guideline.
Safety Endpoints:
Part A
Adverse events (AEs), serious adverse events (SAEs), assessments of clinical and laboratory values, and vital 
signs measurements following a single dose administ ration of pevonedistat at 50 mg/m2.
Part B
AEs, SAEs, assessments of clinical and laboratory values, and vital signs measurements following administration 
of pevonedistat in combination with either docetaxel or carboplatin+paclitaxel.
Statistical Consider ations:
Statistical analy ses will be primarily descriptive and will be listed and/or summarized in tabular and/o r graphical form. 
No formal statistical hypothesis testing will be performed. A formal statistical analysis plan will be developed and 
finalized before database lock. 
Demographic and baseline characteristics will be summarized, including sex, age, race, ethnicity, weight, height, bod y 
surface area (BSA), baseline disease characteristics, and other parameters as appropriate.
All available efficacy and safety  data will be included in data listings and/or tabulations and/or graphs.
Individual values and descriptive statistics of pevonedistat plasma concentration time data and PK parameters 
including but not limited to CL, V ss, and t 1/2zwill be listed and tabulated by Day 1 (pevonedistat in the absence of 
rifampin) and Day 10 (pevonedistat in the presence of rifampin).
For pevonedistat -rifampin drug -drug interaction assessment, the ratios of geometric mean C max, AUC last, and AUC ∞of 
pevo nedistat in the presence of rifampin versus C max, AUC last, and AUC ∞in the absence of rifampin and associated 
90% CIs will be calculated.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 16of 102
Protocol Incorporating Amendment 02 04 September 2018
Sample Size Justification: The sample size calculation is based on the expected two -sided 90% CI for the difference 
in the paired, log -transformed area under the plasma concentration -time curve (AUC) (or C max) means of pevonedistat 
co-administered with rifampin and pevonedistat adm inistered alone. Based on the preliminary data obtained from 
Study C15011, the within -subject coefficient of variation was estimated to be 13% for AUC and 58% for C max, 
respectively. Assuming the AUC (or C max) ratio is 1.0, with a sample size of 12 evaluab le patients, the 90% CI of the 
ratio of geometric means is expected to be (0.907, 1.102) for AUC and (0.671, 1.49) for C maxbased on the previousl y 
discussed variance assumptions. If the ratio is X, the 90% CI of the ratio of geometric means is expected to be within 
(0.907X, 1.102X) and (0.671X, 1.49X), respectively. Patients who are not PK evaluable will be replaced to ensure 
availability  of approximately 12 PK-evaluable patients for the final analysis.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 17of 102
Protocol Incorporating Amendment 02 04 September 2018
3.0 STUDY REFERENCE INFO RMATION
3.1 Study -Related Responsib ilities 
The sponsor will perform all study -related activit ies wi th the except ion of those i dentified in the 
Clinical Study  Supplier List. The i dentified vendors in the template for specific study -related 
activit ies will perform these act ivities in full orin partnership with the sponsor.
3.2 Principal Investigator
Takeda will select a Signatory Coordinating Investigator fro m the invest igators who participate in 
the study . Selection criteria for thi s investi gator will include significant knowledge of the study  
protocol , the study  medicat ion, thei r experti se in the therapeutic area and the conduct of clinical 
research as well as study participat ion. The Signatory Coordinat ing Investigator will be required to 
review and sign the clinical study  report and by  doing so agrees that it accurately  describes the 
resul ts of the study .
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 18of 102
Protocol Incorporating Amendment 02 04 September 2018
3.3 List of Abbreviations
AE adverse event
ALP alkaline phosphatase
ALT alanine aminotransferase
AML acute my eloid leukemia
ANC absolute neutrophil count
aPTT activated partial thromboplastin time
AST aspartate aminotransferase
AUC area under the plasma concentration -time curve
AUC ∞ area under the plasma concentration versus time curve from time 0 to infinity
AUC last area under the plasma concentration -time curve from time 0 to time of the last quantifiable 
concentration 
BCRP breast cancer resistance protein
BP blood pressure
BSA body surface area
CDLs cullin -dependent ubiquitin E3 ligases
CL total clearance afte r intravenous administration
Cmax maximum observed plasma concentration
CR complete response
CrCl creatinine clearance
CRO contract research organization
CT computed tomography
CYP cytochrome P -450
DDI drug-drug interaction
ECG electrocardiogram
ECOG Eastern Cooperative Oncology Group
eCRF electronic case report form
EOS end of study
FDA Food and Drug Administration
FSH follicle -stimulating hormone
GCP Good Clinical Practice
GFR glomerular filtration rate
GI gastrointestinal
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonisation
IEC independent ethics committee
IRB institutional review board
IV intravenous
LVEF left ventricular ejection fraction
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 19of 102
Protocol Incorporating Amendment 02 04 September 2018
MRI magnetic resonance imaging
MTD maximum tolerated dose
NAE NEDD8 -activating enzyme
NCI CTCAE Natio nal Cancer Institute Common Terminology Criteria for Adverse Events
NEDD8 neural precursor cell expressed, developmentally down -regulated 8
NPO nothing -by-mouth (nil per os)
NSCLC non–small cell lung cancer
Pgp P-glycoprotein
PD progressive disease
PK pharmacokinetic(s)
PR partial response
PTA post trial access
PTE pretreatment event
QD once daily
QTc corrected QT interval
RECIST Response Evaluation Criteria in Solid Tumors
RBC red blood cell
RP2D recommended phase 2 dose
SAE serious adverse event
SC subcutaneous
SD stable disease
SOC standard of care
SOE Schedule of Events
SUSAR suspected unexpected serious adverse reaction
t1/2z terminal disposition phase half -life
TEAE treatment -emergent adverse event
ULN upper limit of normal
USP United States Pharmacopeia
USPI United States package insert
Vss volume of distribution at steady state after intravenous administration
WBC white blood cells
3.4 Corporate Identification 
Millennium Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda 
Pharmaceutical Company Limited.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 20of 102
Protocol Incorporating Amendment 02 04 September 2018
4.0 INTRODUCTION
4.1 Background
Pevonedistat is a cy totoxic agent and cannot be administered to healthy subjects. Pevonedistat is 
currently in phase 2/3 of clinical development for higher -risk myelodysplast ic syndro mes, chronic 
myelo monocy tic leukemia, and low -blast acute myelo id leukemia (AML). The recommended 
phase 2 dose (RP2D) of pevonedistat administered as a single agent in pat ients with advanced 
hematol ogic malignancy  is 50 mg/m2on Days 1, 3, and 5 in 21 -day cycles. In solid tumors, the 
maximum tolerated dose (MTD) and RP2D of pevonedistat in combinat ion with docetaxel is 
25mg/m2pevonedistat dosed on Days 1, 3, and 5, and do cetaxel 75 mg/m2on Day 1 in 21- day 
cycles. The MTD and RP2D of pevonedistat in combinat ion with pacli taxel+carbopl atin is 
20mg/m2pevonedistat dosed on Days 1, 3, and 5 and 175 mg/m2pacli taxel+carboplatin (AUC5) 
on Day 1 in 21- day cycles.
4.1.1 Study Drug
Pevonedistat (TAK -924/MLN4924) is a first -in-class, small mo lecule inhibitor of neural precursor 
cell expressed, developmentally down -regul ated 8 (NEDD8) -activat ing enzyme (NAE) under 
development for the treatment of malignancies. NAE, an E1 ligase, is an ess ential component of 
the NEDD8 conjugat ion pathway  that controls the activit y of a subset of ubiquit in E3 ligases, 
multiprotein co mplexes that transfer ubiquit in molecules to protein substrates that are then 
targeted to the proteasome for degradation. Culli n-dependent ubiquit in E3 ligases (CDLs) require 
conjugation to NEDD8 to be activated. CDLs control the timely ubiquit ination and consequent 
proteasomal degradat ion of proteins wit h important roles in cell cycle progression and signal 
transduction, cellular processes that are integral to tumor cell growth, proliferat ion, and survival. 
Inhibitors of NAE activit y may be of therapeutic value in the treatment of various cancers, such as 
solid tumors, by  inhibi ting the degradati on of  a subset of proteins that are
regulated by  the 
proteasome. Pevonedistat treatment results in tumor growth inhibit ion in mouse tum or xenografts 
models.
4.1.2 Nonclinical Background Information
Pevonedistat is a potent and selective inhibitor of NAE activit y. Pevonedistat also inhibits human 
carbonic anhydrase II, which may  explain the extensive part itioning of pevonedistat in red blood 
cells (RBCs) that has been observed in animal species and humans (see the current Invest igator’s 
Brochure [IB]).
Pevonedistat demonstrated antitumor activit y in xenograft m odels when administered to 
immunocom promised mice by  the subcutaneous (SC) route. The degree of the pharmacodynamic 
effect in HCT -116 xenograft tumors was dose dependent and correlated with dose -dependent 
antitumor activit y after 21 consecut ive days of twice -daily  treatm ent. Pevonedistat also 
demonstrated a dose -dependent pharmacodynamic response in addit ional xenograft models (AML 
model HL-60, the Cal u-6 lung tum or model, and 2 xenograft models o f diffuse large B cell 
lympho ma: OCI -Ly10 and OC I
-Ly19). Pevonedistat demonstrated antitumor activit y in these 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 21of 102
Protocol Incorporating Amendment 02 04 September 2018
models with less frequent treatm ent, showing that continuous dosing is not necessary for antitumor 
activit y.
Pevonedistat showed medium permeabilit y in Caco -2 cells.
Plasma clearance ranged fro m relatively low in chimpanzees, to moderate in dogs and monkeys, to 
relatively high in rats. The plasma terminal disposition phase half -life (t 1/2z), calculated as ln(2)/λz, 
varied fro m <1 hour in rats to approximately 15 hours in mo nkeys.
The m ajor elimi nation pathway  of pevonedistat in animals is through the hepat ic route. Urinary 
excret ion of unchanged pevonedistat was negligible in rats, monkeys, and chimpanzees. After an 
intravenous (IV) dose of [14C]-pevonedistat, radioactivit y was primarily  excreted in the feces in 
intact rats and in the bile in bile duct cannulated rats; excret ion was almo st com plete by  24 hours 
postdose. No plasma metabo lite accounted for more than 10% of the total plasma radioactivit y, 
suggest ing potentially low systemic exposure to metabolites.
Detailed informat ion regarding the nonclinical pharmaco logy and toxico logy of pevonedistat ma y 
be found in the current IB.
4.1.3 Clinical Background Information
4.1.3.1 Clinical Pharmacokinetics
Popul ation pharmacokinet ic (PK) analysis was conducted using data fro m pevonedistat 
single- agent studi es (C15001, C15002, C15003, and C15005) and pevonedistat in combinat ion 
with standard- of-care chemotherapy  (C15009 and C15010) in pat ients with solid tum or or 
hematol ogical malignancies. The database contained 335 subjects contribut ing 3768 PK 
observat ions. Pevonedistat plasma concentration -time profiles were well described by a 
2-compartment m odel with linear eliminat ion. Body surface area (BSA) was an important 
predi ctor of total  clearance after intravenous a dministrati on (CL), distribut ional clearance, and 
both central and peripheral vo lumes. For a typical  patient with a BSA of 1.73 m2, an alpha half -life 
of 1.27 hours and a beta (eliminat ion) half -
life of 7.85 hours are estimated. Concurrent 
administration o f carboplatin and paclitaxel decreased the CL of pevonedistat by  approximately  
44%, translat ing to an approximately 80% higher pevonedistat exposure (area under the plasma 
concentration -time curve [AUC]) during coadministration with carboplat in and paclita xel, 
consistent with pevonedistat concentration data observed in C15010. Coadministration with 
azacit idine, gemcitabine, or docetaxel did not appear to affect the CL of pevonedistat. Race, sex, 
age, tumor ty pe (hematol ogic vs solid), mild or moderate renal impairment (creatinine clearance 
[CrCl ] ≥30 mL/minute), or mildly impaired liver funct ion, to the extent represented in this dataset, 
had no impact on pevonedistat PK.
In a drug-drug interaction (DDI) study  (C15011), preliminary data from 26 evaluable pat ients 
(13from the itraconazole arm and 13 from the fluconazole arm) demo nstrate that steady -state 
exposures to fluconazo le had a minimal effect on the single -dose IV pevonedistat PK at 8 mg/m2, 
while mean systemic exposure to pevonedistat increased by app roximately  23% in the presence o f 
itraconazo le.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 22of 102
Protocol Incorporating Amendment 02 04 September 2018
On the basis of these observat ions, addi tional patients were enrolled to evaluate the effects of 
itraconazo le on pevonedistat PK at the clinical dose of 20 mg/m2. Preliminary  data f rom 
11patients who complet ed protocol -specified dosing and PK evaluat ions indicated that 
pevonedistat sy stemic exposures fo llowing IV administration at 20 mg/m2in the presence of 
itraconazo le were similar to those in the absence of itraconazo le (geo metric mean rati o of 0.996 
with an associ ated 90% CI of 0.913 and 1.09). These findings with established moderate and 
strong cy tochrom e P-450 (CYP)3A inhibitor probes indicate a minor contribut ion of CYP3A to 
pevonedistat metabo lism in humans. On the basis of these results, moderate and strong CYP3A 
inhibitors and P-glycoprotein ( Pgp) inhibitors can be used in pat ients receiving pevonedistat. For 
individual studies in the pevonedistat clinical program, reference should be made to the respective 
protocol s for specific information relating to excluded and permitted medicat ions.
4.1.3.2 Clinical Experience
As of 22 January  2017, the clinical development program includes 9 clinical studies in pat ients 
with advanced malignancies. Four of the 9 clinical studies are completed phase 1 monotherapy  
studi es (C15001, C15002, C15003, and C15005) and 5 are ongoing phase 1/1b/2 studi es (Studi es 
C15009, C15010, C15011, Pevonedistat -1012, and Pevonedistat -2001). Pevonedistat is under 
development as a component of regimens with azacit idine (Study C15009, Pevonedistat- 1012, and 
Pevonedistat -2001) and with docetaxel or in co mbinat ion with carbopl atin and paclitaxel 
(Study C15010), and DDIs of pevonedistat with fluconazole or itraconazole (Study  C15011). Per 
the data available as of 22 January 2017, a total  of approxima tely 451 patients received at least 
1dose of pevonedistat in the overall clinical development program.
4.1.4 Potential Risks and Benefits
Pevonedistat will be administered in Part A of this study as a single 1 -hour IV infusio n at 50 mg/m2
on Day s 1 and 10. Pati ents will also receive rifampin (Days 3 through 11), a strong CYP3A 
inducer. In vitro, pevonedistat is predominant ly metabolized by the CYP isozyme 3A4; however, 
the in vivo contribut ion of CYP3A to overall clearance is inferred to be minimal, based on the lack 
of clinically meaningful effect of the strong CYP3A inhibitor itraconazole on pevonedistat PK. 
Because this is an induct ion DDI evaluat ion, it is hypothesized that the exposures of pevonedistat 
may be decreased upon co -administration with rifampin. T he safet y profile of this combination 
(pevonedistat+rifampin) is not known at this t ime.
It is anticipated that the chemotherapies used in Part B of this study may provide clinical benefit to 
patients. Study  C15010 was an open -label, phase 1b study  whose pri mary  objective was to 
establish the MTD and assess the safet y and tol erabili ty of pevonedistat in co mbinat ion with 
docetaxel, carboplat in, paclitaxel+carboplat in, or gemcitabine in patients with solid tumors. As of 
22 January 2017, enrollment was complet e. As of October 2017, 2 patients in complete response 
(CR) (still act ive in cycles 43+) remain on the study.
Data are available for 64 patients who received at least 1 dose of pevonedistat in co mbination wit h 
standard of care (SOC) (data cutoff: 15 Februa ry 2016). The safet y profile of pevonedistat in 
combinat ion with docetaxel (75 mg/m2), in pat ients with solid tumors was favorable, and the study 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 23of 102
Protocol Incorporating Amendment 02 04 September 2018
objective to establish the MTD for pevonedistat (25 mg/m2on Days 1, 3, and 5 of a 21 -day 
treatm ent cycle) was achieved. The safet y profile of pevonedistat in combinat ion with pacli taxel  
(175 m g/m2) and carbopl atin (AUC5) in patients wit h solid tumors was favorable. No new safet y 
signals were observed for pevonedistat in this study  com pared to an earlier so lid tum or study of 
pevonedistat as a single agent.
The most commo n (any grade) adverse event (AE) for patients in Arm 1 (pevonedistat+docetaxel) 
and Arm 2 (pevonedistat+carboplat in+paclitaxel) were fat igue (55%, 65%), nausea (36%, 54%), 
diarrhea (41%, 42%), anemi a (32%, 46%), const ipation (18%, 42%), increased aspartate 
aminotransferase (AST) (27%, 35%), vomit ing (18%, 42%), and alopecia (23%, 38%), 
respectively . For patients who had an AE ≥Grade 3 in Ar m 1 and Ar m 2, the most commo n events 
were decreased neutrop hil count (27% each arm) and increased AST (18% and 23%), respectively.
Of the 54 response -evaluable pat ients diagnosed wit h a solid tumor, responses o f stable disease 
(SD) or better were observed in 41 patients. Twelve patients experienced a best response of CR or 
partial response (PR); 15.8% in response -evaluable pati ents in Arm 1 (pevonedistat+docetaxel) 
and 34.8% in Arm 2 (pevonedistat+paclitaxel+carboplat in). For patients treated in Arm 2 
(pevonedistat+paclitaxel+carboplat in), the median duration of re sponse (CR and PR) was 
7.375 months or 10 cy cles (8 pati ents); and for Arm 1 (pevonedistat+docetaxel), the median 
durati on of  response (PR) was 3.060 months or 5 cycles (3 patients). For the 12 patients with a 
response of CR or PR, the time to response was between 1 and 3 months in all treatment arms. 
Two patients achieved a best response of CR that, at the time of data cutoff (15 February 2016), 
had durations of 6.57 (9 cycles) and 8.48 months (11 cycles), respectively , indicating that with 
repeat cy clic d osing of pevonedistat in co mbinat ion with pacli taxel+carbopl atin a complete 
response was feasible for at least 11 cycles.
The addit ional benefit in response rate derived from the co mbinat ion of pevonedistat and SOC 
compared to historical data from SOC did not appear to be associated with addit ional toxicit y with 
the except ion of increased liver function tests. Broad -based activit y in the various tumor ty pes 
offers clinical benefit in variet y of patient populat ions, including pat ients with adenocarcinoma 
andsquamous carcino ma.
4.1.4.1 Risks of Pevonedistat Therapy
Safety informat ion gained fro m single- agent clinical  studi es of pevonedistat and from toxicology  
studi es in rats and dogs has been used to guide the safet y evaluat ion of pevonedistat. Addit ional 
inform ation on ri sks is provided in the current IB, which includes the development core safet y 
inform ation.
The ri sks of pevonedistat treatment, based on preliminary  findings from  the single -agent clinical 
studi es and the toxicit ies noted in the toxico logy studi es done in rats and dogs, are presented 
below. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 24of 102
Protocol Incorporating Amendment 02 04 September 2018
Identified Risks
Increased heart rate.
Diarrhea.
Nausea.
Vomit ing.
Pyrexia.
Liver function test abnormal.
Musculoskeletal pain.
Myalgia.
Potential Risks
There are potential risks in the pevonedistat program that requi re further m onitoring. While the 
potenti al toxi cities listed below may be severe or life -threatening, it is ant icipated that they can be 
managed by  clinical  monitoring and intervent ion. Pati ents will  be monitored f or these potential 
toxicities and for unant icipated toxi cities for at l east 30 days after their last dose of pevonedistat.
Potential Risks From Phase 1 Studies (at High Doses)
There are events that have been reported in phase 1 studies at doses and schedules substantially 
higher ( ≥110 m g/m2) than those being used in current clinical studies of pevonedistat. These 
events are considered potential risks for the doses and schedules proposed in this study .
Multi-organ failure that could result in death.
Renal failure. 
–The events of mult i-organ failure (hepat ic, renal, and cardiac) with a fatal outcome, and 
renal failure alone, have been reported at doses of pevonedistat ranging fro m 110 to 
278mg/m2. Ref er to the current IB for additional informat ion about m ulti-organ failure 
and dosing.
Cardi ac ar rhythmias.
–All events were supraventricular arrhy thmias; all except 1 were unrelated. The case of 
atrial fibrillat ion, assessed by  the invest igator as related, occurred in a pat ient with a risk 
factor for cardiovascular disease (uncontrolled hypertension).
Myel osuppressi on with increased suscept ibility to infect ion, bleeding, and anemia.
Acute phase response.
Gastrointestinal (GI) toxicit y including or result ing in dehydrat ion and electrolyte imbalance.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 25of 102
Protocol Incorporating Amendment 02 04 September 2018
Hypophosphatemia.
Potential Risks Confounded by Underl ying Disease or Malignancy
Events have been reported fro m clinical studies that are confounded by the patients’ underlying 
medical condit ions, including malignancy. These events are noted in the absence of rando mized, 
controlled data:
Fatigue.
Chills.
Decr eased appet ite.
Neutropenia.
Febrile neutropenia.
GI bl eeding.
–All events were assessed by the investigator as unrelated; most occurred in the setting of 
thrombocy topenia.
Multi-organ failure in the setting of infect ion.
Potential Risks Primarily Based on Findings From Animal Studies
Potenti al risks that are derived from findings in animal studies in rats and dogs include the 
following:
Myocardial  degenerat ion and thrombosis.
Pulmo nary hypertensio n.
Cardi ovascular changes that could result in tachycardia, decreased or increased systo lic blood 
pressure (BP), and increased diastolic BP.
Enteropathy  (incl uding dehydrat ion and electrolyte loss) with secondary sepsis.
Effects on the testes and ovaries that represent a reproductive hazard, including sterilit y.
Increased developmental risk to the fetus or embryo.
Decreased trabecular bone (graded minimal to moderate) noted in the femur and in the sternu m 
in rats at all dose groups (low, medium, and high) but not in dogs. This finding was considered 
adverse in the h igh-dose group; however, no bone fractures were noted at any  of the doses.
Prolongati on of  the act ivated partial thromboplastin time (aPTT).
Local  tissue injury when administered SC.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 26of 102
Protocol Incorporating Amendment 02 04 September 2018
It is possible that pevonedistat will have toxicit ies, which may be sever e or fatal , that were not 
observed in or predicted fro m the studies completed in rats and dogs or have not yet been ident ified 
in patients.
Hepatotoxicit y has been noted following administration o f pevonedistat in pat ients with advanced 
malignancy, including elevat ions of liver transaminases, alkaline phosphatase (ALP), and 
bilirubin. Liver enzymes and liver funct ion are frequent ly monitored during clinical studies of 
pevonedistat. Acetaminophen and acetaminophen -containing compounds may be used judi ciously 
and should not exceed a dose of 2 g of acetaminophen in a 24 -hour peri od (see Secti ons 8.4and 
8.5).
Patients m ust be carefully  evaluated at screening and before each pevonedistat dose for early  
symptoms and signs of hemodynamic co mpromise or active infect ion. Parti cular attenti on shoul d
be paid to unexplained fever, tachycardia, hypotension, orthostasis, tachy pnea, recent nausea and 
vomiting, and clinical evidence o f dehydrat ion. Guidance on rehydrat ion is provided in 
Secti on8.7.1 .
These potential toxicit ies will be managed by careful, frequent monitoring and intervent ion, as 
needed, wi th supportive care. It is possible that pevonedistat will have toxicit ies that were not 
observed in or predicted fro m the studies completed in rats and dogs or have not yet been ident ified 
in patients.
This study  will be conducted in com pliance wi th the protocol , Good Clinical Practice (GCP), and 
the applicable regulatory  requi rements (incl uding Inte rnational Council for Harmonisat ion [ICH] 
guidelines).
4.1.4.2 Risks of Docetaxel Treatment
Details of risks related to docetaxel treatment are provided in the applicable United States package 
insert (USPI).
4.1.4.3 Risks of Pevonedistat and Docetaxel as Combination Therapy
The fo llowing potenti al risks, based on the known individual safet y profiles of pevonedistat and 
docetaxel, of co mbination therapy may apply: death, hypersensit ivity, hepatotoxicit y, neutropenia, 
and fluid retention (cardiac/pulmo nary). Wi th regard to d ocetaxel, treatment related mortalit y 
increases wit h abnormal liver funct ion, at hi gher doses, and in patients with non –small  cell lung 
cancer (NSCLC) who received prior plat inum -based therapy  receiving docetaxel  at 100 m g/m2.
4.1.4.4 Risks of Carboplatin and Pacl itaxel Therapy
Details of risks related to carboplat in and paclit axel therapy  are provi ded in the applicable USPIs.
4.1.4.5 Risks of Pevonedistat and Carboplatin+Paclitaxel as Combination Therapy
The fo llowing potenti al risks, based on the known individual safet y profiles of pevonedistat and 
carbopl atin+paclitaxel, of co mbination therapy may apply: bone marrow suppression, 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 27of 102
Protocol Incorporating Amendment 02 04 September 2018
hypersensit ivity/anaphylaxis react ions, and hepatotoxicit y. Renal  effects of nephrotoxic 
compounds [1](see  Appendix E) may be potenti ated by  carbopl atin. 
Given limited exist ing clinical experience, it is not known whether patients will benefit fro m 
participat ion in this study . However, a number of patients wi th solid tum ors treated wi th 
pevonedistat as a single agent did demonstrate clinical benefit based primarily on prolonged SD. In 
addition, it is ant icipated that the SOC therapies used in Part B of this study may provide addit ional 
clinical ben efit to patients. Forty -eight patients have been treated with pevonedistat in combinat ion 
with docetaxel , carbopl atin, or carboplat in+paclitaxel. On the basis of preliminary data, these 
combinat ions have shown evidence o f clinical benefit in the form of mu ltiple PRs, limited CRs, 
and extended durations of SD.
4.2 Rationale for the Proposed Study
The primary  object ive of this study  is to eval uate the effects of rifampin, a strong metabolic 
enzyme inducer, on the PK of pevonedistat. Pevonedistat is predo minantly cleared via 
metabo lism, based on in vitro and nonclinical in vivo data, and is also a substrate for the drug 
transporters Pgp and breast cancer resistance protein (BCRP). Strong inducers of metabo lic 
enzymes and transporters, such as rifampin may be expect ed to result in decrease pevonedistat 
exposures and reduced efficacy . Current clinical studi es prohibi t use of  strong enzyme inducers 
(eg, rifampin, carbamazepine, phenyto in). The results of this study will inform the risk assessment 
for potenti al DDIs wi th conco mitant use of strong metabo lic enzyme inducers during the clinical 
development of pevonedistat.
4.2.1 Rationale for Dose and Duration of PK Assessments in Part A
The pevonedistat dose of 50 mg/m2selected to be evaluated in this study  is based on the 
consideration of 50 mg/m2as the RP2D of pevonedistat in the monotherapy setting and dose -linear 
PK of pevonedistat that should permit translat ion of the results of this study  (ie, est imated 
magnitude of DDI) to lower doses such as those used in combinat ion settings (eg, 20 mg/m2in 
combinat ion with azaci tidine). Approximately  12evaluable pat ients will be required to provide 
the protocol -specified dosing and PK data in order to permit adequate assessment of the effects of 
rifampin on single -dose pevonedistat P K.
The eliminat ion half -life o f pevonedistat is approximately 9 hours. Serial PK sampling up to 
48hours fo llowing pevonedistat single dosing on Day 1 and Day 10 permits characterizat ion of 
PK profiles of pevonedistat in the absence (Day 1) and in the presence (Day 10) of  rifampin. 
Patients will  begin to receive once daily  (QD) doses of oral  capsules of 600 mg rifampin on 
Days 3through 11 in order to achieve steady -state of enzyme induct ion. The duration of PK 
assessment in Part A is approximately 12 days.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 28of 102
Protocol Incorporating Amendment 02 04 September 2018
4.2.2 Rationale for Continued Treatment With Pevonedistat in Combination With 
Chemotherapy in Optional Part B
After complet ing Part A, patients will have the optio n to continue in the study  by parti cipating in 
Part B, where they  will receive combinat ion treatment with pevonedistat and chemotherapy. Two 
chemotherapy regimens, docetaxel and carboplatin+paclitaxel, which have been previously 
studi ed as combinat ion partners with pevonedistat, will be used in this study . On the basis of the 
MTDs determined in Stu dyC15010, pati ents will receive pevonedistat 25 mg/m2in combinat ion 
with docetaxel  75mg/m2or pevonedistat 20 mg/m2in co mbination wit h carboplat in 
AUC5+paclitaxel 175 mg/m2.
Docetaxel is indicated as a single agent for locally advanced or metastatic br east cancer and for 
locally advanced or metastatic NSCLC after plat inum therapy failure. 
Paclitaxel is indicated for the treatment of breast cancer after failure of co mbinat ion chemotherap y 
for metastati c disease or rel apse wit hin 6 mo nths of adjuvant che motherapy . Pacli taxel is also 
indicated for the second -line treatment of acquired immunodeficiency syndrome –related Kaposi’s 
sarcoma. In addit ion, paclitaxel in co mbinat ion with cisplat in is indicated for the first -line 
treatm ent of NSCLC in patients who a re not candidates for potentially curative surgery and/or 
radiation therapy .
Carbopl atin is indicated for the init ial treatment of advanced ovarian carcino ma in co
mbinat ion 
with other approved chemotherapeut ic agents (1 established co mbinat ion regimen cons ists of 
carbopl atin and cyclophosphamide). Carboplat in is also indicated for the palliat ive treatment of 
patients wi th ovari an carcino ma recurrent after prior chemotherapy , including pat ients who have 
been previously treated with cisplat in.
Docetaxel and pacli taxel+carbopl atin are also approved in combinat ion with other 
chemotherapeut ic agents to treat other indicat ions; refer the applicable USPIs.
In addit ion to the approved indicat ions outlined above, these agents are widely used to treat a 
variet y of malignancies in patients for whom prior therapies have failed. Paclitaxel+carboplat in is 
also wi dely used to treat patients with newly  diagnosed NSCLC.
For a detailed description o f each of these medicat ions, see Section 8.9. The cho ice o f the above 
chemotherapy agents in combinat ion with pevonedistat in this study  is based on the following 
considerations:
These chemotherapy agents have been well recogn ized as SOC in a number of malignancies in 
first-line (carboplat in+paclitaxel) or in various relapse settings (both regimens).
The safet y profiles, risks, and benefits have been widely studied and reported.
Addit ive/synergist ic effects of these agents in c ombinat ion with pevonedistat have been studied in 
a number of in vitro and in vivo models by  the sponsor.
The MTD and RP2Ds have been determined for the combinat ion of pevonedistat+docetaxel and 
pevonedistat+carboplat in/paclitaxel.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 29of 102
Protocol Incorporating Amendment 02 04 September 2018
Therefore, it is conside red that the above chemotherapy agents will serve as reasonable partners in 
combinat ion with pevonedistat for invest igations in patients with various so lid tumors in this 
study .
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 30of 102
Protocol Incorporating Amendment 02 04 September 2018
5.0 STUDY OBJECTIVES AND ENDPOINTS
5.1 Objectives
5.1.1 Primary Objectives
The primary  objec tive is to assess the effect of multiple -dose administration o f rifampin on the 
single- dose PK of pevonedistat in adult patients with advanced solid tumors (Part A).
5.1.2 Secondary Objectives
The secondary  objectives are as follows:
Part A
To further characteri ze pevonedistat PK fo llowing a single dose at 50 mg/m2in the absence 
or presence of rifampin.
Part B
To evaluate disease response that may be observed fo llowing treatm ent wi th pevonedistat 
in combinat ion with either docetaxel  or carbopl atin+paclitaxel in patients wi th advanced 
solid tumors.
5.1.3 Safety Objectives
The safet y object ive for Part A is to evaluate the safet y and tolerabilit y of pevonedistat i n pat ients 
with advanced so lid tumors fo llowing a single IV dose at 50 mg/m2in the absence or presence of 
rifampin.
The safet y objective for Part B is to evaluate the safet y and tol erabilit y of pevonedistat in 
combinat ion with either docetaxel or carboplat in+paclitaxel in pat ients with advanced so lid 
tumors.
5.1.4 Exploratory/Additional Objectives
None.
5.2 Endpoints
5.2.1 Primary Endpoint
The primary  endpoint of the study  is the rati os of  geom etric mean pevonedistat maximum 
observed plasma concentration (C max), area under the plasma concentration -time curve fro m time 
0 to time of the last quantifiable concentration (AUC last), and area under the plasma concentration 
versus time curve from time 0 to infinit y (AUC ∞) in the presence of rifampin in reference to C max, 
AUC last, and AUC ∞in the absence o f rifampin and associated 90% confidence intervals (CIs).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 31of 102
Protocol Incorporating Amendment 02 04 September 2018
5.2.2 Secondary Endpoints
The secondary  endpoints are as follows:
Part A
PK parameters: CL, vo lume of distribut ion at steady -state after intravenous administratio n 
(Vss), and t 1/2zof pevonedistat fo llowing a single dose administration of 50 mg/m2on 
Day 1 (in the absence of rifampin ) and Day 10 (in the presence of rifampin).
Part B
Measures of disease response based on the invest igator’s assessment using the Response 
Evaluat ion Cri teria in Solid Tumors (RECIST, Version 1.1) guideline.
5.2.3 Safety Endpoints
The safet y endpo ints for Part A of this study is AEs, serious adverse events (SAEs), assessments of 
clinical laboratory values, and vital signs measurements fo llowing a single -dose IV administratio n 
of pevonedistat at 50 mg/m2in the absence or presence of rifampin. The safet y endpo int for Part B 
of this study is AEs, SAEs, assessments of clinical laboratory values, and vital signs measurements 
following administration of pevonedistat in co mbinat ion with either docetaxel or 
carbopl atin+paclitaxel.
5.2.4 Exploratory/Additional Endpoints
There ar e no exploratory  or addi tional endpoints in this study .
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 32of 102
Protocol Incorporating Amendment 02 04 September 2018
6.0 STUDY DESIGN
6.1 Overview of Study Design
This i s a 2-part, open -label, DDI study  in adult patients who have a histologically or cytologically 
confirmed metastatic or locally advanced solid tumor that is appropri ate for treatm ent wi th 
pevonedistat in combinat ion with either docetaxel or carboplat in+paclitaxel in Part B of this study, 
or have progressed, despite standard therapy , or f or whom  convent ional therapy is not considered 
effect ive. Approximately 20 patients will be enrolled to obtain approximately 12 PK-evaluable 
patients.
Eligible pat ients will receive a single dose of 50 mg/m2pevonedistat via a 1 -hour IV infusio n on 
Day 1. Plasma PK samples will be co llected at a series of predetermined time poin ts up to 48 hours 
(Day  3) following the single dose of pevonedistat. Patients will then receive an oral dose of 600 mg 
rifampin QD starting fro m Day 3 (after collect ing the 48 -hour PK sample) through Day  11. There 
will be no pevonedistat doses from Day 2 t hrough Day 9. On Day 10, a single dose of 50 mg/m2
pevonedistat will be administered, and plasma samples will be co llected at predetermined time 
points up to 48 hours (Day  12) fo llowing the second single dose of pevonedistat. Study  drug will 
be discont inued early  if a pati ent experi ences study drug ‒related toxicit ies.
Patients m ay discontinue therapy  at any  time, for any reason. Patients in Part A who do not
continue to the optional Part B will attend an End of Study  (EOS) visit 30 (+10) day s after 
receiving their last dose of study  drug in Part A.
Both doses of pevonedistat (Day s 1 and 10) will be administered in the clinic, fo llowed by the 
requi red PK sampling. Serial blood plasma samples for determination o f the plasma concentration 
of pevonedista t will be obtained during Part A at prespecified t ime points as described in 
Appendix A, Table A . The first dose of rifampin will be given orally in the clinic on the morning 
of Day  3 after collect ion of the 48- hour PK sample. Patients will self -administer rifampin (oral 
capsules) QD on Day s 4, 5, 6, 7, 8 and 9 at home. Patients are encouraged to take rifampin at 
approximately  the same t ime each day (± 2 hours from the time of first rifampin dose). On Days 10 
and 11, patients will report to the clinic to continue to receive oral 600 mg rifampin 
co-administered with pevonedistat on Day 10, and at the time of the 24 -hour pevonedistat PK 
sampling on Day  11. T he last PK sam pling is on Day  12 (48 -hour post pevonedistat infusion on 
Day 10). There will be no pevonedistat dosing on Days 11 and 12. There will be no rifampin 
dosing on Day  12.
All doses o f rifampin will be administered on an empt y stom ach wi th patients taking 
nothing -by-mouth (NPO) except for water and prescribed medicat ions for 2 hours before and at 
least 1 hour after each rifampin dose. Patients who miss any rifampin doses on Days 3 to 9 will not 
be considered evaluable; hence, pevonedistat dosing an d PK sampling on Day  10 will  not be 
requi red for these patients. Patients will have a washout period fro m the last dose of rifampin for at 
least 1 week to allow reversal o f met abolic enzyme induct ion before the start of Part B of the study.
After complet ion of Part A of this study , patients will have the option of participat ing in Part B. 
Any patient who decides to participate in Part B will need to meet the continuation criteria
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 33of 102
Protocol Incorporating Amendment 02 04 September 2018
(Secti on7.3) of the study  before treatm ent in Part B can begin. Pat ients will receive pevonedistat 
in combinat ion with either docetaxel  or carbopl atin+paclitaxel, as reco mmended by the 
investigator. As in Part A, safet y asses sments will also be conducted in Part B of the study . In 
addition, Part B will conduct disease assessments using radio logical  evaluati ons (com puted 
tomography  [CT] scan or m agnet ic resonance imaging [MRI]).
The Schedule of Events (SOEs) for Part A and Part B are provided in Appendix A. Toxicit y will be 
evaluated according to National Cancer Inst itute Commo n Termino logy Criteria for Adverse 
Events (NCI CTC AE), Version 4.03, effect ive date 14 June 2010 [2]. AEs will be assessed, and 
laboratory  values and vital signs will be obtained to evaluate the safety  and tol erabilit y of 
pevonedistat. See
 Figure 6.afor an overview of the study  design of Parts A and B.
Figure 6.a Study Overview
D=day .
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 34of 102
Protocol Incorporating Amendment 02 04 September 2018
6.2 Number of Patients
Approximately  20 pati ents (for approximately  12 PK -evaluable pat ients) will be enro lled. A 
patient is considered to be enrolled when the first dose of any study drug has been administered. In 
Part A, patients who are withdrawn fro m treatm ent before com pleting protocol required 
procedures, or are not considered evaluable for Part A will be replaced. Four to 6 study  centers in 
the US will are planned to participate in the study .
6.3 Duration of Study
6.3.1 Duration of an Individual Patient’s Study Participation
6.3.1.1 Part A: PK Assessment
It is ant icipated that an individual pat ient will participate in this study for approximately 12 days in 
Part A, with an EOS visit 30 (+10) days after receivin g thei r last dose of study  drug to permit the 
detection of any delayed treatment -related AEs. If patients continue to the optional part of the 
study , Part B, they  will forgo the EOS visit after Part A and be evaluated per the Part B 
continuat ion criteria (see Section 7.3). At least 1 week washout will take place before the start of 
Part B.
6.3.1.2 Part B (Optional): Continued Treatment With Pevonedistat in C ombination With SOC 
Eligible pat ients will have the option to continue to receive treatment in Part B of this study  until 
discontinuat ion criteria are m et (see Secti on 9.6). If a pat ient chooses to continue to Part B, that 
patient may  enter Part B after meeting the entry  criteri a and wit hin approximately 1 week o f 
completing Part A; however, patients entering Part B must begin treatment within 1 to2weeks of 
completing Part A. The maximum durat ion of treatment will be 12 cy cles; however, if it is 
determined, after discussio n between the invest igator and the sponsor, that a patient would derive 
clinical benefit from cont inued treatment, the patient ma y remain on the current combinat ion 
therapy  or receive pevonedistat as a single agent bey ond 12 cycles.
After complet ion of at least 6 cy cles of treatm ent, pati ents will  be permi tted to take treatm ent 
breaks, at the invest igator’s discretion, that are no l onger than 2 weeks in durat ion (up to 4 weeks 
after consul ting wit h the sponsor); treatment breaks may not be taken consecut ively. The 
investigator will confirm pat ient eligibilit y for continued treatment (Section 7.3) upon return fro m 
a treatment break, before resuming treatment.
Patients who have achieved clinical benefit from combinat ion therapy  
(chemotherapy+pevonedistat) and who have developed i ntolerance that is reasonably attributable 
to the chemotherapy after 2 or more cycles may cont inue on single- agent pevonedistat at the same 
dose and schedule, upon request by  the investi gator and agreem ent by  the sponsor. 
Patients will attend an EOS visit 30 (+10) days (safety fo llow-up) after the last dose of study drug 
or before the start of subsequent therapy  for thei r indicat ion, if that occurs sooner.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 35of 102
Protocol Incorporating Amendment 02 04 September 2018
6.3.2 EOS/Study Completion Definition and Planned Reporting
The analyses for the clinical study  report m ay be conducted after all pat ients enro lled in the study  
have co mpleted Part A, to meet the primary  (PK assessment) obj ective of the protocol, or have 
discontinued treatm ent. Pati ents still on therapy  at thi s point will cont inue in the study  through 
their EOS visit. The est imated time frame for study co mpletion is approximately 18 months for 
Parts A and B co mbined.
6.3.3 Timeframes for Primary and Secondary Endpoints to Support Disclosures
Please refer to Table 6.afor disclosures information for primary  and secondary  endpoints for 
Part A and
 Table 6.bfor Part B, respectively.
Table 6.a Primary and Secondary Endpoints for Disclosures: Part A
Endpoint DefinitionMaximum Time Frame
(per Individual Patient)
Primary : Pevonedistat C max, AUC last, and AUC ∞geometric 
mean ratios in the presence of rifampin in reference to 
Cmax, AUC 0-last, and AUC ∞in the absence of rifampin 
(Section 5.2.1)DDI assessme nt, ratios of 
geometric mean, 90% CIs.Up to 12 days.
Secondary: PK parameters: CL, V ssand t 1/2zof 
pevonedistat following a single dose administration of 
50mg/m2on Day 1 (in the absence of rifampin) and 
Day 10 (in the presence of rifampin) (Section 5.2.2 ).DDI assessment, 
descriptive statistics of PK 
parameters.Up to 12 days.
Table 6.b Primary and Secondary Endpoints for Disclosures: Part B
Endpoint Definition Maximum Time Frame
Primary : not applicable Not applicable Not applicable
Secondary: To evaluate disease response that may be 
observed following treatment with pevonedistat in 
combinatio n with either docetaxel or 
carboplatin+paclitaxel in patients with advanced solid 
tumors (Section 5.2.2)Disease response to 
pevonedistat in 
combinatio n with SOC, 
based on the best overall 
response as determined by 
the investigator using 
RECIST Version 1.1 
guidelines.Up to 12 months, 
depending on patient 
response.(a)
(a) The maximum duration of treatment will be 12 cycles; however, if it is determined, after discussion between the 
investigator and the sponsor, that a patient would derive benefit from continued treatment, the patient may remain on 
the current combination therapy or receive pevonedistat as a single agent beyond 12 cycles.
6.3.4 Total Study Duration
It is ant icipated that this study  will last for approximately 18 months for Part A and Part B 
combined. The maximum duration of treatment in Part B will be 12 cycles; however, if it is 
determined, after discussio n between the invest igator and the sponsor, that a patient would derive 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 36of 102
Protocol Incorporating Amendment 02 04 September 2018
benefit from cont inued treatment, the patient may remain on the current combinat ion therapy  or 
receive pevonedistat as a single agent bey ond 12 cycles.
Patients who have achieved objective clinical benefit f rom combinat ion therapy  
(chemotherapy+pevonedistat) and who have developed intolerance that is reasonably attributable 
to the chemotherapy after 2 or more cycles may cont inue on single- agent pevonedistat at the same 
dose and schedule, upon request by  the i nvestigator and agreement by the sponsor.
6.3.5 Post Trial Access
Current ly, there is no post trial access (PTA) protocol available in the pevonedistat development 
program. If during conduct of the Pevonedistat -1015 study , an open -label, roll over PTA study  
shoul d becom e an opti on and the invest igator and the sponsor agree that a patient would derive 
benefit from cont inued treatment in Part B or would be harmed without continued access to the 
medicat ion, the pati ent m ay be given the opportunity  to enroll . Pati ents who participate in a 
rollover study  will be considered to have completed Study  Pevonedistat -1015. The patient would 
then be able to con tinue receiving his/her current study  treatm ent (combinat ion or single -agent 
pevonedistat).
6.3.6 Duration of PTA
In the event of a roll over PTA study , continued access to pevonedistat for participants will be 
terminated for those individuals who no longer benefit from treatment (eg, they  have com pleted 
the recommended course of therapy or their disease has improved or resolved), the benefit -risk no 
longer favors the individual, or an appropriate alternat ive therapy beco mes available. PTA may be 
terminated in a country  or geographi cal region where the development of pevonedistat has been 
suspended or stopped by  the sponsor, or pev onedi stat can no l onger be supplied.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 37of 102
Protocol Incorporating Amendment 02 04 September 2018
7.0 STUDY POPULATION
The patient populat ion for this study  will be adult patients who have a histologically or 
cytologically  confirmed metastati c or l ocally  advanced solid tum or that i s appropri ate for 
treatm ent wi th pevone distat in combinat ion with either docetaxel or carboplat in+paclitaxel in 
Part B of this study, or have progressed, despite standard therapy, or for whom convent ional 
therapy  is not considered effect ive. Confirmat ion of eligibilit y must be obtained before t he patient  
can enter the study . After com pletion of Part A, patients who elect to continue into the optional 
Part B m ust meet the cri teria for continuat ion listed in Sect ion 7.3.
7.1 Inclusion Criteria
Each patient must meet all the fo llowing inclusio n criteria to be enro lled in the study :
1.Male or female pat ients 18 years or older.
2.Adult patients who have a histologically  or cy tologically confirmed metas tatic or l ocally  
advanced so lid tumor that is appropriate for treatment with pevonedistat in co mbination wit h 
either docetaxel  or carboplatin+paclitaxel in Part B of this study , or have progressed despite 
standard therapy , or f or whom  conventi onal therapy  is not consi dered effective.
3.Eastern Cooperative Oncology  Group (ECOG) performance status of 0 to 1 ( Appendix D).
4.Expected survival o f at least 3 m onths from the date of enrollment in the study .
5.Recovered (ie, ≤Grade 1 toxicit y) fro m the effects of prior antineoplast ic therapy.
6.Clinical laboratory  values as specified below:
Hem oglobin ≥9 g/dL. Pati ents may  be transfused to achieve this value.
Total  bilirubin ≤ upper limit o f norm al (ULN).
Alanine aminotransferase (ALT), AST, and ALP ≤2.5×ULN.
–For patients to be treated with pevonedistat+docetaxel in Part B, AST and ALT must be 
≤1.5×ULN, and total bilirubin should be within the normal range.
Calculated CrC l ≥50 mL/min (CrCl is defined in Section 9.4.13 ).
Absolute neutrophil count (ANC) ≥1,500/mm3.
Platelet coun t ≥100,000/mm3.
Prothrombin t ime and aPTT ≤1.5×ULN.
Albumin ≥2.7 g/dL.
7.Suitable venous access for the study -requi red bl ood sam pling (including PK sampling).
8.Female pat ients who meet any of the fo llowing:
Are postm enopausal  for at l east 1 y ear before the screening visit (see Appendix F).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 38of 102
Protocol Incorporating Amendment 02 04 September 2018
Are surgically  sterile.
If they are of childbearing potential, they and their male partners agree to practice 1 highly 
effect ive method o f contraception (see Appendix G) and 1 addit ional effective (barrier) 
method at the same t ime, fro m the time of signing the informed consent through 4 months 
after the l ast dose of study  drug, or
Agree to practice true abst inence, when this is in line wit h the preferred and usual lifest yle 
of the subject. (Periodic abst inence [eg, calendar, ovulat ion, symptothermal, postovulat ion 
methods], withdrawal, sp ermicides only, and lactatio nal amenorrhea are not acceptable 
methods of contraception. Female and male condoms should not be used together.)
9.Male patients, even if surgically  sterilized (ie, status postvasectomy), who meet either of the 
following:
Agree t o practice effective barrier contraception during the ent ire study  treatm ent peri od 
and through 4 months after the last dose of study  drug, or
Agree to practice true abst inence, when this is in line wit h the preferred and usual lifest yle 
of the subject. (P eriodic abst inence [eg, calendar, ovulat ion, symptothermal, postovulat ion 
methods], withdrawal, spermicides only, and lactatio nal amenorrhea are not acceptable 
methods of contraception. Female and male condoms should not be used together.)
10.Patients who are willing to refrain fro m donat ing blood for at least 90 days after their last dose 
of pevonedistat and (for male patients) willing to refrain fro m donat ing semen for at least 
4months after their last dose of pevonedistat.
11.Voluntary  written consent must be given before performance o f any study -related procedure 
not part of standard medical care, with the understanding that consent may be withdrawn by 
the pati ent at any  time wi thout prej udice to future medical care.
7.2 Exclusion Criteria
Patients m eeting any o fthe following exclusio n criteri a are not to be enrolled in the study :
1.Inabilit y to comply with study visits and procedures including required inpat ient confinement.
2.Treatment with any systemic antineoplast ic therapy or any invest igational products within 
21days before the first dose of study  treatm ent.
3.Major surgery  within 14 days before the first dose of study  treatm ent or scheduled surgery  
during Part A of the study . 
4.Prior treatm ent wi th radiation therapy  involving ≥25% of the hematopoiet ically active bone 
marrow.
5.Use of strong CYP3A inducers within 2 weeks before the first dose of study  drug. (The 
non-exhaust ive list of clinically significant strong CYP3A inducers is provided in Appendix K.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 39of 102
Protocol Incorporating Amendment 02 04 September 2018
6.Known hypersensit ivity or history of severe intolerance or toxicity to chemotherapeut ic agents 
including known history  of severe hypersensit ivity reacti ons to docetaxel (polysorbate 
80-based formulat ions) for patients to be treated wit h pevonedistat+docetaxel; history  of 
hypersensit ivity to carboplat in for patients to be treated with pevonedistat+ 
carbopl atin+paclitaxel; or history  of severe hypersensit ivity to paclitaxel (Cremophor -based 
formulations) for pati ents to be treated with pevonedistat+carboplat in+ paclitaxel.
7.Life-threatening illness or serious (acute or chronic) medical or psychiatric illness unrelated to 
cancer that may increase the risk associated with trial participat ion or invest igational produc t 
administration or may  interfere wi th the interpretatio n of tri al resul ts or, in the investigator’s 
opinio n, could potentially interfere with the completion of treatment according to this protocol.
8.Active, uncontrolled infect ion or severe infect ious di sease, such as severe pneumo nia, 
meningit is, septicemia, or methicillin -resistant Staphylococcus aureus infect ion within 
2weeks before dosing.
9.Known human immunodeficiency virus seropositive or known hepat itis B surface ant igen 
seroposi tive or known or suspe cted active hepat it
is C infect ion. Note: patients who have 
isolated posi tive hepat itis B core antibody (ie, in the setting of negat ive hepat itis B surface 
antigen and negative hepat itis B surface antibody) must have an undetectable hepatit is B vira l 
load.
10.Persi stent di arrhea ( ≥Grade 2) lasting >3 days within 2 weeks before the first dose of study  
treatm ent.
11.Known hepat ic cirrhosis or severe pre -exist ing hepati c impai rment.
12.Uncontrolled high BP (ie, systolic BP >180 mm Hg, diastolic BP >95 mm Hg).
13.Left ventr icular eject ion fract ion (LVEF) <50% within 6 months prior to study enrollment. If a 
resul t within this time frame is unavailable, LVEF must be determined by echocardiography at 
screening .
14.Patients wi th ischemic heart disease who have had acute coronary  syndrom e, my ocardi al 
infarction, or revascularizat ion (eg, coronary artery bypass graft, stent) in the past 6 months are 
excluded. However, patients with ischemic heart disease who have had acute coronary  
syndro me, myocardial infarct ion, or revascularizatio ngreater than 6 months before screening
and who are without cardiac symptoms may enro ll. Patients with congest ive heart failure (New 
York Heart Associat ion Class III or IV) or New York Heart Associat ion Class II with recent 
decom pensat ion requiring hospita lization wit hin 4 weeks before screening and pati ents wi th 
severe pulmo nary arteri al hypertensi on (see Appendix J) are excluded.
15.Arrhyt hmia (eg, history  of polym orphic ventri cular fibrillat ion or torsade de pointes, 
perm anent atri al fibrillati on defined as continuous atrial fibrillat ion for ≥6 months, and 
persistent atrial fibrillat ion, defined as sustained atrial fibrillat ion lasting 7 day s and/or 
requi ring cardioversio n in t he last 4 weeks before screening ). However, patients with <Grade 3 
atrial fibrillat ion for a peri od of  at least 6 m onths may enroll. Grade 3 atrial fibrillat ion is 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 40of 102
Protocol Incorporating Amendment 02 04 September 2018
defined as symptomat ic and inco mpletely control led medically , or controlled wit h device (eg, 
pacemaker) or ablat ion, and is excluded. Patients with paroxysmal atrial fibrillat ion are 
permitted to enroll.
16.Prolonged rate corrected QT interval (QTc) ≥500 msec, calculated according to inst itutional 
guidelines.
17.Implantable cardioverter defibrillator.
18.Patients wi th a cardi ac pace maker whose heart rate is set at a fixed rate and patients on 
concomitant medicat ion that m ay limit increase in heart rate in response to hy potensi on (eg, 
high-dose beta blocker).
19.Moderate to severe aortic stenosis, moderate to severe mitral stenosis, or other valvulopathy 
(ongoing).
20.Known moderate to severe chronic obstructive pulmo nary disease, intersti tial lung di sease, 
pulmo nary fibrosis, or pulmo nary arteri al hypotensi on.
21.Female patients who are lactating and breastfeeding or who have a posit ive serum pregnancy 
test during the screening period or a positive urine pregnancy test on Day 1 before the first dose 
of study  drug.
22.Female pat ients who intend to donate eggs (ova) during the course of this study  or 4 m onths 
after receiving their last dose of study  drug.
23.Male patients who intend to donate sperm during the course of this study  or 4 m onths after 
receiving their last dose of study  drug.
24.Patient requi ring chronic treatment with BC RP inhibitors. Refer to Table 8.bfor the list of 
known BCRP inhibitors.
7.3 Criteria for Continuation into Optional Part B
After complet ing Part A of the study , pati ents m ay choose to enter the optional part of the study , 
Part B. To be eligible for Part B, patients must have completed Part A and be reassessed to 
determine if they meet the continuat ion criteria for Part B. Only  patients who m eet the followin g 
criteria m ay cont inue into Part B:
1.ECOG performance status of 0 to 1.
2.ANC ≥1500/mm3.
3.Platelet coun t ≥100,000/mm3.
4.Laboratory  values for hemoglo bin, total bilirubin, ALT, AST, ALP, and serum creatinine or 
calculated/measured CrCl , as specified in Inclusio n Cri terion #6.
5.Diarrhea symptom s reso lved to Grade 1 or better.
6.QTc interval <500 msec.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 41of 102
Protocol Incorporating Amendment 02 04 September 2018
7.CT scan or MRI of the chest, abdomen, and pelvis within 28 days o f Cycle 1 Day 1.
Radiological evaluat ions (CT scan or MRI) of the chest, abdomen, and pelvis are requi red as entry 
criteria for Part B to assess the status of the patient’s underlying disease. If the patient has had 
appropriate imaging scans performed within 28 days before Cycle 1 Day 1 of Part B, the results of 
those scans may be used. During the study , CT scans or MRIs enco mpassing the known sites of 
disease will  be perform ed at the end of Cycle 2 and every  3 cycles thereafter. An EOS/early 
termination CT scan does not need to be completed/repeated if a scan was performed wit hin the 
previous 28 days.
For patients to begin dosing in optional Part B, their predose Cycle 1 Day 1 assessments in Part B 
must return to the baseline values of Part A or Grade ≤1 or to a level considered acceptable by the 
investigator, after discussion wit h the project clinician or designee, and must meet all the 
continuat ion criteria specified in this sect ion (Section 7.3).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 42of 102
Protocol Incorporating Amendment 02 04 September 2018
8.0 STUDY DRUG
8.1 Study Drug Administration
All protocol -specific criteria for administration o f study drug must be met and documented before 
drug administration. Study  drug will be administered only  to eli gible pat ients under the 
supervisio n of the invest igator or ident ified subinvestigator(s).
8.1.1 Part A: Pevonedistat and Rifampin Administration
8.1.1.1 Pevonedistat Administration
Patients will  receive a single dose of 50 mg/m2pevonedistat via an approximate 1- hour 
(60±5 minutes) IV infusio n on Day  1. Pl asma PK sam ples will  be collected at a series of 
predetermined time poin ts up to 48 hours (Day 3) following the single dose of pevonedistat. The
start and end times of the IV infusio n should be recorded accurately. If the IV infusio n is 
interrupted, 2 addi tional PK samples (1 sam ple drawn when the infusio n is stopped and 1 sam ple 
drawn when the infusio n is restarted) should be co llected so that the patient may be considered 
evaluable. The exact date and time of each addit ional sample co llection and the actual start and 
stop times o f the infusio n should be recorded accurately. Patients will not be considered evaluable 
and need to be replaced if, in the assessment of the Takeda clinical pharmaco logist, the infusio n 
interrupti on com promises PK evaluabilit y. All infusi on times must be recorded. Refer to the 
Pharmacy  Manual for the p reparati on of  the IV infusi on. 
There will be no pevonedistat doses from Day 2 through Day  9. On Day  10, a single dose of 
50mg/m2pevonedistat will be administered via a 1 -hour IV infusio n, and plasma samples will be 
collected at predetermined t ime points up to 48 hours (Day 12) fo llowing the second single dose of 
pevonedistat.
Both doses of pevonedistat (Day s 1 and 10) will be administered in the clinic, fo llowed by the 
requi red PK sampling. There will be no pevonedistat dosing on Days 11 and 12.
8.1.1.2 Rifampin Administration
The first dose of rifampin 600 mg will be given orally in the clinic on the morning o f Day 3 after 
collect ion of the 48
-hour PK sample. Patients will self -administer rifampin (oral capsules) QD on 
Days 4, 5, 6, 7, 8 and 9 at home. Patients are encouraged to take rifampin at approximately  the 
same time each day  (±2 hours from  the time of first rifampin dose). On Days 10 and 11, patients 
will report to the clinic to continue to receive oral 600 mg rifampin co -administered with 
pevonedistat on Day 10, and at the time of the 24 -hour pevonedistat PK sampling on Day  11. 
There will be no rifampin dosing on Day 12.
All doses o f rifampin will be administered on an empt y stom ach wi th patients taking NPO except 
for water and prescribed medicat ions for 2hours before and at least 1 hour after each rifampin 
dose. Patients who miss any rifampin doses on Days 3 to 9 will not be considered evaluable; hence, 
pevonedistat dosing and PK sampling on Day 10 will not be required. Patients will have a washout 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 43of 102
Protocol Incorporating Amendment 02 04 September 2018
periodfrom the last dose of rifampin for at least 1 week to allow reversal of metabo lic enzyme 
induct ion before the start of Part B of the study .
8.1.2 Part B (Optional): Pevonedistat in Combination With SOC Chemotherapy Agents
Patients will  be re-evaluated per the e ntry criteria before treatment in Part B can begin. Patients 
opting to continue into Part B will receive co mbination therapy wit h pevonedistat and SOC 
chemotherapy. Two SOC chemotherapy  regimens, docetaxel and carboplat in+paclitaxel, will be 
used in this s tudy in combination wit h pevonedistat, as recommended by the invest igator. 
Study  drug(s) will be administered only  to eli gible pati ents under the supervisio n of the 
investigator or ident ified subinvestigator(s). 
8.1.2.1 Pevonedistat Administration
Patients will  receive pevonedistat diluted with 5% dextrose in a 250 mL bag via an approximate 
1-hour (60±5 minutes) IV infusio n. Pevonedistat should be administered through central or 
peripheral  venous access. The infusio n may be slowed or stopped and restarted for any associ ated 
infusio n
-related reacti ons. All infusio n times must be recorded. The total time fro m drug dilut ion 
in 5% dextrose to the end of infusio n must not exceed 6 hours.
The ent ire contents of the pevonedistat IV bag will be infused at a constant rate over approximately 
60minutes. The start and end times of IV infusio n should be recorded accurately. To ensure that 
all the pevonedistat is administered, the infusio n line will be flushed with saline or 5% dextrose 
immediately  after administrati on. The vo lume used for line flushing is not considered part of the 
volume of the pevonedistat IV bag to be documented.
On Day  1 of a 21 -day cycle, patients will receive eit her pevonedistat 25 mg/m2in combinat ion 
with docetaxel  or pevonedi stat 20 m g/m2in combinat ion with carbopl atin+paclitaxel. A t ime-out 
of approximately 15 minutes is required between the end of infusio n of the chemotherapy regime n 
and the start of infusio n of pevonedistat. On Days 3 and 5, patients will receive pevonedistat alone. 
8.1.2.2 Docetaxel Admin istration
On Day  1 of each cy cle, when all study  drugs are administered together, docetaxel 75 mg/m2will 
be administered first as a 1 -hour IV infusio n. After a mandatory approximately 15 -minute time- out 
(pevonedistat -free period), pevonedistat will be administered IV. On Days 3 and 5, only 
pevonedistat will be given. The duration of each cycle will be 21 days. Refer to the applicable 
USPI for further details regarding docetaxel administration.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 44of 102
Protocol Incorporating Amendment 02 04 September 2018
Premedication for Docetaxel -Associated Hypersensitivity or Othe r Acute Reactions Guidelines
Prem edicat ion to prevent docetaxel- associated (hypersensit ivity or other) reactions is 
recommended according to inst itutional guidelines or l ocal practi ces. For exam ple, pati ents m ay 
be treated with dexamethasone (4 mg twice da ily for 3 day s), which shoul d start 24 hours before 
docetaxel administration.
8.1.2.3 Carboplatin+Paclitaxel Administration
On Day  1 of each cy cle, when all study  drugs are administered together, paclitaxel will be given 
first as an IV infusio n over approximately  3hours, fo llowed by  carbopl atin as an approximately 
30-minute IV infusio n. After a m andatory  approximately 15 -minute time -out (pevonedistat -free 
period), pevonedistat will be administered IV. On Days 3 and 5, only pevonedistat will be given. 
The durati on of each cycle will be 21 days.
Refer to the applicable USPI for further details regarding carboplat in administration.
If a patient’s glo merular filtrat ion rate (GFR) is estimated using serum creat inine 
measurements by  the standardized isotope dilut ion mass spectrom etry method, the US Food 
and Drug Administration (FDA) recommends that physicians consider capping the dose of 
carbopl atin for desi red exposure (AUC) to avoid potential toxicit y caused by overdosing. 
Using the Calvert formula described in the carb oplatin label , the m aximum  doses can be 
calculated as follows:
Total  carbopl atin dose (mg)=(target AUC) (GFR+25) [Calvert formula]
Maximum carboplat in dose (mg)=target AUC (mg min/mL) (150 m L/min)
The maximum dose is based on a GFR est imate that is capped at 125 mL/min for patients wit h 
norm al renal funct ion. No hi gher estimated GFR values should be used.
For a target AUC=5, the maximum dose is 5 150=750 mg.
For a target AUC=4, the maximum dose is 4 150=600 mg.
Refer to the applicable USPI for further detai ls regarding paclitaxel administration.
Prem edicat ion to prevent paclitaxel -associ ated (hypersensit ivity or other) reactions is 
recommended according to inst itutional guidelines or l ocal practi ces. For exam ple, pati ents 
may be treated with either dexametha sone (10 mg) 24 hours before and on the day of paclitaxe l 
dosing or methylpredniso lone immediately before paclitaxel dosing.
8.2 Reference/Control Therapy
No reference or placebo treatment will be used in this study . All eligible pat ients will receive 
treatm ent wi th pevonedistat in Part A. Participat ion in Part B of the study  is opti onal.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 45of 102
Protocol Incorporating Amendment 02 04 September 2018
8.3 Dose Modification Guidelines (Part B)
8.3.1 Criteria for Beginning or Delaying a Subsequent Treatment Cycle
For individual pat ients experi encing specific toxi cities, treatm ent in each new cycle will be 
delayed unt il toxicity is reduced to Grade ≤1, patient’s baseline, or to a level considered acceptable 
by the investigator after discussio n with the proj ect clinician or designee.
Patients will  receive pevonedistat in combinati on wi th chem otherapy  on a dose regimen that has 
been established fro m Study  C15010. If dosing with pevonedistat is held for toxicit y during any 
given cycle, dosing may resume within that same cycle when toxicit y is reso lved (ALT/AST to 
Grade ≤1 or bilirubi n wit hin normal range). Alternatively, dosing may be held until the next cycle. 
The start of the next cycle may also be delayed for up to 3 weeks to allow pat ients to recover fro m 
any safety concerns, so that pevonedistat may be administered in co mbinat ionwith chemotherapy .
In Part B only , Day 1 dosi ng may be delayed by up to 2 day s (of any cycle) to accommodate 
inclement weather, holidays, vacat ions, or other administrative reasons.
8.3.2 Criteria for Dose Interruption During a Cycle
In Part B, the infusio n may be slowed or stopped and restarted for any  associ ated 
infusio n-related reacti ons; however, this should be avo ided in Part A. The exact date and time 
of each addi tional sample collect ion and the actual start and stop times of the infusio n shoul d 
be recorde d accurately.
8.3.3 Criteria for Dose Reduction
When a dose modificat ion is warranted for safet y, consider dose reductions for chemotherapy first, 
if appropriate. Dose modification of pevonedistat (by 1 dose level=5 mg/m2) may  also be 
considered for events judge d by the invest igator to be direct ly related to pevonedistat or for 
chemotherapy related toxicit ies that may have been exacerbated by pevonedistat in the 
combinat ion setting.
Alopecia o f any duration will not lead to dose modificat ion or treatment delay.
Patients receiving pevonedistat+docetaxel may have a maximum of 2 docetaxel dose 
modificati ons. Docetaxel  is initially dosed at 75mg/m2, dose reductions up to 60 mg /m2and 
45mg/m2may be considered (if applicable) or modificat ion of pevonedistat ( see abov e).
Patients receiving pevonedistat+carboplat in+paclit axel may  have no m ore than 1 dose 
modificati on(if applicable) of chemotherapy  agents, as outlined below, or modificat ion of 
pevonedistat ( see above ). Paclitaxel is init ially dosed at 175 mg/m2. One dos e reducti on to 
135mg/m2may be considered. Carboplat in is initially dosed at AUC5. One dose reduction to 
AUC4 m ay be considered.
The decisio n to treat at a reduced dose level of chemotherapy is at the discretion o f the 
investigator. Discussions with the p roject clinician or designee are encouraged.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 46of 102
Protocol Incorporating Amendment 02 04 September 2018
Table 8.aoutlines the dose modification guidelines for specific toxicit ies. Treatment cannot be 
withheld for longer than 3 weeks for any  toxicity Grade >1, as indicated in Section 8.3.4 .
Table 8.a Dose Modification Guidelines for Specific Toxicities
Pathologic Condition Severity Action on Study Drug
Hematologic:
ANCFebrile neutropenia Hold dosing on Day 1 of Cycles ≥2 up to 3 weeks (see Section 8.3.4 ) 
until febrile neutropenia is resolved, then resume dosing as appropriate. 
Consider use of growth factor or reduce chemotherapy by 1 dose level, as 
appropriate.
ANC <1500 cells/ L on 
Day1 of Cycles ≥2Initiation (Day 1) of Cycles ≥2 should be delayed for up to 3 weeks (see 
Section 8.3.4 ) until ANC is ≥1500 cells/L. Consider use of g rowth 
factor or reduce chemotherapy by 1 dose level as appropriate.
Grade ≥3 neutropenia 
lasting >7 daysInitiation (Day 1) of Cycles ≥2 should be delayed until ANC is 
≥1500 cells/L. Consider use of growth factor or reduce chemotherapy 
by 1 dose level as appropriate.
Hematologic:
PlateletsPlatelet count <100,000/ L 
on any dosing day of Cycles 
≥2Dosing in Cycles ≥2 should be delayed for up to 3 weeks (see 
Section 8.3.4 ) until platelet count is ≥100,000 cells/L. Dose of 
chemotherapy may be reduced by 1 dose level as appropriate.
Grade 4 thrombocytopenia 
lasting >7 days or platelet 
count <25,000 cells/L at 
any timeDosing in Cycles ≥2 should be delayed until platelet count is 
≥100,000 cells/L (see Section 8.3.4 ). Dose of chemotherapy may be 
reduced by 1 dose level as appropriate.
Hematologic:
AnemiaGrade ≥1 No dose modification is allowed for anemia. Transfusion and/or 
erythropoietin may be given, as clinically indicated, for the treatment of 
anemia (see Section 8.7.3 ).
Nausea, emesis, or 
diarrhea despite maximal 
prophylaxisGrade 3 On day s when both chemotherapy and pevonedistat are administered, 
hold dosing for up to 3 weeks (see Section 8.3.4 ) or until the toxicity 
returns to Grade ≤1, then restart at the next lower dose of chemotherapy. 
On day s when pevonedistat is given as a single agent, hold pevonedistat 
dosing for up to 3 weeks (see Section 8.3.4 ) or until the toxicity returns 
to Grade ≤1 before dosing is resumed. Note : Ensure that optimal 
prophylaxis has been employed before dose reduction. Supportive care 
with moderate or strong CYP3A inhibitors/inducers should be avoided.
Neurotoxicity
(paclitaxel or 
docetaxel only)Grade 2 Hold treatment until patient recovers to Grade 1 toxicity, then resume 
treatment at the next lower dose level (see Section Section 8.3.4 ). This 
will be a permanent dose reduction. Carboplatin or pevonedistat dose is 
not to be modified.
Allergic reaction
(paclitaxel or docetaxel 
onlyModerate symptoms Stop infusion. Give IV diphenhydramine 25 to 50 mg, IV dexamethasone 
10 mg, and/or treatment per institutional guidelines. After recovery of 
symptoms, resume infusion at a low infusion rate. If no further 
symptoms occur, resume full dose rate until infusion is complete. If 
sympt oms recur, stop infusion and discontinue patient.
8.3.4 Criteria for Discontinuation of Study Drug
Patients receiving pevonedistat+docetaxel may have a maximum of 2 dose modificat ions (if 
applicable) or modificat ion of pevonedistat (see Section 8.3.3 ). Patients who require more than 
2dose m odificat ions will be discontinued fro m the study .
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 47of 102
Protocol Incorporating Amendment 02 04 September 2018
Patients receiving pevonedistat+carboplat in+paclit axel may  have no m ore than 1 dose 
modificati on (if applicable) of chemotherapy  agents or m odificat ion of pevonedistat (see 
Secti on8.3). Patients wh o requi re addi tional dose m odificati ons will be discont inued fro m the 
study .
Patients wi th unreso lved toxicit ies Grade >1 lasting 3 weeks or longer fro m the date of the next 
scheduled treatment will be discont inued fro m the study .
For further details on di scont inuat ion criteria for specific toxi cities, see Secti on 8.7.
8.4 Excluded Concomitant Medications and Procedures
8.4.1 Part A
Table 8.blists the medicat ions and procedures that are prohibited during Part A of the study .
Table 8.b Excluded Concomitant Medications and Procedures During Part A
Drug Class/Therapy Comment
Acetaminophen and acetaminophen -containing 
productsMay be used judiciously and should not exceed a dose of 2 g in 
24 hours
Any investigatio nal agent other than pevonedistat Excluded during the study
Known BCRP inhibitors Examples: cyclosporine and eltrombopag
Strong CYP3A4 inducers See Appendix K.
8.4.2 Part B
Table 8.clists the medicat ions and procedures that are prohibited in Part B.
Table 8.c Excluded Concomitant Medications and Procedures During Part B
Drug Class/Therapy Comment
Acetaminophen and acetaminophen -containing products May be used judiciously and should not exceed a dose 
of 2g in 24 hours
Any investigatio nal agent other than pevonedistat Excluded during the study
Known BCRP inhibitors (eg, cyclosporine and eltrombopag) Generally excluded during the study but may be used 
as specified in Table 8.e
Systemic antineoplastic therapy, unless specified in the 
protocol as part of the combination with pevonedistat
Strong CYP3A4 inducers See Appendix K.
This list is not all -inclusive; consult the docetaxel, carboplatin, and paclitaxel applicable USPIs for additional 
information regarding precautions, warnings, and contraindications.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 48of 102
Protocol Incorporating Amendment 02 04 September 2018
8.5 Permit ted Concomitant Medications and Procedures
8.5.1 Part A
Medicat ions and procedures that are specifically permitted during Part A are listed in Table 8.d. 
Other supportive care medicat ions are also permitted, unless specifically excluded in 
Secti on8.4.1 .
Table 8.d Permitted Concomitant Medications and Procedures During Part A
Therapy Comment/Exceptions
Nephrotoxic medications, 
including nonsteroidal 
anti-inflammatory drugsCaution shou ld be used with nephrotoxic concomitant medications (see Appendix E). 
Alternative concomitant nonnephrotoxic medications should be used whenever possib le. 
Antiemetic agents Antiemetic agents may be administered at the discretion of the investigator, but 
prophylactic antiemetic agents should not be administered if nausea or vomiting is not 
observed. 
RBC transfusion For all patients with anemia, and especially for patients with hemoglobin values <9 g/dL 
during the conduct of the study, consideration should be given for RBC transfusions based 
on the patient’s risk of inadequate oxygenation, underlying cardiopulmonary status, 
clinical judgment, and hosp ital guidelines.
RBC transfusions must be administered at least 1 day before administration of study drug. 
Each transfusion episode, including the type of transfusion (RBC), should be recorded.
8.5.2 Part B
Medicat ions and procedures that are specifically permitted during Part B are listed in Table 8.e. 
Other supportive care medicat ions are also permitted , unless specifically excluded in 
Secti on8.4.2 .
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 49of 102
Protocol Incorporating Amendment 02 04 September 2018
Table 8.e Permitted Concomitant Medications and Procedures During Part B
Therapy Comment/Exceptions
Antiemetic agents Antiemetic agents, including for prophylactic use, may be administered at the discretion 
of the investigator. 
Known BCRP inhibitors 
(eg,cyclosporine and 
eltrombopag)Limited use is permitted only if clinically necessary and no suitable alternative exists. The 
patient may receive a BCRP inhibitor from 24 hours after the last pevonedistat dose to 
72hours before the next pevonedistat dose. For example, if a patient receives pevonedista t 
on a Monday (Day 1), Wednesday (Day 3), and Friday  (Day 5) schedule, then a BCRP 
inhibito r may  be administered (if clinically necessary and no suitable alternative exists) 
from the Saturday after the Day 5 dose (Day 6) up to the Friday (Day 19) before th e 
Monday dose of the next cycle.
Nephrotoxic medications, 
including nonsteroidal 
anti-inflammatory drugsCaution should be used with nephrotoxic concomitant medications (see Appendix E). 
Alternative concomitant nonnephrotoxic medications should be used whenever possible.
RBC transfusion For all patients with anemia, and especially for patients with hemoglobin values <9 g/dL 
during the conduct of the study, consideration should be given for RBC transfusions based 
on the patient’s risk of inadequate oxygenation, underlying cardiopulmonary status, 
clinical judgment, and hospital guidelines.
RBC transfusions must be administered at least 1 day before admi nistration of study drug. 
Each transfusion episode, including the type of transfusion (RBC), should be recorded.
8.6 Precautions and Restrictions
Concomitant medicat ions and procedures that are excluded or must be used with caut ion are 
described in Sections 8.4.1 and 8.4.2and Sections 8.5.1 and 8.5.2 , respectively.
Certain situat ions may warrant further caution, such as modifying th e dose of study  drug(s). Dose 
modificati on guidelines are provided in Sect ion 8.3.
8.6.1 Pevonedistat
It is not known what effects pevonedistat has on hu man pregnancy  or devel opment of the embry o 
or fetus. Therefore, female pat ients parti cipating in this study  shoul d avoi d becoming pregnant, 
and male patients should avo id impregnating a female partner. Nonsterilized female pat ients of 
reproducti ve age and male patients should use highly effect ive methods of contraception through 
defined periods during and after study  treatment, as specified below.
Use only contraceptive methods that are locally approved in each country . 
Female pat ients must m eet any  of thefollowing:
Postmenopausal  for at l east 1 year before the screening visit (see Appendix F).
Surgically sterile .
If they  are of  childbearing potential (as defined in Section 9.4.7 ), they  and thei r male 
partners agree to practice 1 highly  effect ive method and 1 additional effect ive (barrier) 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 50of 102
Protocol Incorporating Amendment 02 04 September 2018
method of contraception (see Appendix G) at the sam e time, from  the time of signing the 
inform ed consent form  (ICF) thr ough 4 months after the last dose of study drug.
Agree to practice true abst inence, when this is in line wit h the preferred and usual lifest yle 
of the subject. (Periodic abstinence [eg, calendar, ovulat ion, symptothermal, and 
postovulat ion methods], withdr awal, spermicides only , and l actati onal amenorrhea are not 
acceptable methods of contraception. Female and male condo ms should not be used 
together.)
Agree to not donate eggs (ova) during the course of this study  or 4 months after receiving 
their last dose of study  drug.
Male patients, even if surgically  sterilized (ie, status postvasectomy), must agree to any  of the 
following:
Practi ce effect ive barrier contracepti on during the ent ire study  treatm ent peri od and 
through 4 months after the last dose of study drug. (If barri er methods are not l ocally  
approved to be used by males, then their female partners should use effect ive contraceptive 
methods, as described in above.)
Practi ce true abstinence, when this is in line wit h the preferred and usual lifest yle of the 
subject. (Periodic abst inence [eg, calendar, ovulat ion, symptothermal, and postovulat ion 
methods], withdrawal, spermicides only, and lactatio nal amenorrhea are not acceptable 
methods of contraception. Female and male condoms should not be used togethe r.)
Donate sperm during the course of this study  or 4 months after receiving their last dose of 
study  drug.
8.6.2 Rifampin
8.6.2.1 Pregnancy
There are no adequate and well -controlled studies of rifampin in pregnant women. Refer to the 
applicable USPI for additional info rmation regarding pregnancy .
8.6.2.2 Geriatric Use
In general, dose selection for an elderly pat ient should be cautious, reflecting the greater frequenc y 
of decreased hepat ic function and of conco mitant disease or other drug. Refer to the applicable 
USPI for furth er details relat ing to use with geriatric pat ients.
8.6.3 Docetaxel
8.6.3.1 Pregnancy
Docetaxel is a pregnancy Category  D drug. There are no adequate and well -controlled studies in 
pregnant women using docetaxel. If docetaxel is used during pregnancy, or if the patient becomes 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 51of 102
Protocol Incorporating Amendment 02 04 September 2018
pregnant while receiving this drug, the patient should be apprised o f the potenti al hazard to the 
fetus. Refer to the applicable docetaxel USPI for more information.
8.6.3.2 Geriatric Use
In general, dose selection for an elderly pat ient should be cautious , reflecting the greater frequenc y 
of decreased hepat ic, renal, or cardiac function and of conco mitant disease or other drug therapy .
Refer to the applicable docetaxel USPI for information relat ing to use in the geriatric populat ion 
with different ty pes o fcancer .
8.6.4 Carboplatin
8.6.4.1 Pregnancy
Carbopl atin is a pregnancy Category  D drug. Carboplat in inject ion may cause fetal  harm  when 
administered to a pregnant woman. Refer to the applicable carboplat in inject ion USPI for more 
inform ation.
8.6.4.2 Geriatric Use
Because renal funct ion is often decreased in the elderly, renal funct ion should be considered in the 
select ion of carboplat in dosage. Refer to the applicable carboplat in USPI for addit ional 
inform ation on geri atric use.
8.6.5 Paclitaxel
8.6.5.1 Pregnancy
Paclitaxel is a pregnan cy Category  D drug. Paclitaxel inject ion can cause fetal harm when 
administered to a pregnant woman. Refer to the applicable paclitaxel injection USPI for more 
inform ation.
8.6.5.2 Geriatric Use
Refer to the applicable paclitaxel USPI for information regarding use in the geriatric populat ion.
8.7 Management of Clinical Events
The m ost comm on adverse drug reactions for docetaxel and for paclitaxel+carboplatin are 
described in Section 4.1.4 . Refer to the applicable USPIs for addit ional details regarding the 
management of clinical events attributed to these agents.
Patients who experience an AE with pevonedistat should be fo llowed closely  for a recurrence of 
similar or other AEs upon subsequent dosing of pevonedistat.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 52of 102
Protocol Incorporating Amendment 02 04 September 2018
8.7.1 Guidance for Clinical Assessment and Management of Hemodynamic Compromise 
(Part A and Part B)
It is essential that the patient is carefully evaluated at screening and before each pevonedistat dose 
for early  symptoms and signs of hemodynamic compromise and/or active infect ion. Parti cular 
attenti on shoul d be paid to unexplained fever, tachycardia, hypotension, orthostasis, tachypnea, 
recent nausea and vo miting, and clin ical evidence of dehydrat ion. 
For those patients for whom there is a concern o f dehydrat ion, the fo llowing gui dance for 
rehydration before pevonedistat dosing may be considered: 500 mL/hour of 0.5 N saline given 
over 2 to 4 hours for a total o f 1 to 2 L o f fluid as clinically appropriate; each infusion of IV fluids 
shoul d be recorded in the electronic case report forms (eCRFs).
For all patients with anemia, and especially  for patients wi th hemoglo bin values <9 g/dL at 
screening or during the conduct of the study , RBC transfusio ns should be considered before 
pevonedistat dosing on the basis of the patient’s risk of inadequate oxy genat ion, underlying 
cardi opulm onary status, clinical judgment, and/or hospital guidelines; each RBC transfusion 
shoul d be recorded in the eCRFs.
Patients who experience signs and symptoms of hemodynamic compromise after pevonedistat 
dosing (eg, tachy cardia, hypotension, orthostasis, changes in mental status, syncope, and 
dizziness) should be fo llowed clo sely and managed with supporti ve care, including hospitalizat ion 
as clinically indicated. 
Patients who experience an untoward reaction wit h pevonedistat should be fo llowed cl osely  on 
subsequent dosing.
8.7.2 Guidance for Use of Granulocyte -Colony Stimulating Factor
Use of growth factors suc h as granulocyte -colony stimulat ing factor are permitted at the 
investigator’s discret ion.
8.7.3 Guidance for Clinical Assessment and Management of Anemia
Transfusio n and/or erythropoiet in may be given as clinically indicated for the treatment of anemia. 
These s hould be recorded in the eCRFs.
For all patients with anemia, and especially  for patients wi th hemoglo bin values <9 g/dL at 
screening or during the conduct of the study , RBC transfusio ns should be considered before 
pevonedistat dosing on the basis of the p atient’s risk of inadequate oxy genat ion, underlying 
cardi opulm onary status, clinical judgment, and/or hospital guidelines; each RBC transfusion 
shoul d be recorded in the eCRFs.
Use of ery thropoi etin may be considered at the investigator’s discret ion and ac cording to 
institutional guidelines.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 53of 102
Protocol Incorporating Amendment 02 04 September 2018
8.7.4 Guidance for Management of Extravasation
Based on nonclinical findings as detailed in the IB, pevonedistat is considered a nonvesicant drug. 
Although no published guidelines are available for extravasat ion of nonvesican ts, the invest igator 
is encouraged to fo llow inst itutional guidelines. Some general advice in case of extravasat ion 
includes immediately stopping drug infusion and elevat ing the affected limb to minimize swelling.
8.8 Blinding and Unblinding
This is an open -label study . 
8.9 Description of Investigational Agents
8.9.1 Pevonedistat
Pevonedistat Concentrate for Solution for Infusio n form ulation consists of 10 mg/mL (as free 
base) of pevonedistat HCl in an aqueous solut ion containing citric acid (anhydrous) , trisodi um 
citrate dihydrate, and betadex sulfo butyl ether sodium (Captiso l) at pH 3.3. Each United States 
Pharmacopeia (USP) Ty peI glass vial contains 5 mL co mpounded sterile so lution, sealed wit h a 
fluoropolymer -coated butyl rubber stopper, and oversealed with an alumi num seal and a pl astic 
cap. Pevonedistat Concentrate for Solut ion for Infusion needs to be diluted in 5% dextrose for 
administration.
8.9.2 Rifampin
Rifampin is a semisynt hetic ant ibiotic derivat ive of rifamycin SV. Rifampin capsules for oral 
administration contain 300 mg of rifampin per capsule.
For precautions, warnings, contraindications, and AEs associated with rifampin therapy , refer to 
the applicable rifampin USPI. For this study , all doses of rifampin should be administered on an 
empty stom ach, wi th patients rem aining NPO except water from 2 hours before unt il at least 
1hour after rifampin dosing. Addit ionally, antaci ds shoul d not be administered from 2 hours 
before rifampin dosing until at least 2 hours after dosing.
8.9.3 Docetaxel
Docetaxel is obtained fr om commercial sources according to local practice standards and is 
provi ded as a commercially  available dose formulation. Addit ional details are provided in the 
applicable USPI for docetaxel.
8.9.4 Carboplatin
Carbopl atin is obtained from co mmercial sources acco rding to local practice standards and is 
provi ded as a commercially  available dose formulation. Addit ional details are provided in the 
applicable USPI for carboplatin .
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 54of 102
Protocol Incorporating Amendment 02 04 September 2018
8.9.5 Paclitaxel
Paclitaxel is obtained from commercial sources according to local practice standards, and it is 
provi ded as a commercially  available dose formulation. Addit ional details are provided in the 
applicable USPI for paclitaxel.
8.10 Preparation, Reconstitution, and D ispensation
Parenteral  drug products should be inspected visually  for parti culate matter and disco loration 
before administration, whenever solut ion and container permit.
Docetaxel, paclitaxel, and carboplatin are anticancer drugs, and as with other potenti ally toxic 
compounds, cauti on shoul d be exercised when handling pevonedistat and these chemotherapy  
agents.
8.10.1 Pevonedistat
For a detailed preparation of the infusio n, refer to the Pharmacy  Manual . The bag, needle, and 
syringe must be di sposed of in a proper biohazard container.
8.10.2 Docetaxel, Carboplatin, Paclitaxel and Rifampin
For instructions and precaut ions regarding preparatio n, refer to the applicable USPIs for docetaxel, 
paclitaxel, carboplat in, and rifampin.
8.11 Packaging and Labeling
8.11.1 Pevonedistat
The drug pr oduct i s labeled Pevonedistat (TAK -924/MLN4924) Concentrate for Solution for 
Infusio n.
Pevonedistat Concentrate for Solution for Infusio n will be provided in USP Ty pe I glass vials. 
Each Pevonedistat Concentrate for Solut ion for Infusion vial contains 50 mg Pevonedistat, as free 
base.
Pevonedistat Concentrate for Solution for Infusio n will be supplied by the sponsor as detailed in 
the Study /Pharmacy Manual.
8.11.2 Docetaxel, Carboplatin, and Paclitaxel
Docetaxel, paclitaxel, carboplat in may be sourced locally by  the clinical site when arrangements 
have been made and agreed to by  Takeda and when regulat ions allow for clinical site sourcing, 
appropriate labeling, and co mpliance wit h local and regi onal regulations. As requi red by l ocal 
regul ations, any modificat ions to the pl an for drug supply.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 55of 102
Protocol Incorporating Amendment 02 04 September 2018
8.11.3 Rifampin
Rifampin will be provided by the sponsor as oral capsules. As required by local regulat ions, any  
modificati ons to the pl an for drug supply or storage will be communicated to the invest igator and 
detailed in the pharmacy manual .
8.12 Storage, Handling, and Accountability
8.12.1 Pevonedistat
Pevonedistat inject ion is an invest igational ant icancer drug. As with other potentially toxic 
compounds, cauti on shoul d be exercised when handling pevonedistat. Refer to inst itutional 
guidelines regarding the proper handling and disposal o f toxic agents.
Pevonedistat Concentrate vials should be stored at 2°C to 8°C. The vials are suitable for use up to 
6 hours after removal fro m the storage condit ion of 2°C to 8°C. If the drug product vial is not t o be 
used within the 6 -hour time frame, the vial should be returned to storage. Each vial is for single use 
only.
Once Pevonedistat Concentrate is diluted in 5% dextrose, the prepared pevonedistat IV bag must 
be used wit hin 6 hours if stored at ambient tem perature or el se must be discarded. Alternatively, 
the prepared pevonedistat IV bag may be stored for up to 18 hours at 2°C to 8°C, after which the 
prepared IV bag can be used wit hin 3 hours upon removal fro m 2°C to 8°C storage or must be 
discarded.
The vi al must not be shaken at any  time during dose preparation.
Discard bags, needles, and sy ringes in a proper biohazard container according to inst itutional 
guidelines.
Detailed reconst itution and dosage preparation instructions are provided in the Direct ionsfor Use 
located in the Pharmacy  Manual .
8.12.2 Docetaxel, Carboplatin, Paclitaxel and Rifampin
For instructions and precaut ions regarding preparatio n, refer to the applicable USPIs for docetaxel, 
paclitaxel, carboplat in, and rifampin.
8.13 Other Protocol -Specified Ma terials
Refer to the Pharmacy Manual for any other protocol -specified materials to be used in the study .
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 56of 102
Protocol Incorporating Amendment 02 04 September 2018
9.0 STUDY CONDUCT
This tri al will be conducted in com pliance wi th the protocol , GCP, applicable regulatory  
requi rements, and ICH guidelines.
9.1 Study Personnel and Organizations
The contact informat ion for the proj ect clinician for this study , the central  laboratory  and any 
additional clinical  laboratories, the coordinat ing investigator for each member state/country , the 
interact ive vo ice response syste m/interact ive web response system provider, and the contract 
research organizat ion (CRO) team may be found in the Study Manual. A full list of invest igators is 
available in the sponsor’s investigator database. For 24- hour contact informat ion, refer to the 
Project Management Plan.
9.2 Arrangements for Recruitment of Patients
Recrui tment and enro llment strategies for this study may include recruit ment from the 
investigator’s local practice or referrals from other physicians. If advert isements become part of 
the recruit ment strategy , they  will be reviewed by  the inst itutional review board 
(IRB)/independent ethics co mmittee (IEC). Any other arrangements will be described in the Study 
Manual.
9.3 Treatment Group Assignments
All patients will receive the same study  treatm ent in Part A.
In opti onal Part B, pati ents will  be assigned, as recommended by  the invest igator, to pevonedistat 
25mg/m2in combinat ion with docetaxel 75 mg/m2or pevonedistat 20 mg/m2in combinat ion wit h 
carbopl atin AUC5+paclitaxel 175 mg/m2.
9.4 Study Proc edures
Refer to the SOE ( Appendix A) for timing of assessments. Addit ional details are provided as 
necessary  in the secti ons that follow.
9.4.1 Informed Conse nt
Each patient must provide written informed consent before any  study -requi red procedures are 
conducted, unless those procedures are performed as part of the patient’s standard care.
9.4.2 Patient Demographics
The date of birth, race, ethnicit y, and sex of the patient are to be recorded during screening .
9.4.3 Medical History
During the screening period, a complete medical history, including prior therapy, will be co mpiled 
for each pat ient. The history  will emphasize the background and progress of the patient’s 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 57of 102
Protocol Incorporating Amendment 02 04 September 2018
malign ancy and include a descript ion of prior therapies for it. In addit ion, concomitant 
medicat ions will be recorded as specified in Sect ion 9.4.8 .
9.4.4 Phys ical Examination
A co mplete physical examinat ion or symptom -directed phy sical examinat ion will be completed 
per SOC at the times specified in the SOE ( Appendix A).
9.4.5 Patient Height
Height will be measured only during screening .
9.4.6 Vital Signs
Vital signs, including diastolic and systolic BP, heart rate, weight, and body  temperature, will be 
collected as indicated in the SOE ( Appendix A) and as clinically  indicated.
When the timing of vital signs assessment coincides with the timing o f a blood draw, vital signs 
will be co mpleted before the collect ion of the blood sample, unless otherwise noted in the SOE 
(Appendix A).
9.4.7 Pregnancy Test
A serum pregnancy test will be performed fo r women of childbearing potential at screening . In 
Part A, a serum or urine pregnancy test will be performed on Day 1 predose, Day  10 predose, and 
at the EOS visit ( Appendix A). In Part B, a serum or urine pregnancy  test m ust al so be performed 
for wom en of childbearing potential at every cycle (typically performed on Day 1 predose of each 
cycle; however, if a serum pregnancy  test i s used, this may  be perf ormed up to 3 days before 
Day 1), with negative results available before the first dose is administered in the respective cycle. 
A serum or urine pregnancy test will also be performed for women of childbearing potential at the 
EOS/Early  Terminat ion visit i n Part B. Pregnancy tests may also be repeated during the study if 
requested by  an IEC/IRB or if required by  local regul ations.
Women of childbearing potential are defined as any sexually active female subjects who meet the 
following criteria:
Those who have not undergone hysterectomy or bilateral oophorectomy.
Those who have not had natural menopause 
(Appendix F) for 12 consecutive months or 
longer (i e,follicle -stimulat ing horm one [ FSH] >40IU/L and no menopausal period for at 
least 12 consecutive months; loss of menopausal periods fo llowing chemotherapy  may not 
rule out childbearing potential).
9.4.8 Concomitant Medications and Procedures
Concomitant medicat ions, therapies, and procedures will be recorded in the eCRF fro m the time of 
the first dose of any study  drug through 30 (+10) days after the last dose of study  drug(s). See 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 58of 102
Protocol Incorporating Amendment 02 04 September 2018
Secti ons 8.4and Sect ion 8.5for addi tional details regarding excluded and permitted concomitant 
medicat ions and procedures.
9.4.9 AEs
Moni toring of AEs, serious and nonserious, will be conducted throughout the study as specified in 
the SOEs ( Appendix A). Ref er toSection 10.1 for details regarding definit ions, docum entati on, 
and reporting of pretreatment events (PTEs), AEs, and SAEs.
For Part B only , refer to Table 8.afor dose modifications related to AEs.
9.4.10 Enrollment
Enrollment is achieved when the first dose of any study  drug has been administered. Procedures 
for com pleting the enrollment informat ion are described in the Pharmacy and Study  Manuals.
9.4.11 Electrocardiogram
A 12 -lead el ectrocardi ogram  (ECG) will be administered at screening (Part A only ), on Day  1 
(predose), and at the EOS visit.
9.4.12 Echocardio
gram
If no historical data for LVEF within 6 months prior to study enrollment are available, LVEF 
shoul d be assessed by echocardiography  at screening .
9.4.13 Clinical Laboratory Evaluations
Clinical laboratory  evaluat ions will be performed locally. Handling and s hipment of clinical 
laboratory  samples will be outlined in the Study  Manual. Clinical laboratory  evaluat ions will be 
perform ed as outlined below.
For Part B only , refer to Table 8.afor dose modifications related to abnormal laboratory  
evaluat ions.
Blood sam ples f or analysis of the clinical chemistry  and hematol ogic parameters shown in 
Table 9.aand urine samples for analysis o f the param eters shown in  Table 9.bwill be obtained as 
specified in th e SOE 
(Appendix A).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 59of 102
Protocol Incorporating Amendment 02 04 September 2018
Table 9.a Clinical Chemistry and Hematology Tests
Hematology Serum Chemistry
Hemoglobin
Hematocrit
Leukocytes (white blood cells) with differential
Neutrophils (ANC)
Platelet (count)ALT
Albumin
ALP
AST
Bilirubin (total)
Blood urea nitrogen
Creatinine
Direct bilirubin
Glucose Lactate dehydrogenase
Phosphate 
Potassium
Sodium
Urate
Calcium
Chloride
Carbon dioxide/bicarbonate
Magnesium
Part A Screening: 
aPTT
Coagulation panel (a)
Prothrombin time international normalized ratio
D-dimer
Fibrinogen
Parts A and B:
Coagulation panel, if applicable (a)
(a) If the initial coagulation screen is positive (ie, results are outside the laboratory’s normal range) in Part A, 
coagulatio n studies in Part B should include a full coagulation panel. If the initial coagulation screen is negative 
(ie,results are within the laboratory’s normal range ) in Part A, no further coagulation studies need to be done.
Table 9.b Clinical Urinalysis Tests
Urinalysis
Leukocytes
Nitrite
Occult blood
Microscopic assessment pH
Protein
Specific gravity
If CrCl is to be estimated, the Cockroft- Gault formula will be emplo yed as fo llows:
For female patients, the result of the formula above should be mult iplied by 0.85. 
9.4.14 Disease Assessment
Com puted tom ography  scans wi th IV contrast (unless medically  contraindicated) , or MRI, of the 
chest, abdomen, and pelvis will be performed as entry  criteria for Part B.               =[(140−   )∗    (  )]/[72∗                (  /  )]
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 60of 102
Protocol Incorporating Amendment 02 04 September 2018
CT scans with IV contrast encompassing the known sites o f disease will  also be perform ed at the 
end o f Cycle 2 and as specified in the Schedules o f Events thereaft er. A scan should be taken at the 
EOS vi sit if a scan has not been co mpleted wi thin the past 28 days. 
If CT scan does not provide adequate imaging, MRI may be used to evaluate sites of disease. If the 
patient has had appropriate imaging scans performed wi thin 28 days of Cycle 1 Day  1, then the 
resul ts of those scans may be used to satisfy the entry  criteria for Part B. For each site of disease, 
the imaging modalit y (CT scan or MRI) used at entry for Part B must be used throughout the study. 
Tumor response will be assessed by  the invest igator at these times using the RECIST guideline 
(Versi on 1.1) [3].
9.4.15 Biomarker, Pharmacodynamic, and PK Samples
9.4.15.1 Primary Specimen Collection
Specimen Name is
Schedule of ProceduresPrimary Specimen Description of Intended Use Sample Collection
Plasma Sample for Pevonedistat PK Plasma PK measurements Mandatory
9.4.16 PK Measurements
Details regarding the preparat ion, handling, and shipping of samples are provided in the Study and 
Laboratory  Manuals. 
As shown in the table in Appendix A, seri al blood samples ( approximately  3mL each ) for PK 
analysis o f pevonedistat will be co llected in Part A predose and prespecified time po ints on Day 1 
and Day 10 and over a 48 -hour period on Days 1, 2 (24 hours after the Day 1 dose) and 3 (48 hours 
after the Day 1 dose), 10, 11 (24 hours after the Day 10 dose) and 12 (48 hours after the Day 10 
dose).
The exact date and time of each sample collect ion and the actual start and stop times of theinfusio n 
shoul d be recorded accurately, wit h particular care given to the recording of blood sampling t imes 
that occur close to the infusio n. If t he IV infusio n is interrupted, 2 addit ional P K samples (1 sample 
drawn when the infusio n is stopped and 1 sample drawn when the infusio n is restarted) should be 
collected so that the patient may  be considered evaluable. The exact date and time of each 
additional sample collect ion and the actual start and stop times of the infusion should be recorded 
accurately.
There is no protocol -specified PK sampling for Part B.
The primary  purpose of PK sampling in this study  is to m easure pevonedistat concentrations in 
plasma. However, these PK samples may also be used for the exploratory measurement of plasma 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 61of 102
Protocol Incorporating Amendment 02 04 September 2018
concentrations of metabo lites of  pevonedistat, if technically feasible and considered necessary for 
further understanding the metabo lism of pevonedistat in pat ients with cancer.
To ensure that the measurements are representative of plasma exposure, blood draws will be 
conducted in the arm opposite to the patient’s IV infusio n. If only  a single arm  is available, blood 
shoul d be drawn as di stal to the si te of the IV infusio n as feasible, and the site of the blood draw 
shoul d be docum ented.
9.4.17 Pharmacodynamic Measurements
Not a pplicable to this study .
9.4.18 DNA Measurements 
Not applicable to this study .
9.4.19 Banked Tumor Specimen Measurements
Not applicable to this study .
9.4.20 Immunogenicity Sample Collection
Not applicable to this study .
9.5 Completion of Study Treatment (for Individual Patients)
9.5.1 Part A
Patients will  be considered to have completed Part A of the study  if they have com pleted the 
protocol -specified dose requirement and PK assessments to provide data necessary for assessment 
of effects of rifampin on pevonedistat PK within Part A of the protocol.
An EOS visit is needed in Part A only if the patient does not continue into Part B for any reason. 
The EOS visit will include physical examinat ion (including ECOG performance status, vital signs, 
and weight); pregnancy test; laboratory  assess ments (hematology , chemistry , and urinalysis); 
12-lead ECG; mo nitoring of conco mitant m ediat ions, therapies, and procedures; and recording o f 
AEs/SAEs. The EOS visit will be conducted 30 (+10) days after the last dose of study drug in Part 
A. If the EOS vi sit occurs earlier than 30 days after the last dose of pevonedistat, the patient should 
be contacted via telephone on Day 30to assess for any new or ongoing AEs or SAEs that may  
have occurred since the previous visit.
9.5.2 Part B
Patients will be considered to have completed Part B of the study if they have completed 12 cycles 
of treatm ent wi th study  drug, or if treatment is discontinued for any  of the reasons outlined in 
Secti on9.6.
 Patients who have completed Part A and participate in a rollover study  (see 
Secti on6.3.5 ) will be considered to have co mpleted Study  Pevonedistat -1015. If the patient 
continues into Part B, the EOS visit will occur 30 (+10) days after the last dose of study drug(s) in 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 62of 102
Protocol Incorporating Amendment 02 04 September 2018
Part B or before the start of subsequent therapy for the patient’s indicat ion, if that occurs sooner. If 
the EOS visit occurs earlier than 30 days after the last dose of pevonedistat, the patient should be 
contacted via telephone on Day  30 to assess for any  new or on going AEs or SAEs that may have 
occurred since the previous visit. Patients in Part B may also be considered to have completed 
Study Pevonedistat -1015 if they a enter roll -over or PTA study  (see Sect ion 6.3.5 ).
9.6 Discontinuation of Treatment With Study Drug and Patient Replacement
Study  drug m ay be perm anently discont inued for patients meet ing any o f the following criteria:
AE.
Protocol  deviat ion.
Progr essive disease (PD)
Symptom atic deteri oration.
Unsat isfactory  therapeuti c response.
Study  terminated by  sponsor.
Withdrawal by subject.
Lost to follow -up.
Other (to be specified).
Once study  drug has been discont inued, all study  procedures outlined for the EOS visit will be 
completed as specified in the SOE ( Appendix A). The primary  reason for study  drug 
discontinuat ion will  be recorded in the eCRF. In Par t A of the study , pati ents who are not PK 
evaluable will be replaced. 
Note: In opti onal Part B of the study , pati ents m ay receive pevonedistat until they experience PD 
or unacceptable pevonedistat -related toxicit ies or discontinue treatment for any  reason . 
Patients who have achieved objective clinical benefit from co mbinat ion therapy  
(chemotherapy+pevonedistat) and who have developed intolerance that is reasonably attributable 
to the chemotherapy after 2 or more cycles may cont inue on single- agent pevoned istat at the same 
dose and schedule, upon request by  the investi gator and agreem ent wi th the sponsor.
9.7 Withdrawal of Patients From Study
A pat ient may be wi thdrawn from  the study  for any  of the f ollowing reasons:
Lost to follow -up.
Study  terminated by  sponsor.
Withdrawal by subject.
Com pleted study .
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 63of 102
Protocol Incorporating Amendment 02 04 September 2018
Death. 
Other.
PD.
Initiation of  hematopoi etic stem cell transplant. 
The consequence of study  withdrawal  is that no new informat ion will be collected from the 
withdrawn pati ent and added to the exist ing dat a or any database.
9.8 Study Compliance
Study  drug will be administered or dispensed only to eligible pat ients under the supervisio n of the 
investigator or ident ified subinvest igator(s). The appropriate study personnel will maintain records 
of study  drug recei pt and dispensing.
The clinical team and the clinical research associate will review treatment compliance during 
investigat ional visits and at the completion of the study. Tests and procedures should be performed 
on schedule, but unless otherwise specified, occasional changes are allowable within a 2 -day 
window for holidays, vacat ions, and other administrative reasons. If the study  schedule is shifted, 
both assessments and dosing must be shifted to ensure that collect ion of assessments is co mpleted
before dosi ng. This 2- day window i s allowed f or Part B but does not apply for Part A.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 64of 102
Protocol Incorporating Amendment 02 04 September 2018
10.0 ADVERSE EVENTS
10.1 Definitions
10.1.1 PTE Definition
A PTE i s any  untoward m edical occurrence in a patient or subject who has signed informed 
consent to participate in a study  but before administration of any study  medicat ion; it does not 
necessarily have to have a causal relationship with study  participati on.
10.1.2 AE Definition
AE means any untoward medical occurrence in a patient or subject administered a pharmaceut ical 
product; the untoward medical occurrence does not necessarily have a causal relat ionship wit h this 
treatm ent. An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory  finding), symptom, or disease temporally  associ ated wi th the use of a medicinal 
(invest igational) product whether or not it is related to the medicinal product. This includes any 
newly occurring event, or a previous condit ion that has increased in severit y or frequency since the 
administration of study  drug.
An abnormal la boratory  value will not be assessed as an AE unless that value leads to 
discontinuat ion or delay in treatment, dose modification, therapeutic intervent ion, or is considered 
by the investigator to be a clinically significant change fro m baseline.
10.1.3 SAE Defini tion
SAE m eans any untoward medical occurrence that at any  dose:
Results in death.
Is life -threatening refers to an AE in which the patient was at risk o f death at the time of the 
event. It does not refer to an event which hypothetically might have caused death if it were 
more severe).
Requi res inpat ient hospi talizat ion or prolongat ion of an exist ing hospi talizat ion (see 
clarificati onin the paragraph in Sect ion 10.2 on planned hospitalizat ions).
Results in persistent or significant disabilit y or incapacit y. Disabilit y is defined as a substant ial 
disrupt ion of a person’s abilit y to conduct normal life funct ions.
Isa congenital ano maly/birth defect.
Is a m edically important event. This refers to an AE that may  not resul t in death, be 
immediately  life threatening, or require hospitalization, but may be considered serious when, 
based on appropriate medical judgment, m ay jeopardi ze the pati ent, requi re medical or 
surgi cal interventi on to prevent 1 of the outcomes listed above, or involves suspected 
transmissio n via a medicinal product of an infect ious agent. Examples of such medical events 
include allergic bronchospasm requi ring intensive treatment in an emergency room or at home, 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 65of 102
Protocol Incorporating Amendment 02 04 September 2018
blood dyscrasias or convulsio ns that do not result in inpatient hospitalizat ion, or the 
development of drug dependency  or drug abuse; any  organism , virus, or infecti ous parti cle 
(eg,prion prot ein transmitt ing transmissible spongiform encephalopathy), pathogenic or 
nonpathogenic, is considered an infect ious agent.
In thi s study , intensi ty for each AE, including any  lab abnormalit y, will be determined using the 
NCI CTCAE, Versi on 4.03, effective date 14 June 2010 [2].Clarificat ion should be made between 
an SAE and an AE that is considered severe in intensit y (Grade 3 or 4), becau se the terms serious 
and severe are NOT synonymous. The general term severe is often used to describe the intensit y 
(severit y) of a specific event; the event itself, however, may be of relat ively minor m edical  
significance (such as a Grade 3 headache). Thi s is NOT the same as serious , which is based on 
patient/event outcome or action criteria described above, and is usually associated with events that 
pose a threat to a patient’s life or abilit y to functi on. A severe AE (Grade 3 or 4) does not 
necessarily n eed to be considered serious. For example, a white blood cell count of 1000/mm3to 
less than 2000 is considered Grade 3 (severe) but may not be considered serious. Seriousness (not 
intensity) serves as a guide for defining regulatory  reporting obligations.
10.2 Procedures for Recording and Reporting AEs and SAEs
All AEs spontaneously reported by  the pati ent and/or in response to an open question fro m study  
personnel or revealed by observation, physical examinat ion, or other diagnostic procedures will be 
recorded on the appropriate page of the eCRF (see Section
 10.3 for the period of observat ion). Any 
clinically relevant deterioration in laboratory assessments or other clinical finding is considered an 
AE. When possible, signs and symptoms indicating a c ommo n underlying patho logy shoul d be 
noted as 1 comprehensive event.
Regardless of causalit y, SAEs and serious PTEs (as defined in Section 10.1) must be reported (see 
Secti on 10.3 for the peri od of  observati on) by  the investi gator to the Takeda Global 
Pharmacovigilance department or designee wi thin 24 hours of becoming aware of the event.
This will be done by transmitting an electronic data capture (EDC) SAE report. If transmissio n of 
an EDC SAE report is not feasible, then a facsimile of the completed Takeda paper -based SAE 
form will be sent. A sample of the paper -based SAE form and processing directions are in the 
Study  Manual. Informat ion in t he SAE report or form must be consistent with the data provided on 
the eCRF.
If informat ion not available at the time of the first report becomes availab le at a later date, the 
investigator will transmit a fo llow-up EDC SAE report (or a paper -based SAE form if an EDC 
SAE report is not feasible) or provide other documentation immediately wit hin 24 hours of receipt. 
Copi es of  any relevant data from the hospi tal notes (eg, ECGs, l aboratory  tests, di scharge 
summary, postmortem results) should be sent to the addressee, if requested.
All SAEs and serious PTEs should be fo llowed up unt il reso lution or perm anent outcome o f the 
event. The timelines and procedure for follow-up reports are the same as those for the init ial report.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 66of 102
Protocol Incorporating Amendment 02 04 September 2018
Planned hospital admissio ns or surgical procedures for an illness or disease that existed before the 
patient was enro lled in the trial orbefore study drug was given are not to be considered AEs unless 
the condi tion deteri orated in an unexpected manner during the trial (eg, surgery  was perform ed 
earlier or later than planned).
For both serious and nonserious AEs, the invest igator must determine both the severit y (toxi city 
grade) of the event a nd the rel ationship of the event to study drug administration. For 
seriousPTEs, the investigator must determine both the severit y (toxi city grade) of the event and 
the causalit y of the event in relation to study  procedures.
Severit y (toxicit y grade) for each AE, including any lab abnormalit y, will be determined using the 
NCI CTCAE, Version 4.03, effect ive date 14 June 2010 [2]. The criteria are provided in the St udy 
Manual.
Relationship of the event to study drug adm inistration (ie, its causalit y)will be determined by the 
investigator responding y es (rel ated) or no (unrelated) to this quest ion: “Is there a reasonable 
possibilit y that the AE is associated with the study  drug?” If the event i s considered “not related” 
to study  drug administration, an alternate etio logy must be provi ded.
10.3 Monitoring of AEs and Period of Observation
AEs, both nonserious and serious, will be mo nitored throughout the study .
AEs will be r eported from  the start of study  drug administrati on through 30 days (+10 days) 
days after administration of the last dose of study  drug and recorded in the eCRFs.
SAEs will be reported as fo llows:
Serious PTEs will be reported to the Takeda Global Pharmaco vigilance department or 
designee fro m the time o f the signing of the ICF up to first dose of study drug, and will also be 
recorded in the eCRF.
Related and unrelated treatment -emergent SAEs and serious PTEs will be reported to the 
Takeda Gl obal Pharmacovig ilance depart ment or designee fro m the signing of the ICF in 
Part A through 30days (+10 days)days after administration of the last dose of study drug and 
recorded in the eCRF. After this period, only related SAEs must be reported to the Takeda 
Global Pha rmacovigilance department or designee. SAEs should be monitored until they  are 
resolved or are clearly  determined to be caused by  a pati ent’s stable or chronic condit ion or 
intercurrent illness(es).
10.4 Procedures for Reporting Drug Exposure During Pregnancy a nd Birth Events
If a woman beco mes pregnant or suspects that she is pregnant while participat ing in this study, she 
must inform the invest igator immediately and permanent ly discont inue study  drug. The sponsor 
must al so be contacted immediately  by faxing a completed Pregnancy Form to the Takeda Global 
Pharmacovigilance department or designee (see Section
 10.2). The pregnancy must be followed 
for the final pregnancy  outcom e.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK-924/MLN4924)
Study No. Pevonedistat-1015 Page 67 of 102Protocol Incorporating Amendment 02 04 September 2018
If a female partner of a male patient becomes pregnant during the male patient’s participation in 
this study, the sponsor must also be contacted immediately by faxing a completed Pregnancy Form 
to the Takeda Global Pharmacovigilance department or designee (see Section 10.2) . Every effort 
should be made to follow the pregnancy for the final pregnancy outcome.
10.5 Procedures for Reporting Product Complaints or Medication Errors (Including 
Overdose)
A product complaint is a verbal, written, or electronic expression that implies dissatisfaction 
regarding the identity, strength, purity, quality , or stability of a drug product. Individuals who 
identify a potential product complaint situation should immediately report this via the phone 
numbers or e-mail addresses provided below.
A medication e rror is a preventable event that involves an  identifiable patient and that leads to 
inappropriate medication use, which may result in patient harm. Whereas overdoses and 
underdoses constitute medication errors, doses missed inadvertently by a patient do not. 
Individuals who identify a potential medication error (including overdose) situation should 
immediately report this via the phone numbe rs or e-mail addresses provided below.
Call center Phone number E-mail Fax
Product complaints in and of themselves are not AEs. If a product complaint results in an SAE, an 
SAE form should be completed and sent to  (refer to Section 10.2)
10.6 Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities
The sponsor will be responsible for reporting all suspected unexpected serious adverse reactions 
(SUSARs) and any other applicable SAEs to regulatory authorities, investigators, and IRBs or 
IECs, as applicable, in accordance with national regulations in the countries where the study is 
conducted. Relative to the first awareness of the event by/or further provision to the sponsor or 
sponsor’s designee, SUSARs will be submitted to the regulatory authorities as an expedited report
within 7 days for fatal and life-threatening events and 15 days for other serious events, unless 
otherwise required by national regulations. The sponsor will also prepare an expedited report for 
other safety issues where these might materially alter the current benefit-risk assessment of an 
investigational medicinal product or that would be sufficient to consider changes in the 
investigational medicinal product’s administration or in the overall conduct of the trial. The 
investigational site also will forward a copy of all expedited reports to his or her IRB or IEC in 
accordance with national regulations.Property of Takwikeda: For Non-Commercial U nd Subject to the Applicable Terms of Uset 
uding ding 
satatisisfacfa
Individundivid
this via his via
ble patle pat ie
WhereaWhere
rtenttently lyb
uding ovding o
l addresaddre
nd
U
elves areves a
and sent d sen
o InvestInve
ponsibleonsib
other appother ap
le, in ac, in a
atative tive to
esignee,esignee
days forays fo
se requse req
er safetr safe
nvestigavesti
invesinve
invinCCI
CCI
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 68of 102
Protocol Incorporating Amendment 02 04 September 2018
11.0 STUDY- SPECIFIC COMMITTEES
Sponsor Safety Assessment
Safety data will be reviewed and assessed periodically by a glo bal pharmacovigilance team and a 
cross -functional safet y management team throughout the conduct of the study . These cross
funct ional reviews will include a global safet y lead fro m the study  team , and other representation 
from other departments at Millennium such as Clinical Research, Pharmacovigilance, 
Biostati stics, Clinical Pharmaco logy, and Clinical Operations.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 69of 102
Protocol Incorporating Amendment 02 04 September 2018
12.0 DATA HANDL ING AND RECORDKEEPIN G 
The full details of procedures for data handling will be documented in the Data Management Plan. 
If selected for coding, AEs, PTEs, medical history, and concurrent condit ions will be coded using 
the Medi cal Dict ionary for Regulatory  Activities. Drugs will be coded using the World Health 
Organizat ion Drug Di ctionary.
12.1 eCRFs 
Com pleted eCRFs are required for each subject who signs an ICF.
The sponsor or its designee will supply invest igative sites with access to eCRFs and will make 
arran gements to train appropriate site staff in the use of the eCRF. These forms are used to transmit  
the informat ion collected in the performance of this study  to the sponsor, CRO partners, and 
regul atory  authori ties. Invest igative sites must complete eCRFs in English.
After complet ion of the entry process, computer logic checks will be run to identify items, such as 
inconsistent dates, missing data, and questionable values. Queries may be issued by Takeda 
personnel (or designees) and will be answered by the si te.
Any change of, modificat ion of, or addit ion to the data on the eCRFs should be made by the 
investigator or appropriate site personnel . Corrections to eCRFs are recorded in an audit trail that 
captures the old informat ion, the new information, ident ification of the person making the 
correcti on, the date the correction was made, and the reason for change.
The principal invest igator must review the eCRFs for completeness and accuracy and must sign 
and date the appropriate eCRFs as indicated. Furthermore, the principal invest igator must retain 
full responsibilit y for the accuracy  and authent icity of all data entered on the eCRFs.
eCRFs will be reviewed for completeness and acceptabilit y at the study  site during peri odic visi ts 
by study  monitors. The sponsor or its designee will be permitted to review the subject’s medical 
and hospital records pertinent to the study to ensure accuracy of the eCRFs. The completed eCRFs 
are the sole property  of the sponsor and should not be made available in any form to third p arties, 
except for authorized representatives of appropriate governmental healt h or regulatory authorities, 
without wri tten permissio n of the sponsor.
12.2 Record Retention
The invest igator agrees to keep the records stipulated in Section 12.1 and those documents that 
include (but are not limited to) the study -specific documents, the ident ificat ion log of all 
participat ing subjects, medical records, tempora ry media such as thermal sensit ive paper, source 
worksheets, all original signed and dated ICFs, subject authorization forms regarding the use of 
personal healt h informat ion (if separate from the ICFs), electronic copy  of eCRFs, including the 
audit trail, and detailed records of drug disposit ion to enable evaluat ions or audits from regulatory 
authori ties, the sponsor or its designees. Any source documentation printed on degradable thermal 
sensit ive paper should be photocopied by the site and filed with the original in the subject’s chart 
to ensure long term legibilit y. Furthermore, ICH E6 Section 4.9.5 requires the invest igator to retain 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 70of 102
Protocol Incorporating Amendment 02 04 September 2018
essent ial documents specified in ICH E6 (Section 8) until at least 2 years after the last approval o f 
a marketing applicat ion for a specified drug indicatio n being invest igated or, if an application is 
not approved, until at least 2 years after the invest igation is discont inued and regulatory authorities 
are notified. In addit ion, ICH E6 Section 4.9.5 states that the study re cords should be retained unt il 
an amount of time specified by  applicable regulatory  requi rements or for a time specified in the 
Clinical Study  Site Agreement between the invest igator and sponsor.
Refer to the Clinical Study Site Agreement for the sponsor’s requirements on record retention. The 
investigator should contact and receive written approval fro m the sponsor before disposing of any 
such documents.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 71of 102
Protocol Incorporating Amendment 02 04 September 2018
13.0 STATISTICAL METHODS
13.1 Statistical and Analytical Plans
A stati stical analysis plan will be prepared and f inalized before database lock. This document will 
provi de further details regarding the definit ion of analysis variables and analysis methodology  to 
address all study  object ives.
13.1.1 Analysis Sets
The populat ions used for analysis will include the fo llowing:
Safety popul ation will include patients who receive at least 1 dose of study drug. The safet y 
popul ation will be used for all safet y analyses.
PK populat ion will  include pat ients who:
–Receive the protocol -specified single pevonedistat dose in Part A .
–Do not receive any excluded conco mitant m edicat ions through the completion o f Part A .
–Have sufficient concentration -time data to permit reliable est imation of PK parameters.
13.1.2 Analysis of Demographics and Other Baseline Characteristics
Dem ographic and baseline cha racteri stics will be summarized, including sex, age, race, ethnicit y, 
weight, hei ght, BSA, baseline disease characterist ics, and other parameters as appropriate.
13.1.3 Efficacy Analysis
Analysis of all efficacy measures collected during Part B will be descri ptive. Disease response to 
pevonedistat in co mbinat ion with SOC will be based on the best overall response as determined by 
the invest igator using RECIST Version 1.1 guidelines ( Appendix H). The durati on of  response 
will be defined in pat ients with disease response (CR or PR) as the time between the first 
docum entati on of  response and PD. Responders without PD will be censored at the last clinical
assessment of response.
13.1.4 PK Analysis
Individual values and summary descript ive statist ics of pevonedistat plasma concentration time 
data and PK parameters will be listed and tabulated as fo llows:
Day 1 (pevonedistat [in the absence of rifampin])
–Pevonedist at C max, AUC last, AUC ∞, CL, V ss, and t 1/2z.
Day 10 (pevonedistat in the presence of rifampin)
–Pevonedistat C max, AUC last, AUC ∞, CL, V ss, and t 1/2z.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 72of 102
Protocol Incorporating Amendment 02 04 September 2018
For pevonedistat -rifampin DDI assessment, the ratios of geometric mean Cmax, AUC last, and AUC ∞
of pevonedist at in the presence of rifampin versus Cmax, AUC last, and AUC ∞in the absence of 
rifampin and associated 90% CIs will be calculated based on mixed -model analysis o f variance.
13.1.5 Safety Analysis
A safet y analysis will be conducted separately  for Part A and Part B to respectively characterize 
the safet y profile of pevonedistat in combinat ion wit h SOC. The safet y population will be used for 
the safet y analysis. Safet y will be evaluated on the basis of the incidence of AEs, severit y and type 
of AEs, and by  changes from baseline in the pat ient’s vital signs, weight, and clinical laboratory  
values using the safet y populat ion. Exposure to study drug and reasons for discontinuation will be 
tabul ated.
A treatment -emergent adverse event (TEAE) in Part A is defined as any AE that occurs after 
administration of the first dose of study  treatm ent in Part A and up through 30 day s after the last 
dose of study  drug in Part A for patients who do not con tinue into Part B; or up through Part B 
Cycle 1 Day  1 (predose) for patients wh o conti nue into Part B.
A TEAE in Part B is defined as any  AE that occurs after administration of the first dose of study  
treatm ent in Part B and up through 30 days after the last dose of study  drug in Part B.
AEs will be tabulated according to Medical Dic tionary  for Regulatory  Activities by System Organ 
Class, Hi gh-Level  Term , and Preferred Term  and will  include the following categories:
TEAEs.
Drug -related TEAEs.
Treatment -emergent Grade 3, 4, and 5 AEs (presented by  grade and overall).
Treatment -emergent drug-related Grade 3, 4, and 5 AEs (presented by  grade and overall).
The m ost comm only reported TEAEs (i e, those events reported by  ≥10% of all pat ients).
SAEs.
Drug -related SAEs.
A listing of TEAEs result ing in study  drug di scont inuat ion will be provided.
The m ost comm only reported TEAEs (i e, those events reported by  ≥10% of all pat ients) will be 
tabul ated by  System  Organ Class and Preferred Term. Tabulat ion also will be provided that 
enumerates AEs by  maximum  intensity. Deaths, SAEs, and AEs result ing instudy  drug 
discontinuat ion will  be tabulated.
Descript ive statistics for the actual values of clinical laboratory parameters (and change fro m 
baseline in clinical laboratory  param eters) will be presented for all scheduled measurements over 
time. Mean labo ratory  values over time will be plo tted for key  laboratory  parameters.
Shift tables for laboratory  parameters will be generated to show changes in NCI CTCAE grade 
from baseline to the worst postbaseline value. Graphical displays of key safet y parameters, s uch as 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 73of 102
Protocol Incorporating Amendment 02 04 September 2018
scatter pl ots of  baseline versus worst postbaseline values, may  be used to understand the 
pevonedistat safet y profile.
Graphical displays will be used to show vital sign parameters over time separately for Part A and 
for Part B. 
All conco mitant m edications collected from screening throughout the study  period will  be 
classified to Preferred Terms according to the World Healt h Organizat ion Drug Di ctionary.
Addit ional safet y analyses may be performed to enumerate rates of toxicit ies and to further define 
the safet y profile of pevonedistat.
13.2 Interim Analysis and Criteria for Early Termination
No interim analysis is planned.
13.3 Determination of Sample Size
The sample size calculat ion is based on the expected two -sided 90% CI for the difference in the 
paired, log-transform ed AUC (or C max) means of pevonedistat co -administered with rifampin and 
pevonedistat administered alone. Based on the preliminary  data obtained from  Study  C15011, the 
within-subject coefficient of variat ion was est imated to be 13% for AUC and 58% for C max, 
respectively . Assuming the AUC (or C max) ratio is 1.0, with a sample size of 12 evaluable patients, 
the 90% CI of the ratio of geometric means is expected to be (0.907, 1.102) for AUC and (0.671, 
1.49) for C maxbased on the previously di scussed vari ance assumpt ions. If the ratio is X, the 90% 
CI of the ratio of geometric means is expected to be within (0.907X, 1.102X) and (0.671X, 1.49X), 
respectively . Pati ents who are not PK evaluable may  be repl aced to ensure availabilit y of 
approximate ly 12 PK -evaluable patients for the final analysis.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 74of 102
Protocol Incorporating Amendment 02 04 September 2018
14.0 QUALITY CONTROL AND QUALITY ASSURANCE
14.1 Study -Site Monitoring Visits
Moni toring visit s to the study  site will  be made peri odically  during the study  to ensure that all 
aspects of the protocol are fo llowed. Source documents will be reviewed for verificat ion of data 
recorded on the eCRFs. Source documents are defined as original documents, data, and records. 
The invest igator and inst itution guarantee access to source documents by  the sponsor or i ts 
designee (C RO) and by  the IRB or IEC.
All aspects of the study and its documentation will be subject to review by the sponsor or designee 
(as long as blinding is not jeopardized), including but not limited to the Invest igator’s Binder, 
study  medicat ion, subject medic al records, inform ed consent docum entati on, docum entati on of  
subject authorizat ion to use personal healt h information (if separate fro m the ICFs), and review of 
eCRFs and associated source documents. It is important that the investigator and other study  
personnel are available during the monitoring visit s and that sufficient time is devoted to the 
process.
14.2 Protocol Deviations
The invest igator should not deviate fro m the protocol , except where necessary  to eliminate an 
immediate hazard to study subjects. Sho uld other unexpected circumstances arise that will require 
deviat ion from protocol -specified procedures, the investigator should consult with the sponsor or 
designee (and IRB or IEC, as required) to determine the appropriate course of action. There will be
no exempt ions (a prospectively approved deviat ion) from the inclusio n or exclusio n criteria.
The site should document all protocol deviat ions in the subject’s source documents. In the event of 
a significant devi ation, the si te shoul d notify  the sponsor or its designee (and IRB or EC, as 
requi red). Si gnificant devi ations include, but are not limited to, those that invo lve fraud or 
misconduct, increase the health risk to the subject, or confound interpretation of primary study 
assessment.
14.3 Quality Assurance A udits and Regulatory Agency Inspections
The study  site also m ay be subject to qualit y assurance audi ts by  the sponsor or desi gnees. In this 
circumstance, the sponsor -designated audi tor will  contact the si te in advance to arrange an 
auditing visit. The audi tor m ay ask to vi sit the f acilities where laboratory  samples are collected, 
where the medication is stored and prepared, and any other facilit y used during the study . In 
addition, there is the possibilit y that this study may be inspected by regulatory agen cies, including 
those of foreign governments (eg, the FDA, the United Kingdo m Medicines and Healthcare 
products Regulatory  Agency , the Pharmaceut icals and Medical Devices Agency o f Japan). If the 
study  site is contacted for an inspect ion by a regulatory  body, the sponsor should be notified 
immediately . The invest igator and inst itution guarantee access for qualit y assurance auditors to all 
study  docum ents as described in Section 14.1.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 75of 102
Protocol Incorporating Amendment 02 04 September 2018
15.0 ETHICAL ASPECTS OF T HE STUDY
This study  will be conducted wi th the highest respect for the individual participants (ie, subjects) 
according to the protocol, the ethical principles that have their origin in the Declaration of 
Helsinki, and the ICH Harmonised Tripart ite Guideline for GCP. Each investigator will conduct 
the study  according to applicable local or regional regulatory  requi rements and align his or her 
conduct in accordance with the “Responsibilit ies of the Invest igator” that are listed in Appendix B. 
The principles of Helsinki are addressed through the protocol and through appendices containing 
requi rements for informed consent and invest igator responsibilities.
15.1 IRB and/or IEC Approval
IRBs and IECs must be constituted according to the applicable state and federal/local requirements 
of each participat ing regio n. The sponsor or designee will require documentation noting all names 
and tit les of members who make up the respective IRB or IEC. If any member of the IRB or IEC 
has di rect parti cipat ion in this study , written notification regarding his or her abstinence fro m 
voting must also be obtained. Those American si tes unwilling to provi de names and tit les of all 
members because of privacy and conflict of interest concerns should instead provide a Federal 
Wide Assurance Number or comparable number assigned by the Department of Health and 
Hum an Services.
The sponsor o r designee will supply relevant documents for submissio n to the respective IRB or 
IEC for the protocol’s review and approval. This protocol, the IB, a copy  of the ICF, and, if 
applicable, subject recruit ment materials and/or advert isements and other docume nts requi red by 
all applicable laws and regulat ions, m ust be submit ted to a central or local IRB or IEC for 
approval . The IRB’s or IEC’s written approval of the protocol and subject informed consent must  
be obtained and submitted to the sponsor or designee before commencement of the study  (ie, 
before shipment of the sponsor -supplied drug or study specific screening act ivity). The IRB or IEC 
approval  must refer to the study by exact protocol title, number, and versio n date; ident ify versio ns 
of other documen ts (eg, ICF) reviewed; and state the approval date. The sponsor will ship 
drug/notify site once the sponsor has confirmed the adequacy  of site regul atory  docum entati on 
and, when applicable, the sponsor has received permissio n from co mpetent authorit y to be gin the 
trial. Until the si te receives [drug/notificat ion] no protocol  activit ies, including screening may 
occur.
Sites m ust adhere to all requirements stipulated by  their respect ive IRB or IEC. This may include 
notification to the IRB or IEC regarding pro tocol  amendments, updates to the ICF, recruit ment 
materi als intended for viewing by  subjects, l ocal safety reporting requirements, reports and 
updates regarding the ongoing review of the study  at intervals specified by the respect ive IRB or 
IEC, and submis sion of the invest igator’s final status report to IRB or IEC. All IRB and IEC 
approval s and rel evant docum entati on for these i tems must be provi ded to the sponsor or its 
designee.
Subject incentives should not exert undue influence for participat ion. Payme nts to subjects must 
be approved by the IRB or IEC and sponsor.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 76of 102
Protocol Incorporating Amendment 02 04 September 2018
15.2 Subject Information, Informed Consent, and Subject Authorization
Written consent documents will embody  the elements of informed consent as described in the 
Declaration of Helsinki and the ICH Guidelines for GCP and will be in accordance with all 
applicable laws and regulations. The ICF, subject authorizat ion form (if applicable), and subject 
inform ation sheet (if applicable) describe the planned and permitted uses, transfers, and 
disclosures of the subject’s personal and personal healt h informat ion for purposes of conducting 
the study . The ICF and the subject informat ion sheet (if applicable) further explain the nature of 
the study , its obj ectives, and potential risks and benefits, as well as th e date informed consent is 
given. The ICF will detail the requirements of the participant and the fact that he or she is free to 
withdraw at any  time wi thout giving a reason and without prejudice to his or her further medical 
care.
The invest igator is resp onsible for the preparation, content, and IRB or IEC approval of the ICF 
and if applicable, the subject authorizat ion form. The ICF, subject authorization form (if 
applicable), and subject informat ion sheet (if applicable) must be approved by both the IRB or IEC 
and the sponsor before use.
The ICF, subject authorizat ion form (if applicable), and subject informat ion sheet (if applicable) 
must be written in a language fully co mprehensible to the prospective subject. It is the 
responsibilit y of the invest igato r to explain the detailed elements of the ICF, subject authorizat ion 
form (if applicable), and subject informat ion sheet (if applicable) to the subject. Informat ion 
shoul d be given in both oral  and wri tten form  whenever possible and in the manner deemed 
appropriate by the IRB or IEC. In the event the subject is not capable of rendering adequate written 
inform ed consent, then the subject’s legally  acceptable representative may  provide such consent 
for the subject in accordance with applicable laws and regula tions.
The subject, or the subject’s legally acceptable representative, must be given ample opportunit y to: 
(1) inquire about details of the study and (2) decide whether or not to participate in the study. If the 
subject, or the subject’s legally  acceptabl e representative, determines he or she will part icipate in 
the study , then the ICF and subject authorizat ion form (if applicable) must be signed and dated by 
the subject, or the subject’s legally acceptable representative, at the time of consent and before the 
subject entering into the study . The subject or the subject’s legally  acceptable representative 
shoul d be instructed to si gn using thei r legal names, not ni cknames, using blue or black ballpo int 
ink. The investigator must also sign and date the ICF an d subject auth orization (if applicable) at 
the time o f consent and before subject entering into the study; however, the sponsor may allow a 
designee of the investigator to sign to the extent permitted by  applicable l aw.
Once signed, the original ICF, subje ct authori zation form (if applicable), and subject informat ion 
sheet (if applicable) will be stored in the investigator’s site file. The investigator must document 
the date the subject signs the informed consent in the subject’s medical record. Copies of t he 
signed ICF, the signed subject authorizat ion form (if applicable), and subject informat ion sheet (if 
applicable) shall be given to the subject.
All revised ICFs must be reviewed and signed by relevant subjects or the relevant subject’s legally 
acceptabl e representative in the same manner as the original informed consent. The date the 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 77of 102
Protocol Incorporating Amendment 02 04 September 2018
revised consent was obtained should be recorded in the subject’s medical record, and the subject 
shoul d receive a copy  of the revised ICF.
15.3 Subject Confidentiality
The sponsor and designees affirm and upho ld the principle of the subject’s right to protection 
against invasio n of privacy. Throughout this study , a subject’s source data will only be linked to 
the sponsor’s clinical study  database or documentation via a uniqu e identificat ion number. As 
permitted by all applicable laws and regulat ions, limited subject attributes, such as sex, age, or date 
of birth, and subject init ials may be used to verify the subject and accuracy o f the subject’s unique 
ident ificat ion number.
To com ply with ICH Guidelines for GCP and to verify co mpliance with this protocol, the sponsor 
requi res the investigator to permit its monitor or designee’s monitor, representatives fro m any 
regul atory  authori ty (eg, FDA, Medi cines and Heal thcare products Regul atory  Agency, 
Pharmaceut icals and Medical Devices Agency), the sponsor’s designated auditors, and the 
appropriate IRBs and IECs to review the subject’s original medical records (source data or 
docum ents), including, but not limited to, laboratory  test resul t reports, ECG reports, admissio n 
and discharge summaries for hospital admissio ns occurring during a subject’s study participation, 
and autopsy  reports. Access to a subject’s original medical records requires the specific 
authori zation of the subjec t as part of the informed consent process (see Section 15.2).
Copi es of  any subject source documents that are provided to the sponsor must have certain 
personally ident ifiable informat ion rem oved (ie, subject name, address, and other ident ifier fields 
not collected on the subject’s [e]CRF).
15.4 Publication, Disclosure, and Clinical Trial Registration Policy
15.4.1 Publication 
The investigator is obliged to provide the sponsor with complete test results and all data derived by 
the invest igator from the study . During and after the study , only  the sponsor m ay make study  
inform ation available to other study  invest igators or to regulatory  agencies, except as requ ired by  
law or regul ation. Except as otherwise allowable in the clinical study  site agreement, any  public 
disclosure (including publicly accessible websites) related to the protocol or study  resul ts, other 
than study  recrui tment m aterials and/or advertisements, is the sole responsibilit y of the sponsor.
The sponsor may publish any data and informat ion fro m the study (including data and informatio n 
generated by  the invest igator) without the consent of the invest igator. Manuscript authorship for 
any peer -reviewed publicat ion will appropriately reflect contribut ions to the production and 
review of the document. All publicat ions and presentations must be prepared in accordance with 
this secti on and the Clinical Study  Site Agreement.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 78of 102
Protocol Incorporating Amendment 02 04 September 2018
15.4.2 Clinical Trial Registration
In order to ensure that informat ion on clinical trials reaches the public in a timely manner and to 
comply with applicable laws, regulat ions and guidance, Takeda will, at a minimum register 
intervent ional clinical tri als it sponsors anywhere in the worl d on ClinicalTrials.gov or other 
publicly  accessible websites on or before start of study , as defined in Takeda Policy/Standard . 
Takeda contact information, alo ng with invest igator’s cit y, state (for Am ericas invest igators), 
country , and recrui ting status will be registered and available for public viewing. 
As needed Takeda and Investigator/site contact information may be made public to support 
participant access to trials via registries. In certain situations/registries, Takeda may assist 
participants or pote ntial participants to find a clinical trial by helping them locate trial sites closest 
to their homes by providing the investigator name, address, and phone number via email/phone or 
other m ethods callers requesting trial informat ion. Once subjects receive invest igator contact 
inform ation, they  may call the si te request ing enro llment into the trial. The invest igative sites are 
encouraged to handle the trial inquiries according to their established subject screening process. If 
the caller asks addit ional que stions bey ond the topic of trial enro llment, they should be referred to 
the sponsor. 
Any invest igator who objects to Takeda providing this informat ion to callers must provide Takeda 
with a wri tten noti ce request ing that their informat ion not be listed on the registry  site. 
15.4.3 Clinical Trial Results Disclosure
Takeda will post the results of clinical trial son ClinicalTrials.gov or other publicly  accessible 
websites (including the Takeda corporate site) and registries, as required by Takeda 
Policy/Standard, applicable laws and/or regulations. 
Data Sharing :
The sponsor is committed to responsible sharing of clinical data with the goal of advancing 
medical science and improving pat ient care. Qualified independent researchers will be permitted 
to use data collec ted from pat ients during the study to conduct addit ional scient ific research, which 
may be unrelated to the study  drug or the patient’s disease. The data provided to external 
researchers will not include informat ion that i dentifies pat ients personally.
15.5 Insurance and Compensation for Injury
Each subject in the study  must be insured in accordance with the regulations applicable to the site 
where the subject is participat ing. If a local underwriter is required, then the sponsor or sponsor’s 
designee will obtai n clinical study  insurance against the risk o f injury to clinical study subjects. 
Refer to the Clinical Study  Site Agreement regarding the sponsor’s policy on subject 
compensat ion and treatment for injury. If the investigator has questions regarding this p olicy, he or 
she should contact the sponsor or sponsor’s designee.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 79of 102
Protocol Incorporating Amendment 02 04 September 2018
16.0 REFERENCES
1.Naughton CA. Drug -induced nephrotoxicit y. Ameri can Family Physician 2008;78(6):743-50.
2.Commo n Termino logy Criteria f or Adverse Events (CTCAE). National Ca ncer Inst itute, 
National Inst itutes of Healt h, U.S. Department of Health and Human Services  Series v4.03. 
June 14, 2010. Publicat ion No. 09 -5410.
3.Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response 
evaluat ion criteria in solid tum ours: revi sed RECIST gui deline (versio n 1.1). Eur J Cancer 
2009;45(2):228 -47.
4.Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicit y and 
response criteria of the Eastern Cooperative Onco logy Group. Am erican Jour nal o f Clinical 
Onco logy 1982;5(6):649 -55.
5. CARBOPLATIN - carboplat in inject ion, solut ion [package insert]. Princeton, NJ: Sandoz Inc, 
2011.
6.du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, et al. A rando mized clinical tria l 
of cisplat in/pacli taxel  versus carboplatin/paclitaxel as first -line treatment of ovarian cancer. J 
Natl Cancer Inst 2003;95(17):1320- 9.
7.The Cri teria Co mmit tee of  New York Heart Associat ion. Nom enclature and Criteria for 
Diagnosis of Diseases of the Heart and Great Vessel s. 9 ed. Boston, MA: Little, Brown & Co; 
1994.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 80of 102
Protocol Incorporating Amendment 02 04 September 2018
CONFIDENTIALAppendix ASchedules of Events
SOE for Treatment Part A (DDI )
Screening (a)Day 1
Predose Day 1 Day 2Day 3 
(b)Day 4 
(b)Day 10
Predose Day 10 Day 11 Day 12 EOS (c)
Study Drug Administration
Pevonedistat IV solution administration 
(d)X X
Rifampin administration (e) Day 3 through Day 11
Study Procedures
Informed consent X
Inclusion/exclusion criteria X
Demographics X
Complete medical history X
Physical examination X X
Symptom -directed phy sical 
examinationX(f) X
ECOG performance status X X
Height X
Weight X X (f) X X
Vital signs (g) X X X X X X X X X X
12-Lead ECG X X X
Echocardiogram (h) X
Pregnancy test ( i) X X X X
Hematology X X (f) X X X X
Chemistry X X (f) X X X X X
Urinalysis X X
Plasma sample for pevonedistat PK (j) X X X X X X X X
Monitoring of concomitant medications 
and proceduresTo be recorded in the eCRF from the time of the first dose through 30 (+10) days after the last dose of study drug.
AE/SAE reporting Treatment -emergent AEs will be reported from administration of the first dose through 30 (+10) days after the last dose of study drug.
Serious PTEs will be reported from the signing of the ICF up to the first dose of study drug. In addition, related and unrela ted 
treatment -emergent SAEs will be reported from the first dose of study drug through 30 (+10) days after administration of the last dose of 
study  drug. After this period, only related SAEs must be reported.
Footnotes are on the last table page.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 81of 102
Protocol Incorporating Amendment 02 04 September 2018
CONFIDENTIAL(a) Unless otherwise noted, the screening visit must occur within 28 days before the day of the first dose of study drug in Part A. Screening clinical laboratory values must be as 
specified in Inclusion Criterion #6 for patients to be eligible for the study .
(b) Patients can be discharged from clinic any time after all Day 3 PK samples have been collected (Days 3-4) and return to the clinic on Day 10.
(c) An EOS visit is needed in Part A only if the patient does not continue into Part B. The EOS visit will occur 30 days (+10 days) after the last dose of study drug or before the start 
of subsequent therapy for th e patient’s indication, if that occurs sooner.
(d) Patients will receive a single dose of pevonedistat 50 mg/m2(equivalent to approximately 86 mg for a typical individual of 1.73 m2BSA) given as an approximate 1 -hour (60±5 
minutes) IV infusion on Day 1 and Day 10.
(e) The first dose of rifampin 600 mg will be given orally in the clinic on the morning of Day 3 after collection of the 48 -hour PK sample. Patients will self -administer rifampin oral 
capsules QD on Days 4, 5, 6, 7, 8, and 9 at home. Patients ar e encouraged to take rifampin at approximately the same time each day (±2 hours from the time of first rifampin dose). On 
Days 10 and 11, patients will report to the clinic to continue to receive oral 600 mg rifampin co -administered with pevonedistat on Da y 10, and at the time of the 24 -hour pevonedistat 
PK sampling on Day 11.
(f) Procedures conducted during screening that are performed within 3 days of Day 1 can also be used as the Day 1 predose evaluation and do not need to be repeated. Pr edose clinical 
laboratory values must be as specified in Inclusion Criterion #6 to administer the Day 1 dose of pevonedistat.
(g) On days when pevonedistat is administered, vital signs are to be measured predose (20 minutes [±10 min]) before the infus ion of pevonedistat; 30 minutes (±10 min) after the start 
of pevonedistat dosing; and 1 hour (±10 min) and 3 hours (±30 min) after the completion of pevonedistat dosing. When the timing of vital signs assessment coincides w ith the timing 
of a blood draw, vital signs will be me asured before blood sample collection.
(h) Echocardiography will be performed at screening to determine LVEF only for patients who have no historical LVEF data within 6 months prior to study enrollment .
(i) In Part A, a serum pregnancy test will be performed for women of childbearing potential at screening , and a serum or urine pregnancy test be performed on Day 1 predose, Day 10 
predose, and at the EOS visit.
(
j) Time points for blood samples for PK analysis will be collected as specified in Table A.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 82of 102
Protocol Incorporating Amendment 02 04 September 2018
CONFIDENTIALEligible pat ients may continue into opti onal Part B, which can begin wit hin approximately 2 weeks of the patient complet ing Part A 
(ie,when the patient has met the discharge criteria).
SOE for Optional Continued Treatment With Pevonedistat+Chemotherapy, Part B
Pevonedistat+Chemotherapy Treatment
21-Day Cycle EOS/
Early Termination (b) Day 1 Predose (a) Day 1 Day 3 Day 5
Study Drug Administration
Chemotherapy administration (c) X
Pevonedistat administration (c) X X X
Study Procedures
Part B entry criteria/retreatment (d) X
Full physical examination X (e) X
Symptom -directed phy sical 
examination (e)X
ECOG performance status (f) X X
Weight X X
Vital signs (g) X X X X X
12-Lead ECG (f) X X
Tumor assessment for solid tumors 
by RECIST, version 1.1 (h)To be completed before dosing in Part B, end of Cycle 2, Cycle 5, and every 6 cycles thereafterX
Monitoring of concomitant 
medications, therapies, and 
proceduresTo be recorded from start of study administration in Part A through 30 days (+10 days) after the last dose of study drug in Part B
AE/SAE reporting (i) Treatment -emergent AEs will be recorded from start of study administration in Part A through 30 days (+10 day s) after the last dose of 
study drug in Part B.
SAEs (regardless of causality) will be reported from signing of the ICF in Part A through 30 days (+10 days) after the last d ose of study drug in 
Part B. After this period, only related SAEs must be reported.
Samples/Laboratory Assessments
Pregnancy test (j) X X
Hematology (k) X X predose X predose X
Chemistry (l) X X predose X predose X
Urinalysis X X
Footnotes are on the following page.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1015 Page 83of 102
Protocol Incorporating Amendment 02 04 September 2018
CONFIDENTIALTests and procedures should be performed on schedule, but occasional changes are allowable (±2 days) for holidays, vacations, and other administrative reasons.
(a) For patients to be eligible for dosing with pevonedistat+chemotherapy (Part B), they must meet certain entry criteria (se e Section 7.3). 
(b) If the patient continues into Part B, the EOS visit will occur 30 days (+10 days) after the last dose of study drug(s) in Part B or before the start of subsequent therapy for the 
patient’s indication, if that occurs sooner.
(c) The investigator will select which chemotherapy (docetaxel or carboplatin+paclitaxel) that each patient will receive in c ombination with pevonedistat. On Day 1, when 
pevo nedistat and chemotherapy agents are both administered, chemotherapy will be administered first, followed by pevonedistat. Th e infusion of pevonedistat may be slowed or 
stopped and restarted for any associated infusion -related reactions. The dose of pevone distat may be reduced because of toxicities in accordance with Section 8.3.3 . The 
chemotherapeutic agent may be dose reduced because of toxicities in accordance with Section 8.3.3 . See Section 8.1for the details of study drug administration. NOTE: a time -out 
of approximately 15 minutes is required between the end of infusion of the chemotherapy regimen and the start of infusion of pevonedistat.
(d)For patients to be eligible for dosing with pevonedistat+chemotherapy (Part B), they must meet certain entry criteria (see Se ction 7.3). For Cycle 2 and beyond, patients must meet 
the criteria for beginning a new cycle of treatment (Section 8.3.1 ).
(e) A full ph ysical examination is required on Day 1 (predose) of Cycle 1. For Cycle 2 and beyond, a symptom -directed phy sical examination is to be performed on Day 1 predose.
(f) Predose assessment may be performed 1 day in advance if necessary.
(g) On days when study drug is administered, vital signs are to be measured predose (20 minutes [±10 min]) before the infusion of chemotherapy (when pevonedistat and 
chemotherapy agents are both administered) or pevonedistat; 30 minutes (±10 min) after the start of pevonedistat dosing; and 1 hour (±10 min) after the completion of pevonedistat 
dosing. When the timing of vital signs assessment coincides with the timing of a blood draw, vital signs will be measured bef ore blood sample collection. 
(h) Radiological imaging (as CT sc an or MRI) will be required as entry criteria for Part B to assess the status of the patient’s underlying disease. If the pat ient has had appropriate 
imaging scans performed within 28 days of Cycle 1 Day 1 of Part B, then the results of those scans may be used; otherwise, the first assessment will take place before Cycle 1 Day 1. 
Tumor assessment will be performed before the start of Part B and at the completion of Cycle 2, Cycle 5, and every 6 cycles t hereafter. Patients will undergo CT (with IV contrast, 
except for patients with an allergy to contrast agents), MRI, x -ray, and/or bone scanning to monitor and assess disease progression. If the anatomic region cannot be adequately 
imaged by CT, MRI may be used instead; see Section 9.4.14. Response will be determined according to RECIST version 1.1.
(i) Including serious PTEs in Part A; see Section 10.1.1 .
(j) In Part B, a serum or urine pregnancy test must also be performed for women of childbearing potential at every cycle (typ ically  performed on Day 1 predose of each cycle; 
however, if a se rum pregnancy test is used, this may be performed up to 3 days before Day 1), with negative results available before the firs t dose is administered in the respective 
cycle. A serum or urine pregnancy test will also be performed for women of childbearing po tential at the EOS/Early Termination visit in Part B. Pregnancy tests may also be repeated 
during the study if requested by an IEC/IRB or if required by local regulations.
(k) Hematology samples will be collected as part of the entry criteria for Part B an d before dosing with study drug on Days 1, 3, and 5. Samples may be drawn up to 1 day before 
dosing. If dosing falls on a Monday, the collection window may be extended to collect samples on the previous Friday. In addi tion, a sample will be taken at the EO S visit.
(l) Clinical chemistry samples will be collected as part of the entry criteria for Part B and before dosing with study drug o n Day s 1, 3, and 5. On Days 1, 3, and 5, samples may be 
drawn up to 1 day before dosing. In addition, a sample will be tak en at the EOS visit.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK924/MLN4924)
Study No. Pevonedistat -1015 Page 84of 102
Protocol Incorporating Amendment 02 04 September 2018
Table A Blood Sampling Schedule (Part A)
Study DayTime Point (hour) Plasma Sample Collection
Matrix Plasma (PK)
Day 1 Predose(a) X
Day 1 EOI (b) ( 5 to 1 min) X
Day 1 0.5 hour postinfusion (c) (±5 min) X
Day 1 1 hour postinfusion (c) ( 15 min) X
Day 1 2 hours postinfusion (c) ( 15 min) X
Day 1 3 hours postinfusion (c) ( 30 min) X
Day 1 4 hours postinfusion (c) ( 45 min) X
Day 1 8 hours postinfusion (c) ( 1 hour) X
Day 1 10 hours postinfusion (c) ( 1 hour) X
Day 2 24 hours postdose (d) ( 1 hour) X
Day 3 48 hours postdose (d) ( 1 hours) X
Day 10 Predose(e) X
Day 10 EOI (f) ( 5 to 1 min) X
Day 10 0.5 hour postinfusion (g) (±5 min) X
Day 10 1 hour postinfusion (g) ( 15 min) X
Day 10 2 hours postinfusion (g) ( 15 min) X
Day 10 3 hours postinfusion (g) ( 30 min) X
Day 10 4 hours postinfusion (g) (45 min) X
Day 10 8 hours postinfusion (g) ( 1 hour) X
Day 10 10 hours postinfusion (g) ( 1 hour) X
Day 11 24 hours postdose (h) ( 1 hour) X
Day 12 48 hours postdose (h) ( 1 hours) X
EOI=end of infusion.
(a) The sample is to be collected within 1 hour before the start of pevonedistat infusion on Day 1.
(b) The window for collection of the EoI time point is between 5 minutes before completion of infusion and 1 minute after 
completion of infusion. If, during Part A, IV infusion of study drug is inte rrupted or slowed, contact the project clinician or designee 
as soon as possible for consideration of patient replacement, as appropriate. If the IV infusion is interrupted, 2 additional PK 
samples (1 sample drawn when the infusion is stopped and 1 sample drawn when the infusion is restarted) should be collected so 
that the patient may be considered evaluable. The exact date and time of each additional sample collection and the actual start and 
stop times of the infusion should be recorded accurately.
(c) T ime points listed on Day 1 are in reference to the end of pevonedistat IV infusion on Day 1.
(d) Time points listed on Day 2 and Day 3 are in reference to the initiation of the pevonedistat IV infusion on Day 1.
(e) The sample is to be collected within 1 hour before the start of pevonedistat infusion on Day 10.
(f) The window for collection of the EoI time point is between 5 minutes before completion of infusion and 1 minute after 
completion of infusion. If, during Part A, IV infusion of study drug is inter rupted or slowed, contact the project clinician or designee 
as soon as possible for consideration of patient replacement, as appropriate. If the IV infusion is interrupted, 2 additional PK 
samples (1 sample drawn when the infusion is stopped and 1 sample d rawn when the infusion is restarted) should be collected so 
that the patient may be considered evaluable. The exact date and time of each additional sample collection and the actual start and 
stop times of the infusion should be recorded accurately.
(g) Ti me points listed on Day 10 are in reference to the end of pevonedistat IV infusion on Day 10.
(h) Time points listed on Day 11 and Day 12 are in reference to the initiation of the pevonedistat IV infusion on Day 10.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK924/MLN4924)
Study No. Pevonedistat -1015 Page 85of 102
Protocol Incorporating Amendment 02 04 September 2018
Appendix BResponsibilities of the Investigator
Clinical research studies sponsored by  the sponsor are subject to ICH GCP and all the applicable 
local laws and regulat ions.
The invest igator agrees to assume the fo llowing responsibilit ies by signing a Form FDA 1572:
1.Conduct the study  in accordance wit h the protocol.
2.Personally conduct or supervise the staff who will assist in the protocol.
3.If the invest igator/institution retains the services of any individual or party to perform 
study -related duti es and funct ions, th e invest igator/inst itution shoul d ensure that this 
individual or party  is qualified to perform those study -related duti es and functi ons and shoul d 
implement procedures to ensure the integrity  of the study -related duti es and funct ions 
perform ed and any  data generated.
4.Ensure that study related procedures, including study specific (non routine/non standard panel) 
screening assessments are NOT performed on potent ial subjects, before the receipt of written 
approval  from relevant governing bodies/authorit ies.
5.Ensure that all co lleagues and emplo yees assist ing in the conduct of the study are informed of 
these obligat ions.
6.Secure prior approval o f the study and any changes by an appropriate IRB/IEC that conform to 
21 CFR Part 56, ICH, and local regulatory  requi reme nts.
7.Ensure that the IRB/IEC will be responsible for init ial review, continuing review, and approva l 
of the protocol. Promptly report to the IRB/IEC all changes in research act ivity and all 
anticipated risks to subjects. Make at least y early reports on the progress of the study  to the 
IRB/IEC, and issue a final report within 3 months of study  com pletion.
8.Ensure that requirements for informed consent, as outlined in 21 CFR Part 50, ICH and local 
regul ations, are m et.
9.Obtain valid informed consent from each subject who participates in the study , and docum ent 
the date of consent in the subject’s medical chart. Valid informed consent is the most current 
versio n approved by the IRB/IEC. Each ICF should contain a subject authorizat ion section that 
describes the u ses and disclosures of a subject’s personal informat ion (including personal 
healt h informat ion) that will take place in connect ion with the study. If an ICF does not include 
such a subject authorizat ion, then the investigator must obtain a separate subject authorizatio n 
form from each subject or the subject’s legally acceptable representative.
10.Prepare and maintain adequate case histories of all persons entered into the study , incl uding 
eCRFs, hospital records, laboratory  resul ts, etc, and maintain these dat a for a minimum o f 
2years fo llowing notificat ion by the sponsor that all invest igations have been discont inued or 
that the regulatory  authori ty has approved the marketing applicat ion. The invest igator should 
contact and receive written approval fro m the sponsor before disposing o f any such 
docum ents.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK924/MLN4924)
Study No. Pevonedistat -1015 Page 86of 102
Protocol Incorporating Amendment 02 04 September 2018
11.Allow possible inspection and copying by the regulatory  authori ty of GCP -specified essent ial 
docum ents.
12.Maintain current records of the receipt, administratio n, and disposit ion of sponsor -supplied 
drugs, and r eturn all unused sponsor -supplied drugs to the sponsor.
13.Report adverse reactions to the sponsor prompt ly. In the event of an SAE, notify the sponsor 
within 24 hours.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK924/MLN4924)
Study No. Pevonedistat -1015 Page 87of 102
Protocol Incorporating Amendment 02 04 September 2018
Appendix CInvestigator Consent to Use of Personal Informat ion
Takeda will co llect and retain personal information of invest igator, including his or her name, 
address, and other personally identifiable informat ion. In addit ion, invest igator’s personal 
inform ation may be transferred to other parties located in coun tries throughout the world (eg, the 
United Kingdom, United States, and Japan), including the following:
Takeda, its affiliates, and licensing partners.
Business partners assist ing Takeda, its affiliates, and licensing partners.
Regulatory  agencies and othe r health authorit ies.
IRBs and IECs.
Invest igator’s personal informat ion may be retained, processed, and transferred by  Takeda and 
these other parties for research purposes including the fo llowing:
Assessment of the suitabilit y of invest igator for the study and/or other clinical studies.
Management, monitoring, inspect ion, and audit of the study .
Analysis, review, and verificat ion of the study  results.
Safety reporti ng and pharmacovigilance relat ing to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies rel ating to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies relat ing to other medications used in other clinical studies that may contain 
the sam e chemical com pound present in the study  medicat ion.
Inspect ions and invest igations by regulatory  authorit ies relat ing to the study.
Self-inspect ion and internal audit within Takeda, its affiliates, and licensing partners.
Archiving and audit of study  records.
Posting investigator site contact informat ion, study details and results on publicly accessible 
clinical trial registries, databases, and websites.
Invest igator’s personal informat ion may be transferred to other countries that do not have data 
protecti on laws that offer the same level of protection as data protection laws in invest igator’s own 
country .
Invest igator acknowledges and consents to the use of his or her personal information by Takeda 
and other parties for the purpose s described above.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK924/MLN4924)
Study No. Pevonedistat -1015 Page 88of 102
Protocol Incorporating Amendment 02 04 September 2018
Appendix DECOG Scale for Performance Status
Grade Description
0 Normal activity. Fully active, able to carry on all predisease performance without restriction.
1 Symptoms but ambulatory. Restricted in physically strenuous activity, but ambulatory and able to 
carry  out work of a light or sedentary nature (eg, light housework, office work).
2 In bed <50% of the time. Ambulatory and capable of all self -care, but unable to carry out any work 
activities. Up and about more than 50% of waking hours.
3 In bed >50% of the time. Capable of only limited self -care, confined to bed or chair more than 50% of 
waking hours.
4 100% bedridden. Completely disabled. Cannot carry on any self -care. Totally confined to bed or 
chair.
5 Dead
Source: Oken, et al, 1982 [4].
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK924/MLN4924)
Study No. Pevonedistat -1015 Page 89of 102
Protocol Incorporating Amendment 02 04 September 2018
Appendix EDrugs Associated With Nephrotoxicity
The drugs listed in the table below are permitted to be used during the conduct of this study  but 
shoul d be used wi th cauti on.
Drugs Associated With Nephrotoxicity
Analgesics Cardiovascular agents
Nonsteroidal anti -inflammatory drugs Angiotensin -converting enzyme inhibitors, angiotensin 
receptor blockers
Antidepressants/mood stabilizers Clopidogrel (Plavix), ticlopidine (Ticlid)
Lithium Contrast dye
Antimicrobials Diuretics
Acyclovir (Zovirax) Loops, thiazides
Aminoglycosides Triamterene (Dyrenium)
Amphotericin B (Fungizone; deoxycholic acid 
formulation more so than the lipid formulation) Herbals
Beta lactams (penicillins, cephalosporins) Chinese herbals with aristolochic acid
Foscarnet (Foscavir) Others
Ganciclovir (Cytovene) Allopurinol (Zyloprim)
Pentamidine (Pentam) Gold therapy
Quinolones Haloperidol (Haldol)
Rifampin (Rifadin) Pamidronate (Aredia)
Sulfonamides Phenytoin (Dilantin)
Vancomycin (Vancocin) Quinine (Qualaquin)
Antiretrovirals Zoledronate (Zometa)
Adefovir (Hepsera), cidofovir (Vistide), tenofovir 
(Viread)
Indinavir (Crixivan)
Calcineurin inhibitors
Cyclosporine (Neoral)
Tacrolimus (Prograf)
Source: Modified from Naughton, 2008 [1].
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK924/MLN4924)
Study No. Pevonedistat -1015 Page 90of 102
Protocol Incorporating Amendment 02 04 September 2018
Appendix F Definition of Postmenopausal
Definition of Postmenopausal
A postm enopausal  state is defined as no menses for 12 months without an alternat ive medical 
cause. A high FSH level in the postm enopausal  range m ay be used to confirm a postmenopausal 
state in women not using hormonal contraception or hormonal replacement therapy . However, in 
the absence of 12 months of amenorrhea, a single FSH measurement is insufficient. Refer to the 
following sources for addit ional informat ion: European Heads of Medicines Agencies Clinical 
Trial Facili tation Group and 
hma.eu/fileadmin/dateien/Human_Medicines/01 -About_HMA/Working_Groups/CTFG/2014_09
_HMA_ CTFG_Contraception.pdf.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK924/MLN4924)
Study No. Pevonedistat -1015 Page 91of 102
Protocol Incorporating Amendment 02 04 September 2018
Appendix GAcceptable Methods of Contraception Considered Highly Effective
Birth control  methods that can achieve a failure rate of less than 1% per year when used 
consistent ly and correctly  are considered to be highly  effect ive. Such methods include t he 
following:
Combined (estrogen and progestogen containing) hormonal contraception associated with 
inhibit ion of ovulation (a).
–Oral.
–Intravaginal.
–Transdermal.
Progestogen -only hormonal contracepti on associ ated wi th inhibit ion of ovulation (a).
–Oral.
–Injectable.
–Implantable (b).
Intrauterine device (b).
Intrauterine hormone -releasing system (b).
Bilateral tubal occlusio n (b).
Vasectomized partner (b,c).
Sexual abst inence (d).
Methods Considered Less Highly Effective
Acceptable birth control methods tha t resul t in a failure rate of more than 1% per y ear include the 
following:
Progestogen -only oral horm onal contracepti on, where inhibit ion of ovulation is not the primary 
mode of act ion.
Male or female condo m with or wi thout spermicide (e).
Cap, diaphragm, or sponge wi th spermicide (e).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK924/MLN4924)
Study No. Pevonedistat -1015 Page 92of 102
Protocol Incorporating Amendment 02 04 September 2018
(a) Hormonal contraception may be susceptible to interaction with the investigational medicinal product, which may 
reduce the efficacy of the contraception method.
(b) Contraception methods that, in the context of this guidan ce, are considered to have low user dependency.
(c) Vasectomized partner is a highly effective birth control method provided that partner is the sole sexual partner of 
the woman of childbearing potential participant of the study and that the vasectomized p artner has received medical 
assessment of the surgical success.
(d) In the context of this guidance, sexual abstinence is considered a highly effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk asso ciated with the study treatments. The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred 
and usual lifestyle of the subject.
(e) A combination of male condom with either cap, diaphragm , or sponge with spermicide (double -barrier methods) is 
also considered an acceptable, but not a highly effective, birth control method.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK924/MLN4924)
Study No. Pevonedistat -1015 Page 93of 102
Protocol Incorporating Amendment 02 04 September 2018
Appendix HResponse Criteria
Disease Response Criteria for Target and Nontarget Lesions
Evaluation of Target Lesions
CR Disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must 
have reduction in short axis to <10 mm.
PR At least a 30% decrease from baseline in the sum of diameters of target lesions, taking as reference the 
baseline sum of diameters.
PD At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on 
study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase 
of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or 
more new lesions is also considered progression.
SD Neither sufficient shrinkage to qualify for PR nor sufficient increase to qual ify for PD, taking as 
reference the smallest sum of diameters while on study.
Evaluation of Nontarget Lesions
CR Disappearance of all nontarget lesions and normalization of tumor marker level. All lymph nodes must 
be nonpathological in size (< 10 mm short axis). 
Non-CR/ 
Non-PD Persistence of 1 or more nontarget lesion(s) or/and maintenance of tumor marker level above the normal 
limits.
PD Appearance of 1 or more new lesions and/or unequivocal progression of existing nontarget lesions.
Source: Eisenhauer, et al, 2009 [3].
Overall Disease Response Criteria
Target Lesions Nontarget Le sions New Lesions Overall Response
CR CR No CR
CR Non-CR/Non -PD No PR
CR Not evaluated No PR
PR Non-PD or not all evaluated No PR
SD Non-PD or not all evaluated No SD
Not all evaluated Non-PD No Inevaluable
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
Source: Eisenhauer, et al, 2009 [3].
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK924/MLN4924)
Study No. Pevonedistat -1015 Page 94of 102
Protocol Incorporating Amendment 02 04 September 2018
Appendix IHem atologic Toxicity of Carboplatin Alone and in Combination With 
Paclitaxel
In 2 prospectively rando mized, controlled studies conducted by  the Nati onal Cancer Insti tute of  
Canada Clinical Trials Group and the Southwest Onco logy Group, 789 chem otherapy -naïve 
patients wi th advanced ovarian cancer were treated with carboplat in or cisplat in in combinat ion 
with cycl ophosphamide every  28 days for 6 courses before surgical re -evaluat ion. See the table 
below for the hematologic adverse experiences of patients treated with carboplatin in co mbinat ion 
with cycl ophosphamide.
Hematologic Adverse Experiences of Patients With Ovarian Cancer Treated With 
Carboplatin in Combination With Cyclophosphamide
Adverse Experience Laboratory ValueNCIC CTG Study
% Patients
(N=447)SWOG Study
% Patients
(N=342)
Bone Marrow
Thrombocytopenia <100,000/mm370 59
<50,000/mm341 22
Neutropenia <2000 cells/mm397 95
<1000 cells/mm381 84
Leukopenia <4000 cells/mm398 97
<2000 cells/mm368 76
Anemia <11 g/dL 91 88
<8 g/dL 18 8
Infections 14 18
Bleeding 10 6
Transfusions 42 25
Source: Carboplatin US Package Insert 2011 [5].
NCIC CTG=National Cancer Institute of Canada Clinical Trials Group, SWOG=Southwest Oncology Group.
In a rando mized clinical study, 798 patients with ovarian cancer were treated with eit her 
cisplatin+paclitaxel or paclitaxel+carboplatin therapy at 3 -week inter vals for 6 courses. See the 
table bel ow for the hematol ogic adverse experiences of patients treated with 
paclitaxel/carboplat in.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK924/ML N4924)
Study No. Pevonedistat -1015 Page 95of 102
Protocol Incorporating Amendment 02 04 September 2018
CONFIDENTIALHematologic Toxicities and Associated Supportive Care in Patients With Advanced Ovarian Cancer Stratified by Treatment 
Arm and Toxicity Grade
NCI CTC Grade, % Difference (a) in the Proportions 
of Patients With Grades 3/4 
Toxicity, % Paclitaxel+Carboplatin Arm Cisplatin+Paclitaxel Arm
Toxicity Set N 0 1 2 3 4 N 0 1 2 3 4 E 95% CI
Hemogl obin C 2209 29.1 49.4 20.1 1.3 0.1 2095 33.6 49.5 16.1 0.8 0.0 -0.6 -1.3 to 0.0
P 388 9.0 40.7 44.3 5.4 0.5 382 14.7 44.2 37.2 3.9 0.0 -2.0 -5.1 to 1.1
Platelets C 2193 71.9 19.9 5.2 2.5 0.5 2082 93.4 6.2 0.2 0.2 0.0 -2.9 -3.6 to -2.1
P 388 43.3 31.2 12.6 10.1 2.8 382 78.3 19.4 1.3 1.0 0.0 -11.8 -15.3 to -8.4
Transfusions pRBCs 
(a)C 1868 94.3 -- -- 5.7 -- 1766 97.2 -- -- 2.8 -- -2.9 -4.2 to -1.6
P 383 81.7 -- -- 18.3 -- 370 89.5 -- -- 10.5 -- -7.7 -12.7 to -2.8
Leukocytes (WBC) C 2200 37.0 22.6 29.3 10.8 0.3 2073 56.4 23.3 17.3 2.9 0.0 -8.1 -9.6 to -6.6
P 388 13.4 16.0 38.7 30.4 1.5 382 31.4 35.1 32.7 10.5 0.3 -21.2 -26.8 to -15.6
Neutrophils C 1842 56.9 12.9 12.8 12.4 5.0 1864 70.9 10.6 9.8 6.4 2.3 -8.7 -10.8 to -6.5
P 371 31.3 12.9 18.9 21.6 15.4 373 48.0 13.1 16.9 15.0 7.0 -14.9 -21.4 to -8.5
Febrile neutropenia C 2228 98.3 -- -- 1.7 0.0 2110 99.3 -- -- 0.7 0.0 -0.9 -1.6 to -0.3
P 388 92.0 -- -- 8.0 0.0 384 96.4 -- -- 3.6 0.0 -4.3 -7.6 to -1.1
Supportive care: 
antibiotics (b)C 1868 98.3 -- -- 1.7 -- 1768 97.9 -- -- 2.1 -- 0.4 -0.5 to 1.3
P 383 93.2 -- -- 6.8 -- 370 90.5 -- -- 9.5 -- 2.7 -1.2 to 6.6
Supportive care: 
G-CSF (b)C 1868 94.0 -- -- 6.0 -- 1767 98.2 -- -- 1.8 -- -4.2 -5.5 to -3.0
P 383 85.6 -- -- 14.4 -- 370 95.4 -- -- 4.6 -- -9.8 -13.9 to -5.7
Source: du Bois et al, 2003 [6].
The symbol “ --” denotes “not defined.”
C=maximum grade over all cours es, G -CSF=granulocyte colony stimulating factor, E=estimate, N=number of courses in set C and number of patients in set P, NCI CTC= National 
Cancer Institute Common Toxicity Criteria, P=maximum grade over all courses within a patient, pRBCs=packed red blood cells, WBC=white blood cell.
(a) Differences are calculated by subtracting the paclitaxel+carboplatin arm proportion from the cisplatin+paclitaxel arm pro portion; statistically significant differences in proportions 
between the 2 treatment arms are in bol d font. All percentages are rounded to 1 decimal place; therefore, the estimates may differ by ±1 from the difference of the percentages of the 
treatment arm columns.
(b) Transfusion of pRBCs and use of antibiotics and G -CSF were not assessed for the last treatment cycle within a patient. Use of antibiotics and use of G -CSF are graded in the same 
fashion as transfusion of pRBCs. Use of antibiotics/application of G -CSF is coded as a toxicity of Grade 3; a Grade 0 is applied otherwise.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK924/MLN4924)
Study No. Pevonedistat -1015 Page 96of 102
Protocol Incorporating Amendment 02 04 September 2018
Appendix JNew York Heart Association Classification of Cardiac Disease
The fo llowing tabl e presents the New York Heart Associat ion classification of cardiac disease. 
Class Functional Capacity Objective Assessment
I Patients with cardiac disease but without resulting limitations of physical 
activity . Ordinary  physical activity  does not cause undue fatigue, 
palpitatio n, dy spnea, or anginal pain.No objective evidence of 
cardiovascular disease
II Patients with cardiac disease resulting in slight limitation of physical 
activity . They  are comfortable at rest. Ordinary phys ical activity results in 
fatigue, palpitation, dyspnea, or anginal pain.Objective evidence of minimal 
cardiovascular disease
III Patients with cardiac disease resulting in marked limitation of physical 
activity . They  are comfortable at rest. Less than ordinary activity causes 
fatigue, palpitation, dyspnea, or anginal pain.Objective evidence of 
moderately severe 
cardiovascular disease
IV Patients with cardiac disease resulting in inability to carry on any physical 
activity  without discomfort. Symptoms of heart failure or the anginal 
syndrome may  be present even at rest. If any physical activity is 
undertaken, discomfort is increased.Objective evidence of severe 
cardiovascular disease
Source: The Criteria Committee of New York Heart Association, 1994 [7].
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK924/MLN4924)
Study No. Pevonedistat -1015 Page 97of 102
Protocol Incorporating Amendment 02 04 September 2018
Appendix KExcluded Strong CYP3A Inducers
Use of the CYP3A inducers listed in the table belo w shoul d be avoided during pevonedistat 
therapy  unless otherwi se noted in the protocol.
In Vivo Inducers of CYP3A
Strong Inducers ≥80% Decrease in AUC
Carbamazepine
Phenytoin
Phenobarbital
Primidone
Rifabutin
Rifampin
Rifapentine
St. Jo hn’s Wort
This is not an exhaustive list; refer to the following sources: medicine.iupui.edu/flockhart/table.htm and 
fda.gov/CDER/drug/drugInteractions/tableSubstrates.htm for additional information.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK924/MLN4924)
Study No. Pevonedistat -1015 Page 98of 102
Protocol Incorporating Amendment 02 04 September 2018
Appendix LDetailed Description of Amendments to Text
The primary  secti on(s) of the protocol affected by the changes in Amendment 02 are indicated. 
The corresponding text has been revised throughout the protocol.
Change 1:Clarify the exclusio n criterion regarding the assessment of LVEF.
The primary  change occurs in Section 7.2, Exclusion Criteria .
Initial 
wording:13. Left ventricular eject ion fraction <50% as assessed by  echocardi ogram  or 
radionuclide angiography.
Amended 
or new 
wording:13. Left ventricular eject ion fraction(LVEF) <50% as assessed by echocardiogram
or radionuclide angiography within 6 months prior to study enro llment. If a result 
within this t ime frame is unavailable, LVEF must be determined by 
echocardiography at screening .
Rationale for Change:
The intent of the protocol has been to allow sites to use historical LVEF data,if available ,or 
perform  an echocardiogram ,if needed , to determine patient eligibilit yfor the study . This point has 
been clarified in this protocol amendment.
The fo llowing sect ions also contain this change:
Secti on 9.4.12 Echocardi ogram .
Appendix A Schedules of Events (SOE for Treatment Part A [DDI]).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK924/MLN4924)
Study No. Pevonedistat -1015 Page 99of 102
Protocol Incorporating Amendment 02 04 September 2018
Change 2: Delete the requirement that, for inclusion in the study, patients must have a tumor that 
is radiographically or clinically evaluable and/or measurable.
The change occurs in Sect ion 7.1, Inclusio n Cri teria.
Deleted 
text:2. Adult pat ients who have a histologically or cytologically confirmed metastatic or 
locally advanced so lid tumor that is appropriate for treatment with pevonedista t 
in combinat ion with either docetaxel  or carbopl atin+paclitaxel in Part B of this 
study , or have progressed despite standard therapy , or f or whom  convent ional 
therapy  is not considered effective. The tum or m ust be radi ographically  or 
clinically evaluable and/or m easurable.
Rationale for Change:
As this is a phase 1 DDI study, the requirement for measurable disease is not considered essent ial.
Change 3:Change serious adverse event reporting from a paper -based system to electronic data 
capture.
The change occurs in Sect ion 10.2, Procedures for Recording and Reporting AEs and SAEs .
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Pevonedistat (TAK924/MLN4924)
Study No. Pevonedistat-1015 Page 100 of 102Protocol Incorporating Amendment 02 04 September 2018
Initial
wording:All AEs spontaneously reported by the patien t and/or in response to an open question 
from study personnel or revealed by observation, physical examination, or other 
diagnostic procedures will be recorded on the appropriate page of the eCRF (see 
Section 10.3 for the period of observation). Any clinically relevant deterioration in 
laboratory assessments or other clinical finding is considered an AE. When possible, 
signs and symptoms indicating a common unde rlying pathology  should be noted as 1 
comprehensive event.
Regardless of causality, SAEs and serious PTEs (as defined in Section 10.1) must be 
reported (see Section 10.3 for the period of observation) by the investigator to the 
Takeda Global Pharmacovigilance department or designee (contact information 
provided below). Th is should be done by faxing the SAE Form within 24 hours after 
becoming aware of the event. The SAE Form, created specifically by Takeda, will be 
provided to each clin ical study site. A sample of the SAE Form may be found in the 
Study Manual. Follow-up information on the SAE or serious PTE may be requested 
by Takeda. SAE report information must be consistent with the data provided on the eCRF.
SAE Reporting Contact Information *
Property of Takeda: For Non-Commnd Subject to the Applicable Terms of Usein n 
ossible, ssible
noted anoted
oon 10.1n 10
nvestigavestig
ontact inntact in
Form wiorm w
pecificaecific
SAE FoAE F
 or serioor ser
nsistent isten
ontactntacd
CCI
Pevonedistat (TAK924/MLN4924)
Study No. Pevonedistat-1015 Page 101 of 102Protocol Incorporating Amendment 02 04 September 2018
Amended 
or new 
wording:All AEs spontaneously reported by the patien t and/or in response to an open question 
from study personnel or revealed by observation, physical examination, or other 
diagnostic procedures will be recorded on the appropriate page of the eCRF (see 
Section 10.3 for the period of observation). Any clinically relevant deterioration in 
laboratory assessments or other clinical finding is considered an AE. When possible, 
signs and symptoms indicating a common unde rlying pathology  should be noted as 1 
comprehensive event.
Regardless of causality, SAEs and serious PTEs (as defined in Section 10.1)  must be 
reported (see Section 10.3 for the period of observation) by the investigator to the 
Takeda Global Pharmacovigilance department or designee (contact information 
provided below). within 24 hours of becoming aware of the event. This should be 
done by faxing the SAE Form within 24 hours after becoming aware of the event. The 
SAE Form, created specifically by Takeda, will be provided to each clinical study site. 
A sample of the SAE Form may be found in the Study Manual. Follow-up information 
on the SAE or serious PTE may be requested by Takeda. SAE report information must
be consistent with the data provided on the eCRF.
SAE Reporting Contact Information *
This will be done by transmitting an electronic data capture (EDC) SAE report. 
If transmission of an EDC SAE report is not feasible, then a facsimile of the 
completed Takeda paper-based SAE form will be sent. A sample of the 
paper-based SAE form and processing directions are in the Study Manual. 
Information in the SAE report or form must be consistent with the data 
provided on the eCRF.
If information not available at the time of the first report becomes available at a 
later date, the investigator will transmit a follow-up EDC SAE report (or a 
paper-based SAE form if an EDC SAE report is not feasible) or provide other 
documentation immediately within 24 hours of receipt. Copies of any relevant 
data from the hospital notes (eg, ECGs, laboratory tests, discharge summary, 
postmortem results) should be sent to the addressee, if requested.
All SAEs and serious PTEs should be followed up until resolution or permanent 
outcome of the event. The timelines and procedure for follow-up reports are the 
same as those for the initial report.Property of Takeda: For Non-Comone by one by
sion of ion o
ed Taked Tak
-based based
ormatioormat
providerovid
If inIf 
laand Subject to the Applicable Terms of Usein n 
ossible, ssible
noted anoted
oonn10.110
nvestigavestig
ontact inntact inApthe eventhe eve
mingming awt
ovided tvidedtt oudy Manudy MaecTakedaTakedbjCRF.CRF.Su
Contactontacand
CCI
Pevonedistat (TAK924/MLN4924)
Study No. Pevonedistat -1015 Page 102of 102
Protocol Incorporating Amendment 02 04 September 2018
Rationale for Change:
SAEs are being reported by  EDC in this study; the amended text reflects only  a change in 
procedure for reporting SAEs.
Change 4:Clarify the timing of chemistry  and hematol ogy laboratory  assessments before 
administration of the Day  1 dose of pevonedistat in Part A (drug -drug interaction) of the study.
The primary  change occurs in Section 7.1Inclusio n Cri teria.
Deleted 
text:3.Clinical laboratory  values as specified below within 3 days before the first dose of 
study  drug :
Rationale for Change:
To clarify that the clinical laboratory  values specified in Inclusio n Criterion #6 may be determined 
within the 28 -day screening period to determine patient eligibilit yfor the study . If these 
assessments have been performed within 3 days of Day 1, these results can also be used as the 
Day 1 predose evaluat ion to determine whether the patient can receive study drug and do not need 
to be repeated.
Appendix A Schedules of Events (SOE for Treatment Part A [DDI]) Footnotes (a) and ( f)also 
contain this change. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
(/(&7521,& 6,*1$785(6
Signed by Meaning of Signature Server Date 
(dd-MMM-yyyy HH:mm ‘UTC’) 
GH䣃䣯䣧䣰䣦䣯䣧䣰䣶䢢䢲䢴䢢䣶䣱䢢䣃䢢䣒䣪䣣䣵䣧䢢䢳䢢䣕䣶䣷䣦䣻䢢䣶䣱䢢䣇䣸䣣䣮䣷䣣䣶䣧䢢䣶䣪䣧䢢䣇䣨䣨䣧䣥䣶䣵䢢䣱䣨䢢䣔䣫䣨䣣 䣯䣲䣫䣰䢢䣱䣰䢢䣒䣪䣣䣴䣯䣣䣥䣱䣭䣫䣰䣧䣶䣫䣥䣵䢢䣱䣨䢢䣒䣧䣸䣱䣰䣧䣦䣫䣵䣶䣣䣶䢢䣫䣰
䣒䣣䣶䣫䣧䣰䣶䣵䢢䣹䣫䣶䣪䢢䣃䣦䣸䣣䣰䣥䣧䣦䢢䣕䣱䣮䣫䣦䢢䣖䣷䣯䣱䣴䣵
&OLQLFDO3KDUPDFRORJ\$SSURYDO 6HS87&
&OLQLFDO6FLHQFH$SSURYDO 6HS87&
&OLQLFDO$SSURYDO 6HS87&
%LRVWDWLVWLFV$SSURYDO 6HS87&PPD
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of UseeT eate te
ble THH:mm ‘UH:mmTer
ble87&87&

6HSHS
6H